Expression cassette coding for vascular endothelial growth factor

The enhanced expression cassette for VEGF isoforms in adenoviral vectors improves angiogenic effects by optimizing splicing and reducing read-through transcription, achieving efficient and targeted VEGF expression for therapeutic angiogenesis.

WO2024233783A1PCT designated stage expired Publication Date: 2024-11-14CORNELL UNIVERSITY +4
View PDF 63 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028584
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current adenoviral gene transfer vectors expressing vascular endothelial growth factor (VEGF) have limitations in efficiently expressing multiple isoforms, leading to suboptimal angiogenic effects due to inefficient splicing and high read-through transcription, which can interfere with viral gene expression and reduce therapeutic efficacy.

Method used

An expression cassette is designed with a consensus splice site in exon 8 and modified polyA sequences to enhance splicing and reduce read-through, allowing for high-level expression of multiple VEGF isoforms, including VEGF121, 165, and 189, by using a viral promoter and multiple polyA signals, and orienting the expression cassette to prevent interference with viral genes.

Benefits of technology

This approach enables enhanced expression of VEGF isoforms, achieving a higher therapeutic effect with lower vector doses and minimizing the expression of VEGF121, which supports tumor growth, thereby improving angiogenesis and reducing vector requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000038_0001
    Figure IMGF000038_0001
  • Figure IMGF000056_0001
    Figure IMGF000056_0001
  • Figure IMGF000064_0001
    Figure IMGF000064_0001
Patent Text Reader

Abstract

A vector to express one or more VEGF isoforms which vector expresses a high level potent angiogenic mixture of VEGF isoforms, and methods of using the vector, are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] EXPRESSION CASSETTE CODING FOR VASCULAR ENDOTHELIAL GROWTH FACTOR Cross-Reference to Related Applications This application claims the benefit of the filing date of U.S. application No. 63 / 465,156, filed on May 9, 2023, the disclosure of which is incorporated by reference herein. Incorporation by Reference of Sequence Listing This application contains a Sequence Listing which has been submitted electronically in ST26 format and hereby incorporated by reference in its entirety. Said ST26 file, created on May 9, 2024, is name 1676196WO1.xml and is 287,000 bytes in size. Background Adenoviral gene transfer vectors expressing vascular endothelial growth factor (VEGF) are an experimental therapy to induce angiogenesis. The VEGF gene is alternatively spliced to produce both angiogenic and anti-angiogenic isoforms but the major angiogenic isoforms are VEGF121, 165 and 189. While individual VEGF isoforms are angiogenic in the context of gene therapy, they aremore potent in combination (Whitlock et al., 2005). Adenoviral vectors withgenomic / cDNA hybrid genes can be designed that express multiple VEGF isoforms and the splicing pattern can be manipulated to change the ratios of the isoforms (Amano et al., 2005). Summary Vascular endothelial growth factor (VEGF) is a potent angiogenic mediator thatinduces new blood vessel growth. The VEGF gene expresses multiple isoforms, dominated by VEGF 121, 165 and 189 (number indicates the number of amino acids in the isoform). While each isoform is angiogenic, combining the 3 major isoforms generates new blood vessels at a lower dose, e.g., the isoforms together are morepotent than any one isoform alone.This disclosure provides composition and methods to enhance expression, for example, of one or more isoforms, or all native forms, of VEGF from a vector, e.g., an adenovirus gene transfer vector. The vector is useful as a gene therapy vector and as a result of the enhanced expression, less vector may be employed to achieve a prophylactic or therapeutic effect. The vector may be employed to enhance expression of gene products other than VEGF, e.g., by modifying the splice acceptor in E1B, expressing the gene product in reverse orientation, repeating the SV40 polyA sequence (multiple copies), using a different polyA site or combinations of polyA sites, or any combination thereof. In one embodiment, an expression cassette that is not part of an adenovirus gene transfer vector is provided that encodes VEGF and has a consensus splice site in exon 8. The disclosure thus provides a vector to express one or more VEGF isoforms, comprising: an expression cassette comprising a promoter operably linked to a nucleic acid sequence comprising VEGF exons 1-5, 6A, 7, and 8 which is linked to at least one polyA sequence, wherein the polyA sequence has reduced readthrough relative to an individual SV40 polyA sequence, wherein if the vector is an adenovirus vector the polyA sequence has reduced readthrough adenovirus early gene expression and higher transgene expression relative to an individual SV40 polyA sequence, wherein the splice acceptor (SA) of exon 8 is modified to enhance splicing at the splice acceptor of exon 8, wherein a sequence 3’ to the expression cassette is modified to mutate a downstream SA site, wherein the expression cassette is in reverse orientation relative to at least one other functional element that is 5’ or 3’ to the expression cassette, or a combination thereof. In one embodiment, the promoter is a viral promoter. In one embodiment, the promoter is not an adenovirus promoter. In one embodiment, the vector has a plurality of polyA sequences. In one embodiment, the plurality includes two or more copies of the same polyA sequence which is optionally a SV40 polyA sequence. In one embodiment, the polyA sequence comprises a human GAPDH, human TUBB (tubulin), human RPL3 (ribosomal protein large 3), human ITGA1 (Integrin A1), human GH (growth hormone) or rabbit BG (beta globin) polyA sequences, or a combination thereof. In one embodiment, the vector is a viral vector. In oneembodiment, the vector is an adenovirus vector, e.g., a human or non-human serotype.In one embodiment, the expression cassette is in reverse orientation relative to the flanking viral sequences. In one embodiment, the E1b SA is mutated. In one embodiment, the splice acceptor in exon 8 is modified. In one embodiment, the vector expresses two or more isoforms of VEGF. In one embodiment, the vector expressesVEGF121, VEGF165, or VEGF189 or VEGF121, VEGF165 and VEGF189, e.g., theratio of the isoforms is about 1:1:1 or the ratio of the isoforms is VEGF189 > VEGF165 > VEGF121. Further provided is a recombinant adenoviral vector comprising an expression cassette comprising a promoter operably linked to a nucleic acid sequence comprisingVEGF exons 1-5, 6A, 7, and 8 which is linked to at least one polyA sequence, whereinthe polyA sequence has reduced readthrough relative to a single SV40 polyA sequence, wherein the splice acceptor (SA) of exon 8 is modified to enhance splicing at the splice acceptor of exon 8, wherein a sequence 3’ to the expression cassette is modified to mutate a SA site, wherein the expression cassette is in reverse orientation, or a combination thereof. In one embodiment, an E1B splice site is modified. In one embodiment, the splice acceptor in exon 8 is modified. In one embodiment, the polyA sequences comprises a human GAPDH, human TUBB (tubulin), human RPL3 (ribosomal protein large 3), human ITGA1 (Integrin A1), human GH (growth hormone) or rabbit BG (beta globin) polyA sequences, or a combination thereof. In one embodiment, the promoter is a viral promoter. In one embodiment, the promoter is not an adenovirus promoter. In one embodiment, the expression cassette is in reverse orientation relative to the flanking viral sequences. In one embodiment, the vector expresses two or more isoforms of VEGF. In one embodiment, the vector expresses VEGF121, VEGF165. VEGF189 or VEGF121, VEGF165 and VEGF189, e.g., in a ratio of the isoforms is about 1:1:1 or VEGF189 > VEGF165 > VEGF121. In one embodiment, the adenovirus is E1- and / or E3-. In one embodiment, the adenovirus genome or capsid is from a human adenovirus. In one embodiment, the adenovirus genome or capsid is from a non-human primate adenovirus. This disclosure provides composition and methods to provide high level expression, for example, of one or more isoforms, or all native forms, of VEGF from an adenovirus gene transfer vector, e.g., by expressing the gene product in reverse orientation, using one or more polyA signals, and manipulating isoform ratios or any combination thereof. The vector is useful as a gene therapy vector and as a result of the enhanced expression, less vector may be employed to achieve a prophylactic or therapeutic effect. The vector may be employed to enhance expression of gene products other than VEGF, e.g., by expressing the gene product in reverse orientation, using one or more polyA signals, and manipulating isoform ratios or any combination thereof. In one embodiment, the disclosure provides a vector to express one or more VEGF isoforms, comprising: an expression cassette comprising a promoter operablylinked to a nucleic acid sequence comprising VEGF exons 1-5, 6A, 7, and 8 which islinked to at least one polyA sequence, wherein the polyA sequence has low read- through and / or high mRNA level and stability, wherein the expression cassette is in reverse orientation relative to at least one other vector encoded gene or transcriptional element, e.g., 5’ or 3’ end of an adenovirus genome (inverted terminal repeats; ITRs).In one embodiment, the promoter is a strong viral promoter. In one embodiment, thepromoter is not an adenovirus promoter. In one embodiment, the vector has a plurality of polyA sequences. In one embodiment, the polyA sequence comprises a human GAPDH, human TUBB (tubulin), human RPL3 (ribosomal protein large 3), human ITGA1 (Integrin A1), bovine growth hormone (bGH), human GH (growth hormone) orrabbit BG (beta globin) polyA sequences, or a combination thereof. In one embodiment,the vector is a viral vector. In one embodiment, the vector is an adenovirus vector, e.g., a human or non-human serotype. In one embodiment, the expression cassette is in reverse orientation relative to the flanking viral sequences. In one embodiment, the vector expresses two or more isoforms of VEGF. In one embodiment, the vector expresses VEGF121, VEGF165, or VEGF189 or VEGF121, VEGF165 and VEGF189, e.g., the ratio of the isoforms is about 1:1:1 or the ratio of the isoforms is VEGF165 > VEGF189 >> VEGF121. In one embodiment, a gene transfer vector is provided, for example, AdVEGF(3i), that simultaneously expresses the three major angiogenic isoforms of VEGF at high level from a hybrid cDNA / genomic gene. In one embodiment, the gene transfer vector is an adenoviral vector. In one embodiment, the orientation of the VEGF expression cassette in the viral vector is reversed relative to the viral genome, e.g., the adenoviral genome, and is designed to prevent read-through transcription from the transgene expression cassette into the viral coding region(s), e.g., the adenoviral early genes. In one embodiment, there are two strong polyadenylation signals after the VEGF gene that ensure that transgene expression does not interfere with genetic information at the end(s) of the viral genome, e.g., the adenoviral inverted terminal repeats. This orientation may provide for a higher level of VEGF expression compared to the alternate configuration. The splicing signals around VEGF exon 6A may be manipulated so that the isoform ratio is VEGF165>VEGF189>>VEGF121. This minimizes the expression level of VEGF121 which is known to support tumor growth. Further provided is a recombinant adenoviral vector comprising an expression cassette comprising a promoter operably linked to a nucleic acid sequence comprising VEGF exons 1-5, 6A, 7, and 8 which is linked to at least one polyA sequence, wherein the polyA sequence has low read-through and / or high mRNA level and stability, wherein the expression cassette is in reverse orientation relative to at least one other vector encoded gene. In one embodiment, the promoter is a strong viral promoter. In one embodiment, the promoter is not an adenovirus promoter. In one embodiment, the vector has a plurality of polyA sequences. In one embodiment, the polyA sequence comprises a human GAPDH, human TUBB (tubulin), human RPL3 (ribosomal proteinlarge 3), human ITGA1 (Integrin A1), bovine growth hormone (bGH), human GH (growthhormone) or rabbit BG (beta globin) polyA sequences, or a combination thereof. In one embodiment, the vector is a viral vector. In one embodiment, the vector is an adenovirus vector, e.g., a human or non-human serotype. In one embodiment, the expression cassette is in reverse orientation relative to the flanking viral sequences. Inone embodiment, the vector expresses two or more isoforms of VEGF. In oneembodiment, the vector expresses VEGF121, VEGF165, or VEGF189 or VEGF121, VEGF165 and VEGF189, e.g., the ratio of the isoforms is about 1:1:1. In one embodiment, the ratio of the isoforms is VEGF165 > VEGF189 >> VEGF121. In one embodiment, the adenovirus is E1- and / or E3-. In one embodiment, the adenovirusgenome or capsid is from a human adenovirus. In one embodiment, the adenovirusgenome or capsid is from a non-human primate adenovirus. A composition is provided comprising particles comprising mRNA isolated from expression of the vector. In one embodiment, the particles are nanoparticles. In one embodiment, the particles comprise one or more lipids. In one embodiment, the particles comprise DSPC, cholesterol, PEG-DMA, SM-102, or any combination thereof. Further provided is a method of directing blood vessel growth in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising the vector. In one embodiment, the vector that expressed VEGF is directed to a target location based on the site of administration in an organ or a tissue. In one embodiment, the administration is to a region in the mammal affected by a vascular occlusion. In one embodiment, the administration is to a heart. In one embodiment, the administration is to a location suffering from ischemia. In one embodiment, the mammal is a human. In one embodiment, the mammal has, ischemic heart disease or peripheral arterial disease. In one embodiment, the mammal has had a stroke. In one embodiment, the vector expresses two or more isoforms of VEGF. In one embodiment, the vector expresses VEGF121. In one embodiment, the adenovirus expresses VEGF165. In one embodiment, the adenovirus expresses VEGF189. In one embodiment, the adenovirus expresses VEGF121, VEGF165 and VEGF189. In one embodiment, the ratio of the isoforms is about 1:1:1. In one embodiment, the ratio of the isoforms is VEGF165 > VEGF189 >> VEGF121. In one embodiment, the vector is a human adenovirus. In one embodiment, the adenovirus is a non-human primate adenovirus. Brief Description of Figures Figure 1 sets forth the nucleotide sequence comprising cDNA and genomic DNA of a VEGF which promotes the production of VEGF165 and VEGF189 at the expense of VEGF 121 (SEQ ID NO:1). Figure 2 sets forth the amino acid sequence corresponding to the protein encoded by the nucleotide sequence set forth above (SEQ ID NO:2). Figure 3 sets forth the consensus nucleotide sequences of the splice donor, branch point, and splice acceptor sites of a nucleotide sequence encoding a VEGF(SEQ ID Nos. 3-5).Figure 4. Alternate splicing of pre-mRNA in Ad5VEGF-All6A+ to produce mRNA encoding VEGF121, VEGF 165 and VEGF189. Exons 1-5 are provided in the cDNA configuration while exons 6A, 7 and 8 are provided in the genomic configuration including introns 5,6 and 7. VEGF121 result from splicing exon 5 to exon 8. VEGF 165results from joining exon 5 to exon 7 and exon 7 to exon 8. VEGF 189 results fromjoining exon 5 to exon 6A, exon 6A to exon 7 and exon 7 to exon 8. Figure 5. C-terminal products after expected and observed splicing patterns. The end of exon 7 is in black and it is spliced to either exon VEGF exon 8 (blue) or AdE1B (red). The resultant amino acids sequence is shown. (SEQ ID NOS: 60-63) Figure 6. VEGF primary transcripts from AdVEGF-All6A+. Exon 8 is normallycomprised to exon 8a and exon 8b. In AdVEGF-All6A+, exon 8b is deleted. A schematic of the 3’ end of the VEGF transcript is shown. The expected pattern (blue) is for exon 7 (E7) to splice to exon 8a (E8a) with the result that the VEGF protein ends with the amino acid sequence CDKPRR that is seen in all of the major angiogenic isoforms of VEGF (VEGF121, VEGF165 and VEGF189). However, inefficient transcription termination at the SV40 polyadenylation led to a high frequency of read through. As a result, approximately 80% of mRNAs continued into the flanking adenovirus E1B gene where there is a strong spice acceptor sequence. As a result, exon 7 can splice into the E1B gene creating an out of the reading frame junction with the E1B gene. This results in the substitution of the usual last 6 amino acids encoded by exon 8 being replaced by 11 amino acids with sequence SRRRHEHQLV. Figure 7. Schematic of exemplary constructs for eliminating polyA read through and mis-splicing. Figure 8. Schematic of AdVEGF(3i). The adenovirus serotype 5 genome is modified by a partial deletion of the E1 region and another deletion of the E3 region. In the deleted E1 region is an expression cassette directed towards the 5’ adenoviral inverted terminal repeat (Ad-ITR) containing the cytomegalovirus immediate early enhancer and promoter (pCMV), a cDNA / genomic hybrid VEGF gene (VEGF-All6A+) modified to promote expression of the VEFG 189 isoform, two polyadenylation sites from rabbit beta globin (pA-rBG) and human growth hormone (pA-hGH). The orientation of the expression cassette is designed to prevent aberrant splicing between the VEGF expression cassette and the partial E1b gene of adenovirus (Ad E1b). Figure 9. In vitro VEGF expression from AdVEGF(3i). Human foreskin fibroblasts (HFF) were infected in a 12-well plate by AdVEGF(3i) and AdVEGF-All6A+at 1000, 100, and 10 viral particles / cell. After 48 hours, media were collected and VEGF protein was quantified by ELISA and normalized to total protein. Figure 10. In vivo VEGF expression by AdVEGF(3i). Cohorts of C57Bl / 6 mice were injected intravenously with 5x109particle units of AdVEGF(3i) or AdVEGF-All6A+ or with PBS After 3 days, liver was collected for assessment of VEGF mRNA level by qPCR with relative quantitation of mouse Tfrc reference gene and VEGF protein byELISA and. Data is the mean and standard deviation for n=5.Detailed Description Definitions A “vector” refers to a macromolecule or association of macromolecules thatcomprises or associates with a polynucleotide, and which can be used to mediatedelivery of the polynucleotide to a cell, either in vitro or in vivo. Illustrative vectors include, for example, plasmids, viral vectors, liposomes and other gene delivery vehicles. The polynucleotide to be delivered, sometimes referred to as a “target polynucleotide” or “transgene,” may comprise a coding sequence of interest in genetherapy (such as a gene encoding a protein of therapeutic interest), a coding sequenceof interest in vaccine development (such as a polynucleotide expressing a protein, polypeptide or peptide suitable for eliciting an immune response in a mammal), and / or a selectable or detectable marker. “Transduction,” “transfection,” “transformation” or “transducing” as used herein, are terms referring to a process for the introduction of an exogenous polynucleotide into a host cell leading to expression of the polynucleotide, e.g., the transgene in the cell, and includes the use of recombinant virus to introduce the exogenous polynucleotide to the host cell. Transduction, transfection or transformation of a polynucleotide in a cell may be determined by methods well known to the art including, but not limited to, protein expression (including steady state levels), e.g., by ELISA, flow cytometry and Western blot, measurement of DNA and RNA by hybridization assays, e.g., Northern blots, Southern blots and gel shift mobility assays as well as PCR, ddPCR, and a variety of RNA sequencing techniques. Methods used for the introduction of the exogenous polynucleotide include well-known techniques such as viral infection or transfection, lipofection, transformation and electroporation, as well as other non-viral gene delivery techniques. The introduced polynucleotide may be stably or transiently maintained in the host cell. “Gene delivery” refers to the introduction of an exogenous polynucleotide into a cell for gene therapy, and may encompass targeting, binding, uptake, transport, localization, replicon integration and expression. “Gene therapy” refers to the introduction of an exogenous polynucleotide into a cell which may encompass targeting, binding, uptake, transport, localization and replicon integration, but is distinct from and does not imply subsequent expression of the gene. “Gene expression” or “expression” refers to the process of gene transcription, translation, and post-translational modification. An “infectious” virus or viral particle is one that comprises a polynucleotide component which it is capable of delivering into a cell for which the viral species is trophic. The term does not necessarily imply any replication capacity of the virus. The term “polynucleotide” refers to a polymeric form of nucleotides of anylength, including deoxyribonucleotides or ribonucleotides, or analogs thereof. Apolynucleotide may comprise modified nucleotides, such as methylated or capped nucleotides and nucleotide analogs, and may be interrupted by non-nucleotide components. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The term polynucleotide, as used herein,refers interchangeably to double- and single-stranded molecules. Unless otherwisespecified or required, any embodiment of the disclosure described herein that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double- stranded form. An “isolated” polynucleotide, e.g., plasmid, virus, polypeptide or other substancerefers to a preparation of the substance devoid of at least some of the other components that may also be present where the substance or a similar substance naturally occurs or is initially prepared from. Thus, for example, an isolated substance may be prepared by using a purification technique to enrich it from a source mixture. Isolated nucleic acid, peptide or polypeptide is present in a form or setting that is different from that in which it is found in nature. For example, a given DNA sequence (e.g., a gene) is found on the host cell chromosome in proximity to neighboring genes; RNA sequences, such as a specific mRNA sequence encoding a specific protein, are found in the cell as a mixture with numerous other mRNAs that encode a multitude of proteins. The isolated nucleic acid molecule may be present in single-stranded or double-stranded form. When an isolated nucleic acid molecule is to be utilized to express a protein, the molecule will contain at a minimum the sense or coding strand (i.e., the molecule may single-stranded), but may contain both the sense and anti-sense strands (i.e., the molecule may be double-stranded). Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured in relation to a second, potentially interfering substance present in the source mixture. Increasing enrichments of the embodiments are envisioned. Thus, for example, a 2-fold enrichment, 10-fold enrichment, 100-fold enrichment, or a 1000-fold enrichment. A “transcriptional regulatory sequence” refers to a genomic region that controls the transcription of a gene or coding sequence to which it is operably linked. Transcriptional regulatory sequences of use generally include at least one transcriptional promoter and may also include one or more enhancers and / or terminators of transcription. “Operably linked” refers to an arrangement of two or more components, wherein the components so described are in a relationship permitting them to function in a coordinated manner. By way of illustration, a transcriptional regulatory sequence or a promoter is operably linked to a coding sequence if the TRS or promoter promotes transcription of the coding sequence. An operably linked TRS is generally joined in cis with the coding sequence, but it is not necessarily directly adjacent to it. “Heterologous” means derived from a genotypically distinct entity from the entityto which it is compared. For example, a polynucleotide introduced by geneticengineering techniques into a different cell type is a heterologous polynucleotide (and, when expressed, can encode a heterologous polypeptide). Similarly, a transcriptional regulatory element such as a promoter that is removed from its native coding sequence and operably linked to a different coding sequence is a heterologous transcriptionalregulatory element.A “terminator” refers to a polynucleotide sequence that tends to diminish or prevent read-through transcription (i.e., it diminishes or prevent transcription originating on one side of the terminator from continuing through to the other side of the terminator). The degree to which transcription is disrupted is typically a function of thebase sequence and / or the length of the terminator sequence. In particular, as is wellknown in numerous molecular biological systems, particular DNA sequences, generally referred to as “transcriptional termination sequences” are specific sequences that tend to disrupt read-through transcription by RNA polymerase, presumably by causing the RNA polymerase molecule to stop and / or disengage from the DNA being transcribed. Typical example of such sequence-specific terminators include polyadenylation (“polyA”) sequences, e.g., SV40 polyA. In addition to or in place of such sequence- specific terminators, insertions of relatively long DNA sequences between a promoter and a coding region also tend to disrupt transcription of the coding region, generally in proportion to the length of the intervening sequence. This effect presumably arises because there is always some tendency for an RNA polymerase molecule to become disengaged from the DNA being transcribed, and increasing the length of the sequence to be traversed before reaching the coding region would generally increase the likelihood that disengagement would occur before transcription of the coding region was completed or possibly even initiated. Terminators may thus prevent transcription from only one direction (“uni-directional” terminators) or from both directions (“bi-directional” terminators) and may be comprised of sequence-specific termination sequences or sequence-non-specific terminators or both. A variety of such terminator sequences are known in the art; and illustrative uses of such sequences within the context of the present disclosure are provided below. “Host cells,” “cell lines,” “cell cultures,” “packaging cell line” and other such terms denote higher eukaryotic cells, such as mammalian cells including human cells, useful in the present disclosure, e.g., to produce recombinant virus or recombinant fusion polypeptide. These cells include the progeny of the original cell that was transduced. It is understood that the progeny of a single cell may not necessarily be completely identical (in morphology or in genomic complement) to the original parent cell. “Recombinant,” as applied to a polynucleotide means that the polynucleotide is the product of various combinations of cloning, restriction and / or ligation steps, and other procedures that result in a construct that is distinct from a polynucleotide found in nature. A recombinant virus is a viral particle comprising a recombinant polynucleotide.The terms respectively include replicates of the original polynucleotide construct andprogeny of the original virus construct. A “control element” or “control sequence” is a nucleotide sequence involved in an interaction of molecules that contributes to the functional regulation of a polynucleotide, including replication, duplication, transcription, splicing, translation, ordegradation of the polynucleotide. The regulation may affect the frequency, speed, orspecificity of the process, and may be enhancing or inhibitory in nature. Control elements known in the art include, for example, transcriptional regulatory sequences such as promoters and enhancers. A promoter is a DNA region capable under certain conditions of binding RNA polymerase and initiating transcription of a coding regionusually located downstream (in the 3' direction) from the promoter. Promoters includeAAV promoters, e.g., P5, P19, P40 and AAV ITR promoters, as well as heterologous promoters. An “expression vector” is a vector comprising a region which encodes a gene product of interest, and is used for effecting the expression of the gene product in an intended target cell. An expression vector also comprises control elements operatively linked to the encoding region to facilitate expression of the protein in the target. The combination of control elements and a gene or genes to which they are operably linked for expression is sometimes referred to as an “expression cassette,” a large number of which are known and available in the art or can be readily constructed from components that are available in the art. The terms “polypeptide” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, acetylation, phosphorylation, lipidation, or conjugation with a labeling component. The term "exogenous," when used in relation to a protein, gene, nucleic acid, or polynucleotide in a cell or organism refers to a protein, gene, nucleic acid, or polynucleotide which has been introduced into the cell or organism by artificial or natural means. An exogenous nucleic acid may be from a different organism or cell, or it may be one or more additional copies of a nucleic acid which occurs naturally within the organism or cell. By way of a non-limiting example, an exogenous nucleic acid is in a chromosomal location different from that of natural cells, or is otherwise flanked by a different nucleic acid sequence than that found in nature, e.g., an expression cassette which links a promoter from one gene to an open reading frame for a gene product from a different gene. "Transformed" or "transgenic" is used herein to include any host cell or cell line, which has been altered or augmented by the presence of at least one recombinant DNA sequence. The host cells are typically produced by transfection with a DNA sequence in a plasmid expression vector, as an isolated linear DNA sequence, or infection with a recombinant viral vector. The term “sequence homology” means the proportion of base matches betweentwo nucleic acid sequences or the proportion amino acid matches between two amino acid sequences. When sequence homology is expressed as a percentage, e.g., 50%, the percentage denotes the proportion of matches over the length of a selected sequence that is compared to some other sequence. Gaps (in either of the twosequences) are permitted to maximize matching; gap lengths of 15 bases or less areusually used, 6 bases or less or 2 bases or less. When using oligonucleotides as probes or treatments, the sequence homology between the target nucleic acid and the oligonucleotide sequence is generally not less than 17 target base matches out of 20 possible oligonucleotide base pair matches (85%); not less than 9 matches out of 10possible base pair matches (90%), or not less than 19 matches out of 20 possible basepair matches (95%). Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less or 2 or less. Alternatively, two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. The two sequences or parts thereof are more homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program. The term “corresponds to” is used herein to mean that a polynucleotide sequence is structurally related to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is structurally related to all or a portion of (e.g., framework sequence(s) or CDR sequence(s)) a reference polypeptide sequence, e.g., they have at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%, sequence identity. In contradistinction, the term “complementary to” is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence “TATAC” corresponds to a reference sequence “TATAC” and is complementary to a reference sequence “GTATA”. The term “sequence identity” means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term “percentage of sequence identity” means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequencesto yield the number of matched positions, dividing the number of matched positions bythe total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms “substantial identity” as used herein denote a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 85percent sequence identity, at least 90 to 95 percent sequence identity, at least 99percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 20-50 nucleotides, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the polynucleotide sequence which may include deletions oradditions which total 20 percent or less of the reference sequence over the window ofcomparison. “Conservative” amino acid substitutions are, for example, aspartic-glutamic as polar acidic amino acids; lysine / arginine / histidine as polar basic amino acids; leucine / isoleucine / methionine / valine / alanine / glycine / proline as non-polar or hydrophobic amino acids; serine / threonine as polar or uncharged hydrophilic amino acids. Conservative amino acid substitution also includes groupings based on side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur- containing side chains is cysteine and methionine. For example, it is reasonable to expect that replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the properties of the resulting polypeptide. Whether an amino acid change results in a functional polypeptide can readily be determined by assaying the specific activity of the polypeptide. Naturally occurring residues are divided into groups based on common side-chain properties: (1) hydrophobic: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu; (4) basic: asn, gln, his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromatic; trp, tyr, phe. The disclosure also envisions polypeptides with non-conservative substitutions. Non-conservative substitutions entail exchanging a member of one of the classes described above for another. “Nucleic acid sequence” is intended to encompass a polymer of DNA or RNA, i.e., a polynucleotide, which can be single-stranded or double-stranded and which can contain non-natural or altered nucleotides. The terms “nucleic acid” and “polynucleotide” as used herein refer to a polymeric form of nucleotides of any length, either ribonucleotides (RNA) or deoxyribonucleotides (DNA). These terms refer to theprimary structure of the molecule, and thus include double- and single-stranded DNA,and double- and single-stranded RNA. The terms include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and modified polynucleotides such as, though not limited to, methylated and / or capped polynucleotides. Gene Therapy Vectors The disclosure provides a gene therapy vector comprising a nucleic acidsequence which encodes one or more proteins, e.g., one or more isoforms of VEGF. The disclosure further provides a method of using the vector to enhance vascularization of tissue adjacent to and including the gene therapy vector transfected or infected cells after those cells are transplanted. Various aspects of the gene therapy vector andmethod are discussed below. Although each parameter is discussed separately, thegene therapy vector and method comprise combinations of the parameters set forth below to evoke neovascularization. Accordingly, any combination of parameters can be used according to the gene therapy vector and the method. A “gene therapy vector” is thus any molecule or composition that has the ability to carry a heterologous nucleic acid sequence into a suitable host cell where synthesis of the encoded protein takes place. Typically, a gene therapy vector is a nucleic acid molecule that has been engineered, using recombinant DNA techniques that are known in the art, to incorporate the heterologous nucleic acid sequence. Desirably, the gene therapy vector is comprised of DNA. Examples of suitable DNA-based gene therapy vectors include plasmids and viral vectors. However, gene therapy vectors that are not based on nucleic acids, such as liposomes, are also known and used in the art. The gene therapy vector can be based on a single type of nucleic acid (e.g., a plasmid) or non-nucleic acid molecule (e.g., a lipid or a polymer). The gene therapy vector can be integrated into the host cell genome, or can be present in the host cell in the form of an episome. Gene delivery vectors within the scope of the disclosure include, but are not limited to, isolated nucleic acid, e.g., plasmid-based vectors which may be extrachromosomally maintained, and viral vectors, e.g., recombinant adenovirus, retrovirus, lentivirus, herpesvirus, poxvirus, papilloma virus, or adeno-associated virus, including viral and non-viral vectors which are present in liposomes, e.g., neutral or cationic liposomes, such as DOSPA / DOPE, DOGS / DOPE or DMRIE / DOPE liposomes, and / or associated with other molecules such as DNA-anti-DNA antibody-cationic lipid (DOTMA / DOPE) complexes. Exemplary viral gene delivery vectors are described below. Gene delivery vectors may be administered via any route including, but not limited to, intracranial, intrathecal, intramuscular, buccal, rectal, intravenous or intracoronary administration, and transfer to cells may be enhanced using electroporation and / or iontophoresis, and / or scaffolding such as extracellular matrix or hydrogels, e.g., a hydrogel patch. In one embodiment, the gene therapy vector is a viral vector. Suitable viral vectors include, for example, retroviral vectors, lentivirus vectors, herpes simplex virus(HSV)-based vectors, parvovirus-based vectors, e.g., adeno-associated virus (AAV)-based vectors, AAV-adenoviral chimeric vectors, and adenovirus-based vectors. These viral vectors can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., Molecular Cloning, a Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001), and Ausubel et al., CurrentProtocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons,New York, N.Y. (1994). Thus, the viral vector can be any suitable viral vector. Suitable viral vectors include, but are not limited to, reoviruses, adenoviruses, adeno-associated viruses, papovaviruses, parvoviruses, picomaviruses, and enteroviruses of any suitable origin(e.g., of animal origin (e.g., avian or mammalian) and desirably of human origin). Othersuitable viral vectors are known in the art and are well characterized. Examples of such viral vectors are described in, for example, Fields et al., VIROLOGY Lippincott-Raven (3rd ed. (1996) and 4th ed. (2000)); ENCYCLOPEDIA OF VIROLOGY, R. G. Webster et al., eds., Academic Press (2nd ed., 1999); FUNDAMENTAL VIROLOGY, Fields et al., eds., Lippincott-Raven (3rd ed., 1995); Levine, “Viruses,” Scientific American Library No.37 (1992); MEDICAL VIROLOGY, D. O. White et al., eds., Academic Press (2nd ed. 1994); and INTRODUCTION TO MODERN VIROLOGY, Dimock, N. J. et al., eds., Blackwell Scientific Publications, Ltd. (1994). T viral vector may be derived from, or based on, a virus that normally infects animals, such as mammals (such as humans). Adenoviral (Ad) vectors based on human or non-human primate adenoviruses may be used as viral vectors. In one embodiment, the gene therapy vector is a non-integrating viral vector, e.g., Ad, AAV, integration-deficient lentiviral vectors (IDLVs), poxviral and others. Retroviral vectors Retroviral vectors exhibit several distinctive features including their ability to stably and precisely integrate into the host genome providing long-term transgene expression. These vectors can be manipulated ex vivo to eliminate infectious gene particles to minimize the risk of systemic infection and patient-to-patient transmission. Pseudotyped retroviral vectors can alter host cell tropism. Lentiviruses Lentiviruses are derived from a family of retroviruses that include human immunodeficiency virus and feline immunodeficiency virus. However, unlike retroviruses that only infect dividing cells, lentiviruses can infect both dividing and nondividing cells. Although lentiviruses have specific tropisms, pseudotyping the viral envelope with vesicular stomatitis virus yields virus with a broader range (Schnepp et al., Meth. Mol. Med., 69:427 (2002)). In one embodiment, lentiviral vectors may be employed. These vectors do not encode any viral product, as the viral proteins are provided in trans from several packaging plasmids to split the original viral genome. Accessory genes, often responsible for pathogenic features, have been progressively removed from theproduction system. Vectors have also been made self-inactivating (SIN) by deleting thetranscriptional promoter / enhancer from the 3’ LTR in the transfer plasmid; this deletion is copied onto the 5’ end of the vector during the reverse transcription cycle, abolishing expression from the viral LTR. SIN vectors are therefore dependent on an internal promoter to provide transgenic expression40. Additionally, high-efficiency lentiviraltransduction can be achieved with IDLVs, produced through the use of integrasemutations that specifically prevent proviral integration, resulting in the generation of increased levels of circular vector episomes. Lacking replication signals, lentiviral episomes mediate transient transduction in dividing cells and stable expression in quiescent cells. It is also possible to use retroviral vectors for so-called retrovirusparticle-mediated mRNA transfer (RMT), whereby vector mutants unable to startreverse transcription are instead transiently translated, and lentiviral vectors for protein delivery. Adenoviral vectors Adenoviral vectors may be rendered replication-incompetent by deleting the early (E1A and E1B) genes responsible for viral gene expression from the genome and are stably maintained into the host cells in an extrachromosomal form. These vectors have the ability to transfect both replicating and nonreplicating cells and, in particular, these vectors have been shown to efficiently infect cardiac myocytes in vivo, e.g., after direction injection or perfusion. Adenoviral vectors have been shown to result in transient expression of therapeutic genes in vivo, peaking at 7 days and lasting approximately 4 weeks. In addition, adenoviral vectors can be produced at very high titers, allowing efficient gene therapy with small volumes of virus. Adenovirus vector features include efficient delivery to dividing and non-dividing cells, retention as non-integrated nuclear linear episomes, high but transient, and a capacity of ~8 kb. Adenoviruses are a family of DNA viruses with an icosahedral, 70-100nm in diameter, non-enveloped capsid engulfing a double-stranded ds) DNA genome. These viruses can infect quiescent and dividing cells and replicate in the cell nucleus. Human Ad serotypes from a range of >50 Ad subdivisions / clades, with a typicalAd5 vector genome of ~36kb encoding genes that are expressed before (Early, E) and after (Late, L) viral replication. Early transcription units encode proteins required for viral transactivation and host-virus interactions. Non-human primate (NHP) adenoviruses from chimpanzees, bonobos and gorillas and various other species may be employed in the methods. Exemplary non-human including simian, e.g., gorilla, chimpanzee, and rhesus, adenoviruses include but are not limited to GC44, GC45, GC46, Pan5, Pan6, Pan7, Pan9, GRAd, AdC7, AdC21, AdC6, SAdV-11, SAdV-16, PanAd3, ChAd23, ChAd24, sAd16, sAd19, ChAdOx1, AdC68 sAd33, RhAd51, RhAd52 or RhAd53, as well as adenoviruses disclosed in Abbink et al. (J. Virol., 89:1512 (2015)), the disclosure of which is incorporated by reference herein. Conventional Ad vectors are constructedby substituting the E1 region of the adenovirus genome with the transgene cassette ofinterest [E1-]. Adeno-associated virus vectors Recombinant adeno-associated viruses (rAAV) are derived from nonpathogenic parvoviruses, and produce transgene expression lasting months to years in mostsystems. Moreover, like adenovirus, adeno-associated virus vectors also have thecapability to infect replicating and nonreplicating cells and are believed to be nonpathogenic to humans. Plasmid DNA vectors Plasmid DNA is often referred to as "naked DNA" to indicate the absence of amore elaborate packaging system. Direct injection of plasmid DNA to myocardial cellsin vivo has been accomplished. Plasmid-based vectors are relatively nonimmunogenic and nonpathogenic, with the potential to stably integrate in the cellular genome, resulting in long-term gene expression in postmitotic cells in vivo. For example, expression of secreted angiogenesis factors after muscle injection of plasmid DNA, despite relatively low levels of focal transgene expression, has demonstrated significant biologic effects in animal models and appears promising clinically (Isner, Nature, 415:234 (2002)). Furthermore, plasmid DNA is rapidly degraded in the blood stream; therefore, the chance of transgene expression in distant organ systems is negligible. Plasmid DNA may be delivered to cells as part of a macromolecular complex, e.g., a liposome or DNA-protein complex, and delivery may be enhanced using techniques including electroporation. Poxviral vectors, including vaccinia Poxviral vectors features include large- capacity dsDNA viruses (>25 kb of foreign DNA) and transient expression of proteins. Poxviruses are members of the family Poxviridae. They are dsDNA viruses about 200- 400n min length with a genome of about 190kb, which is flanked by ~10kb ITRs, and exist in two forms: an intracellular naked virion (INV) and an extracellular enveloped virion (EEV). Transcription and DNA replication occur in the cytoplasm, where the progeny DNA is generated by the synthesis and resolution of large concatemeric molecules. Recombinant poxviruses have the transgene of interest commonly inserted by homologous recombination and driven by a poxviral promoter rather than a constitutive viral or mammalian promoter, since they are cytoplasmatic viruses and encode their own RNA polymerase. Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox. Recombinant MVAs (rMVAs) can be used for protein production and as vaccines against infectious diseases, cancer and other pathologies64. Other non-integrating viral vector systems include herpes virus vectors, and particularly those based on HSV-1. Sendai virus, an RNA virus with no risk of genomic integration that can infect a wide range of cell types including HSPC, may also be employed. Other DNA molecules for gene delivery include minicircle DNA, mini-intronicplasmids and closed-ended linear duplex (CELiD). In addition to DNA, mRNA can alsobe delivered using non-viral vectors to provide short-term transgene expression. In the case of mRNA, it only needs to enter the cytoplasm to function, nuclear entry is removed as a significant barrier to function. The transient expression obtained with mRNA delivery is useful where expression is needed for only a short period of time. Anumber of non-viral methods for nucleic acid delivery have been developed, which canbe classified as physical or chemical. Physical methods include the use of ultrasound or electrical currents to temporarily increase the permeability of target cells (sonoporation and electroporation, respectively), direct injection of DNA into single cells, ballistic propulsion of DNA-coated particles and hydrodynamic gene delivery involvingthe rapid injection of a large volume of DNA solution (8-10% of body weight). Genedelivery by physical methods is fairly simple but offers no protection from nucleases for the nucleic acid. In contrast, chemical carriers typically encapsulate nucleic acids thereby protecting the payload from nucleases. Chemical gene delivery vectors usually employ a cationic species to condense the anionic nucleic acids and in the process form nanoparticles for delivery. Cationic liposomes have been extensively studied and are among the most widely used non-viral vectors. Later, addition of cationic polymers (producing so-called lipopolyplex) was shown to enhance gene delivery. Mechanistically, the liposome likely provides the mechanism for endosomal escape whilst the polymer enables efficient condensation and packaging of the nucleic acid therefore forming small, stable, discrete and homogenous nanoparticles. Further attempts at improving non-viral formulations have been made with the addition of components to improve bioavailability in vivo through shielding of complexes using polyethylene glycols, to enhance cell-specific targeting using targeting moieties, to aid endosomal escape using fusogenic lipids or pH sensitive polymers, and to improve nuclear entry using nuclear targeting sequences or nuclear localization signal- containing peptides. Electroporation technologies like nucleofection mediate efficient delivery of DNA and mRNA. Exemplary Proteins Exemplary proteins that may be expressed from a gene therapy vector are disclosed below. The VEGF-A (sometimes referred to as “VEGF-1”) gene contains 8 exons and 7 introns that, by alternative splicing, can form at least six isoforms of the protein. The longest protein isoform is VEGF206, whose mRNA contains the entirety of all eight exons encoding a pre-protein of 232 amino acids, which is processed to the mature form of 206 amino acids. Alternative splicing to produce the different isoforms is focused around exons 6, 7, and 8. The VEGF121 isoform results from joining the splice donor at the end of exon 5 directly to the splice acceptor in exon 8, thereby completely eliminating exons 6 and 7. Exon 6 is especially complex with three different potentialsplice donors which can ligate to exon 7, resulting in the VEGF206, VEGF189, andVEGF183 isoforms. The 3′ non-translated end of the gene contains regulatory elements that increase mRNA half-life in response to ischemia. Table 1 Isoforms of human VEGF-A sequence *All isoforms contain exons 1-5 and 8, except VEGF-A165b, which contains an alternative exon 8. The significance of the VEGF isoforms is in their different biological activities. First, the different isoforms have different affinities for the VEGF receptors. At leastthree VEGF receptors (fltl, flkl / KDR, and neuropilin) are known, which are found indifferent cell types and at different times during development. Fltl mediates cell migration, while KDR is required for the proliferative effects of VEGF (see, e.g., Barleon et al., Blood, 87, 3336-3343 (1996)). While VEGF165 has approximately equal affinity to the flkl / KDR receptor and the fltl receptor, VEGF 121 has a much lower affinity for fltl and binds primarily to KDR (see, e.g., Keyt et al., J. Biol. Chem, 271, 7788-7795 (1996)). Thus, VEGF121 is expected to be biologically inactive in tissues lacking fltl. In the same way, neuropilin is believed to enhance the interaction of VEGF165 with KDR (but not fltl), but has no effect on the binding of VEGF121 to KDR (see, e.g., Gitay- Goren et al., J. Biol. Chem., 271, 5519-5523 (1996), and Park et al., J. Biol.Chem., 269, 25646-25654 (1994)). Second, the different VEGF isoforms differ in theirability to bind heparin and other negatively charged cell matrix components. VEGF121 is missing the basic domains located in exons 6 and 7 which determine interaction with heparin. The presence of heparin can modify both the affinity of the VEGF for its receptors and the residency time in tissue (see, e.g., Keyt et al. (1996), supra, andCohen et al. (1995), supra). The heparin binding isoforms, such as VEGF165 andVEGF189, will bind extracellular matrix strongly and can be released as biologically active peptides by proteases such as plasmin (see, e.g., Keyt et al. (1996), supra, Athanassiades et al., Bio. Reprod., 59, 643-654 (1998), and Terman et al., Growth Factors, 11, 187-195 (1994)). The biological significance of the different properties of VEGF isoforms is proven by the phenotype of mice which are unable to make the heparin binding isoform VEGF164 / 188 (note that the mice VEGF isoforms are one amino acid shorter than the human homologues) (see, e.g., Carmeliet et al., Nat. Med., 5, 495-502 (1999)). Complete deletion of only the VEGF gene is lethal to a mouse embryo even when onlyone of the two alleles is deleted (see, e.g., Carmeliet et al., Nature, 380, 435-439(1996)). However, mice can be made with small genomic deletions which encompass exons 6 and 7, thereby making VEGF120 the only isoform that can be produced (see, e.g., Carmeliet et al. (1999), supra). Homozygote VEGF120 knockout mice are lethal neonatally and suffer from impaired myocardial angiogenesis, which results in decreased contractility and ischemic cardiomyopathy. Thus, the developmental roles of VEGF can be furnished by VEGF120 while the postnatal development of the blood supply, especially to cardiac muscle, depends on the VEGF164 / VEGF188 isoforms. This evidence supports the contention that different therapeutic effects might be expected from the production of different isoforms or mixtures of isoforms of VEGF delivered by gene therapy. Exemplary VEGF sequences include but are not limited to: VEGF-121: (With signal sequence = 147 aa) MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPI ETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQG QHIGEMSFLQHNKCECRPKKDRARQEKCDKPRR (SEQ ID NO:7), a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:7; VEGF145 10 MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPI ETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQG QHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVCDKPR R (SEQ ID NO:8), a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or 15 a portion thereof with the activity of SEQ ID NO:8; VEGF165 (with signal sequence = 191 aa) MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPI ETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQG QHIGEMSFLQHNKCECRPKKDRARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDS 20RCKARQLELNERTCRCDKPRR (SEQ ID NO:9), a polypeptide with at least 80%, 82%,84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:9; VEGF189 (with signal sequence = 215 aa) MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPI 25ETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVPCGP CSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR (SEQ ID NO:10), a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion 30thereof with the activity of SEQ ID NO:10;VEGF183 MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPI ETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQG QHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRPCGPCSERRKH 35 LFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR (SEQ ID NO:11), a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:11; or a VEGF encoded by 40 ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCA CCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCA TCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCG AGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAG CCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTG GAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAAC CTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGA ATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAAATGTGACAAGCCGAGGCGG TGA (SEQ ID NO:12); ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCA CCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCA 10 TCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCG AGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAG CCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTG GAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAAC CTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGA 15 ATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAAAAAATCAGTTCGAGGAAAGG GAAAGGGGCAAAAACGAAAGCGCAAGAAATCCCGGTATAAGTCCTGGAGCGTATG TGACAAGCCGAGGCGGTGA (SEQ ID NO:13); ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCA CCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCA 20TCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCGAGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAG CCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTG GAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAAC CTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGA 25ATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACGTGTAAATGTTCCTGCAA AAACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACGAACGTACTTGC AGATGTGACAAGCCGAGGCGGTGA (SEQ ID NO:14); ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCA 30CCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCATCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCG AGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAG CCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTG GAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAAC 35 CTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGA ATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAAAAAATCAGTTCGAGGAAAGG GAAAGGGGCAAAAACGAAAGCGCAAGAAATCCCGTCCCTGTGGGCCTTGCTCAGA GCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACGTGTAAATGTTCCTGCAAAA ACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACGAACGTACTTGCAG 40 ATGTGACAAGCCGAGGCGGTGA (SEQ ID NO:15); ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCA CCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCA TCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCG AGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAG CCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTG GAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAAC CTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGA ATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAAAAAATCAGTTCGAGGAAAGG GAAAGGGGCAAAAACGAAAGCGCAAGAAATCCCGGTATAAGTCCTGGAGCGTTCC CTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACG TGTAAATGTTCCTGCAAAAACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTT AAACGAACGTACTTGCAGATGTGACAAGCCGAGGCGGTGA (SEQ ID NO:16); or ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCA CCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCA TCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCG AGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAG CCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTG GAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAAC CTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGA ATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAAAAAATCAGTTCGAGGAAAGG GAAAGGGGCAAAAACGAAAGCGCAAGAAATCCCGGTATAAGTCCTGGAGCGTGTA CGTTGGTGCCCGCTGCTGTCTAATGCCCTGGAGCCTCCCTGGCCCCCATCCCTGT GGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACGTGTA AATGTTCCTGCAAAAACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAAC GAACGTACTTGCAGATGTGACAAGCCGAGGCGGTGA (SEQ ID NO:17). Other exemplary proteins for use in the vectors include but are not limited to: VEGFC, VEGFD, ANGPT1, ANGPT2, PDGFA, PDGFB, PLGF, THPO, HGF, FGF1, FGF2, TGFB, TNFA, CXCL2, CXCL8, CCL2, IL6, IL8, IL22, or EDN1. An exemplary VEGFC has MHLLGFFSVACSLLAAALLPGPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEE QLRSVSSVDELMTVLYPEYWKMYKCQLRKGGWQHNREQANLNSRTEETIKFAAAHY NTEILKSIDNEWRKTQCMPREVCIDVGKEFGVATNTFFKPPCVSVYRCGGCCNSEGLQ CMNTSTSYLSKTLFEITVPLSQGPKPVTISFANHTSCRCMSKLDVYRQVHSIIRRSLPAT LPQCQAANKTCPTNYMWNNHICRCLAQEDFMFSSDAGDDSTDGFHDICGPNKELDEE TCQCVCRAGLRPASCGPHKELDRNSCQCVCKNKLFPSQCGANREFDENTCQCVCKR TCPRNQPLNPGKCACECTESPQKCLLKGKKFHHQTCSCYRRPCTNRQKACEPGFSY SEEVCRCVPSYWKRPQMS (SEQ ID NO:18), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:18. An exemplary VEGFD has MYREWVVVNVFMMLYVQLVQGSSNEHGPVKRSSQSTLERSEQQIRAASSLEELLRIT HSEDWKLWRCRLRLKSFTSMDSRSASHRSTRFAATFYDIETLKVIDEEWQRTQCSPR ETCVEVASELGKSTNTFFKPPCVNVFRCGGCCNEESLICMNTSTSYISKQLFEISVPLT SVPELVPVKVANHTGCKCLPTAPRHPYSIIRRSIQIPEEDRCSHSKKLCPIDMLWDSNK CKCVLQEENPLAGTEDHSHLQEPALCGPHMMFDEDRCECVCKTPCPKDLIQHPKNCS CFECKESLETCCQKHKLFHPDTCSCEDRCPFHTRPCASGKTACAKHCRFPKEKRAAQ GPHSRKNP (SEQ ID NO:19), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid 10 sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:19. An exemplary ANGPT1 has MTVFLSFAFLAAILTHIGCSNQRRSPENSGRRYNRIQHGQCAYTFILPEHDGNCRESTT DQYNTNALQRDAPHVEPDFSSQKLQHLEHVMENYTQWLQKLENYIVENMKSEMAQIQ QNAVQNHTATMLEIGTSLLSQTAEQTRKLTDVETQVLNQTSRLEIQLLENSLSTYKLEK 15 QLLQQTNEILKIHEKNSLLEHKILEMEGKHKEELDTLKEEKENLQGLVTRQTYIIQELEKQ LNRATTNNSVLQKQQLELMDTVHNLVNLCTKEGVLLKGGKREEEKPFRDCADVYQAG FNKSGIYTIYINNMPEPKKVFCNMDVNGGGWTVIQHREDGSLDFQRGWKEYKMGFGN PSGEYWLGNEFIFAITSQRQYMLRIELMDWEGNRAYSQYDRFHIGNEKQNYRLYLKGH TGTAGKQSSLILHGADFSTKDADNDNCMCKCALMLTGGWWFDACGPSNLNGMFYTA 20GQNHGKLNGIKWHYFKGPSYSLRSTTMMIRPLDF(SEQ ID NO:20), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:20. An exemplary ANGPT2 has 25MWQIVFFTLSCDLVLAAAYNNFRKSMDSIGKKQYQVQHGSCSYTFLLPEMDNCRSSSSPYVSNAVQRDAPLEYDDSVQRLQVLENIMENNTQWLMKLENYIQDNMKKEMVEIQQ NAVQNQTAVMIEIGTNLLNQTAEQTRKLTDVEAQVLNQTTRLELQLLEHSLSTNKLEKQI LDQTSEINKLQDKNSFLEKKVLAMEDKHIIQLQSIKEEKDQLQVLVSKQNSIIEELEKKIVT ATVNNSVLQKQQHDLMETVNNLLTMMSTSNSAKDPTVAKEEQISFRDCAEVFKSGHT 30TNGIYTLTFPNSTEEIKAYCDMEAGGGGWTIIQRREDGSVDFQRTWKEYKVGFGNPSGEYWLGNEFVSQLTNQQRYVLKIHLKDWEGNEAYSLYEHFYLSSEELNYRIHLKGLTGT AGKISSISQPGNDFSTKDGDNDKCICKCSQMLTGGWWFDACGPSNLNGMYYPQRQN TNKFNGIKWYYWKGSGYSLKATTMMIRPADF (SEQ ID NO:21), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 35 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:21. An exemplary PDGFA has MRTLACLLLLGCGYLAHVLAEEAEIPREVIERLARSQIHSIRDLQRLLEIDSVGSEDSLDT SLRAHGVHATKHVPEKRPLPIRRKRSIEEAVPAVCKTRTVIYEIPRSQVDPTSANFLIWP 40 PCVEVKRCTGCCNTSSVKCQPSRVHHRSVKVAKVEYVRKKPKLKEVQVRLEEHLECA CATTSLNPDYREEDTGRPRESGKKRKRKRLKP (SEQ ID NO:22), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:22. An exemplary PDGFB has MNRCWALFLSLCCYLRLVSAEGDPIPEELYEMLSDHSIRSFDDLQRLLHGDPGEEDGA ELDLNMTRSHSGGELESLARGRRSLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANF LVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHL ACKCETVAAARPVTRSPGGSQEQRAKTPQTRVTIRTVRVRRPPKGKHRKFKHTHDKT ALKETLG 10 (SEQ ID NO:23), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:23. An exemplary PLGF has MPVMRLFPCFLQLLAGLALPAVPPQQWALSAGNGSSEVEVVPFQEVWGRSYCRALE 15RLVDVVSEYPSEVEHMFSPSCVSLLRCTGCCGDENLHCVPVETANVTMQLLKIRSGDRPSYVELTFSQHVRCECRPLREKMKPERRRPKGRGKRRREKQRPTDCHLCGDAVPR R (SEQ ID NO:24), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid 20 sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:24. An exemplary THPO has MELTELLLVVMLLPTARLTLSSPAPPACDLRVLSKLLRDSHVLHSKLSQCPEVHPLPTP VLLPAVDFSLGEWKTQMEETKAQDILGAVTLLLEGVMAARGQLGPTCLSSLLGQLSEQ 25 VRLLLGALQSLLGTQLPPQGRTTAHKDPNAIFLSFQHLLRGKVRFLMLVGGSTLCVRR APPTTAVPSRTSLVLTLNELPNRTSGLLETNFTASARTTGSGLLKWQQGFRAKIPGLLN QTSRSLDQIPGYLNRIHELLNGTRGLFPGPSRRTLGAPDISSETSDTGSLPPNLQPGYS PSPTHPPTGQYTLFPLPPTLPTPVVQLHPLLPDPSAPTPTPTSPLLNTSYTHCQNLSQE G 30(SEQ ID NO:25), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%,85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:25. An exemplary HGF has MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTK 35 KVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLY ENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCR NPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQR WDHQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCAD NTMNDTDVPLETTECIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKC 40 KDLRENYCRNPDGSESPWCFTTDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMGN LSQTRSGLTCSMWDKNMEDLHRHIFWEPDASKLNENYCRNPDDDAHGPWCYTGNPL IPWDYCPISRCEGDTTPTIVNLDHPVISCAKTKQLRVVNGIPTRTNIGWMVSLRYRNKHI CGGSLIKESWVLTARQCFPSRDLKDYEAWLGIHDVHGRGDEKCKQVLNVSQLVYGPE GSDLVLMKLARPAVLDDFVSTIDLPNYGCTIPEKTSCSVYGWGYTGLINYDGLLRVAHL YIMGNEKCSQHHRGKVTLNESEICAGAEKIGSGPCEGDYGGPLVCEQHKMRMVLGVI VPGRGCAIPNRPGIFVRVAYYAKWIHKIILTYKVPQS (SEQ ID NO:26), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:26. An exemplary FGF1 has MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTK KVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLY ENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCR NPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQR WDHQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCAD NTMNDTDVPLETTECIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGSESPWCFTTDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMGNLSQTRSGLTCSMWDKNMEDLHRHIFWEPDASKLNENYCRNPDDDAHGPWCYTGNPL IPWDYCPISRCEGDTTPTIVNLDHPVISCAKTKQLRVVNGIPTRTNIGWMVSLRYRNKHI CGGSLIKESWVLTARQCFPSRDLKDYEAWLGIHDVHGRGDEKCKQVLNVSQLVYGPE GSDLVLMKLARPAVLDDFVSTIDLPNYGCTIPEKTSCSVYGWGYTGLINYDGLLRVAHL YIMGNEKCSQHHRGKVTLNESEICAGAEKIGSGPCEGDYGGPLVCEQHKMRMVLGVI VPGRGCAIPNRPGIFVRVAYYAKWIHKIILTYKVPQS (SEQ ID NO:27), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:27. An exemplary FGF2 has MVGVGGGDVEDVTPRPGGCQISGRGARGCNGIPGAAAWEAALPRRRPRRHPSVNP RSRAAGSPRTRGRRTEERPSGSRLGDRGRGRALPGGRLGGRGRGRAPERVGGRGR GRGTAAPRAAPAARGSRPGPAGTMAAGSITTLPALPEDGGSGAFPPGHFKDPKRLYC KNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERGVVSIKGVCANRYLAMKEDGRLL ASKCVTDECFFFERLESNNYNTYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILFLP MSAKS (SEQ ID NO:28), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:28. An exemplary TGFB has MPPSGLRLLPLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLAS PPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHN EIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNN SWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPG ASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS (SEQ ID NO:29), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:29. An exemplary TNFA has MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR EEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGV ELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPC QRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL (SEQ ID NO:30), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:30. An exemplary CXCL2 has MARATLSAAPSNPRLLRVALLLLLLVAASRRAAGAPLATELRCQCLQTLQGIHLKNIQSV KVKSPGPHCAQTEVIATLKNGQKACLNPASPMVKKIIEKMLKNGKSN (SEQ ID NO:31), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:31. An exemplary CXCL8 has MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPFHPKFIKELRVIESGPHC ANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS (SEQ ID NO:32), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:32. An exemplary CCL2 has MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPK EAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT (SEQ ID NO:33), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:33. An exemplary IL6 has MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRY ILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGL LEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLLTKL QAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM (SEQ ID NO:34), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:34, An exemplary IL22 has MAALQKSVSS FLMGTLATSC LLLLALLVQG GAAAPISSHC RLDKSNFQQP YITNRTFMLA KEASLADNNT DVRLIGEKLF HGVSMSERCY LMKQVLNFTL EEVLFPQSDR FQPYMQEVVP FLARLSNRLS TCHIEGDDLH IQRNVQKLKD TVKKLGESGE IKAIGELDLL FMSLRNACI (SEQ ID NO:35), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:35. An exemplary EDN1 has MDYLLMIFSL LFVACQGAPE TAVLGAELSA VGENGGEKPT PSPPWRLRRS KRCSCSSLMD KECVYFCHLD IIWVNTPEHV VPYGLGSPRS KRALENLLPT KATDRENRCQ CASQKDKKCW NFCQAGKELR AEDIMEKDWN NHKKGKDCSK LGKKCIYQQL VRGRKIRRSS EEHLRQTRSE TMRNSVKSSF HDPKLKGKPS RERYVTHNRA HW (SEQ ID NO:36), or is an isoform thereof, a polypeptide with at least 80%, 82%, 84%, 85%, 86%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity thereto, or a portion thereof with the activity of SEQ ID NO:36. Variants of the sequences disclosed above are envisioned. For example, a variant may include one or more conservative amino acid substitutions-that is, for example, aspartic-glutamic as acidic amino acids; lysine / arginine / histidine as polar basic amino acids; leucine / isoleucine / methionine / valine / alanine / proline / glycine non- polar or hydrophobic amino acids; serine / threonine as polar or hydrophilic amino acids. Conservative amino acid substitution also includes groupings based on side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl sidechains is serine and threonine; a group of amino acids having amide-containing sidechains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur- containing side chains is cysteine and methionine. For example, it is reasonable to expect that replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the properties of the resulting peptide, polypeptide or fusion polypeptide. Whether an amino acid change results in a functional peptide, polypeptide or fusion polypeptide can readily be determined by assaying the specific activity of the peptide, polypeptide or fusion polypeptide. Amino acid substitutions falling within the scope of the disclosure, are, in general, accomplished by selecting substitutions that do not differ significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties: (1) hydrophobic: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu; (4) basic: asn, gln, his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromatic; trp, tyr, phe. The disclosure also envisions a peptide, polypeptide or fusion polypeptide with non-conservative substitutions. Non-conservative substitutions entail exchanging a member of one of the classes described above for another. Suitable expression constructs include those designed for propagation and expansion or for expression or both. Examples of suitable expression constructs include plasmids, phagemids, cosmids, viruses, and other vehicles derived from viral or bacterial sources. Any of these expression constructs can be manipulated to include anucleic acid sequence and can be prepared using standard recombinant DNAtechniques described in, e.g., Sambrook et al., Molecular Cloning, a Laboratory Manual, 2d edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (1994). Plasmids are genetically engineered circular double-stranded DNA moleculesand can be designed to contain an expression cassette comprising a nucleic acid molecule encoding VEGF. By complexing the plasmid with liposomes, the efficiency of gene transfer in general is improved. While the liposomes used for plasmid-mediated gene transfer strategies have various compositions, they are typically synthetic cationiclipids. Advantages of plasmid-liposome complexes include their ability to transfer largenucleic acid sequences and their relatively low immunogenicity. While plasmids are suitable for use in the disclosure, the expression construct may be a viral vector. Exemplary Adenovirus Vectors Adenovirus is a 36 kb double-stranded DNA virus that efficiently transfers DNA in vivo to a variety of different target cell types. The Ad vector can be produced in high titers and can efficiently transfer DNA to replicating and non-replicating cells. The Ad vector genome can be generated using any species, strain, subtype, mixture of species, strains, or subtypes, or chimeric adenovirus as the source of vector DNA. Adenoviral stocks that can be employed as a source of adenovirus can be amplified from the adenoviral serotypes 1 through 51, which are currently available from the American Type Culture Collection (ATCC, Manassas, Va.), or from any other serotype of adenovirus available from any other source. For instance, an adenovirus can be of subgroup A (e.g., serotypes 12, 18, and 31), subgroup B (e.g., serotypes 3, 7, 11, 14, 16, 21, 34, and 35), subgroup C (e.g., serotypes 1, 2, 5, and 6), subgroup D (e.g., serotypes 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, and 42-47), subgroup E (serotype 4), subgroup F (serotypes 40 and 41), or any other adenoviral serotype. Given that the human adenovirus serotype 5 (Ad5) genome has been completely sequenced, the adenoviral vector is described herein with respect to the Ad5 serotype. The Ad vector can be any adenoviral vector capable of growth in a cell, which is in some significant part (although not necessarily substantially) derived from or based upon the genome of an adenovirus. The Ad vector can be based on the genome of any suitable wild-type adenovirus. The Ad vector may be derived from the genome of a wild- type adenovirus of group C, especially of serotype 2 or 5. Ad vectors are well known in the art and are described in, for example, U.S. Pat. Nos.5,559,099, 5,712,136, 5,731,190, 5,837,511, 5,846,782, 5,851,806, 5,962,311, 5,965,541, 5,981,225, 5,994,106, 6,020,191, and 6,113,913, International Patent Applications WO 95 / 34671, WO 97 / 21826, and WO 00 / 00628, and Thomas Shenk, “Adenoviridae and their Replication,” and M. S. Horwitz, “Adenoviruses,” Chapters 67 and 68, respectively, in Virology, B. N. Fields et al., eds., 3d ed., Raven Press, Ltd., New York (1996). The Ad vector may be replication-deficient. By “replication-deficient” is meantthat the Ad vector comprises a genome that lacks at least one replication-essential genefunction. A deficiency in a gene, gene function, or gene or genomic region, as used herein, is defined as a deletion of sufficient genetic material of the viral genome to impair or obliterate the function of the gene whose nucleic acid sequence was deleted in whole or in part. Replication-essential gene functions are those gene functions that arerequired for replication (i.e., propagation) of a replication-deficient Ad vector.Replication-essential gene functions are encoded by, for example, the adenoviral early regions (e.g., the E1, E2, and E4 regions), late regions (e.g., the L1-L5 regions), genes involved in viral packaging (e.g., the IVa2 gene), and virus-associated RNAs (e.g., VA- RNA I and / or VA-RNA II). The replication-deficient Ad vector may comprise anadenoviral genome deficient in two or more gene functions required for viral replication.The two or more regions of the adenoviral genome may be selected from the group consisting of the E1, E2, and E4 regions. The replication-deficient adenoviral vector may comprise a deficiency in at least one replication-essential gene function of the E1 region (denoted an E1-deficient adenoviral vector). The E1 region of the adenoviral genome comprises the E1A region and the E1B region. The E1A and E1B regions comprise nucleic acid sequences coding for multiple peptides by virtue of RNA splicing. A deficiency of a gene function encoded by either or both of the E1A and / or E1B regions of the adenoviral genome (e.g., a peptide that performs a function required for replication) is considered a deficiency of a gene function of the E1 region in the context of the disclosure. In addition to such a deficiency in the E1 region, the recombinant adenovirus also can have a mutation in the major late promoter (MLP), as discussed in International Patent Application WO 00 / 00628. The vector may be deficient in at least one replication-essential gene function of the E1 region and at least part of the nonessential E3 region (e.g., an Xba I deletion of the E3 region) (denoted an E1 / E3- deficient adenoviral vector). The adenoviral vector may be “multiply deficient,” meaning that the adenoviral vector is deficient in one or more gene functions required for viral replication in each of two or more regions of the adenoviral genome. For example, the aforementioned E1- deficient or E1 / E3-deficient Ad vector can be further deficient in at least one replication- essential gene function of the E4 region (denoted an E1 / E4-deficient adenoviral vector). An adenoviral vector deleted of the entire E4 region can elicit a lower host immune response. Alternatively, the Ad vector lacks replication-essential gene functions in all or part of the E1 region and all or part of the E2 region (denoted an E1 / E2-deficient adenoviral vector). Ad vectors lacking replication-essential gene functions in all or part of the E1 region, all or part of the E2 region, and all or part of the E3 region also are contemplated herein. If the Ad vector is deficient in a replication-essential gene function of the E2A region, the vector in one embodiment does not comprise a complete deletion of the E2A region, which is less than about 230 base pairs in length. Generally, the E2A region of the adenovirus codes for a DBP (DNA binding protein), a polypeptide requiredfor DNA replication. DBP is composed of 473 to 529 amino acids depending on the viralserotype. It is believed that DBP is an asymmetric protein that exists as a prolate ellipsoid consisting of a globular Ct with an extended Nt domain. Studies indicate that the Ct domain is responsible for DBP's ability to bind to nucleic acids, bind to zinc, and function in DNA synthesis at the level of DNA chain elongation. However, the Nt domainis believed to function in late gene expression at both transcriptional and post-transcriptional levels, is responsible for efficient nuclear localization of the protein, and also may be involved in enhancement of its own expression. Deletions in the Nt domain between amino acids 2 to 38 have indicated that this region is important for DBP function (Brough et al., Virology, 196, 269-281 (1993)). While deletions in the E2Aregion coding for the Ct region of the DBP have no effect on viral replication, deletionsin the E2A region which code for amino acids 2 to 38 of the Nt domain of the DBP impair viral replication. The multiply replication-deficient adenoviral vector may contain this portion of the E2A region of the adenoviral genome. In particular, for example, the desired portion of the E2A region to be retained is that portion of the E2A region of the adenoviral genome which is defined by the 5′ end of the E2A region, specifically positions Ad5(23816) to Ad5(24032) of the E2A region of the adenoviral genome of serotype Ad5. The Ad vector can be deficient in replication-essential gene functions of only the early regions of the adenoviral genome, only the late regions of the adenoviral genome, and both the early and late regions of the adenoviral genome. The adenoviral vector also can have essentially the entire adenoviral genome removed, in which case it may be desirable that at least either the viral (i.e., adenoviral) inverted terminal repeats (Ad ITRs) and one or more promoters or the Ad ITRs and a packaging signal are left intact (i.e., an adenoviral amplicon). The larger the region of the adenoviral genome that is removed, the larger the piece of exogenous nucleic acid sequence that can be inserted into the genome. For example, given that the adenoviral genome is 36 kb, by leaving the Ad ITRs and one or more promoters intact, the exogenous insert capacity of the adenovirus is approximately 35 kb. Alternatively, a multiply deficient Ad vector that contains only an Ad ITR and a packaging signal effectively allows insertion of an exogenous nucleic acid sequence of approximately 37-38 kb. Of course, the inclusion of a spacer element in any or all of the deficient adenoviral regions will decrease the capacity of the adenoviral vector for large inserts. Suitable replication-deficient Ad vectors, including multiply deficient Ad vectors, are disclosed in U.S. Pat. Nos. 5,851,806 and 5,994,106 and International Patent Applications WO 95 / 34671 and WO 97 / 21826. An adenoviral vector for use in the methods is that described in International Patent Application WO 02 / 00906. It should be appreciated that the deletion of different regions of the Ad vector can alter the immune response of a mammal exposed to the Ad vector. In particular, the deletion of different regions can reduce the inflammatory response generated by the Ad vector. Furthermore, the Ad vector's coat protein can be modified so as to decrease theAd vector's ability or inability to be recognized by a neutralizing antibody directedagainst the wild-type coat protein, as described in International Patent Application WO 98 / 40509. The adenoviral vector, when multiply replication-deficient, especially in replication-essential gene functions of the E1 and E4 regions, e.g., includes a spacerelement to provide viral growth in a complementing cell line similar to that achieved bysingly replication deficient Ad vectors, particularly an Ad vector comprising a deficiency in the E4 region. A spacer sequence is defined in the disclosure as any sequence of sufficient length to restore the size of the adenoviral genome to approximately the size of a wild-type adenoviral genome, such that the Ad vector is efficiently packaged intoviral particles. The spacer element can contain any sequence or sequences which areof the desired length. The spacer element sequence can be coding or non-coding and native or non-native with respect to the adenoviral genome, but does not restore the replication-essential function to the deficient region. The spacer can be of any suitable size, desirably at least about 15 base pairs (e.g., between about 15 base pairs and about 12,000 base pairs), about 100 base pairs to about 10,000 base pairs, about 500 base pairs to about 8,000 base pairs, about 1,500 base pairs to about 6,000 base pairs, or about 2,000 to about 3,000 base pairs. The size of the spacer is limited only by the size of the insert that the Ad vector will accommodate (e.g., approximately 38 kb). In the absence of a spacer, production of fiber protein and / or viral growth of the multiply replication-deficient Ad vector is reduced by comparison to that of a singly replication- deficient Ad vector. However, inclusion of the spacer in at least one of the deficient adenoviral regions, e.g., the E4 region, can counteract this decrease in fiber protein production and viral growth. The use of a spacer in an Ad vector is described in U.S. Pat. No.5,851,806. The Ad vector may contain a packaging domain. The packaging domain can be located at any position in the adenoviral genome, so long as the adenoviral genome is packaged into adenoviral particles. The packaging domain may be located downstream of the E1 region. The packaging domain may be located downstream of the E4 region. The replication-deficient Ad vector may lacks all or part of the E1 region and the E4 region. A spacer may be inserted into the E4 region, a desired exogenous nucleic acid sequence of interest (e.g., a nucleic acid sequence encoding TNF-α) is located in the E1 region, and the packaging domain is located downstream of the E4 region. By relocating the packaging domain, the amount of potential overlap between the Ad vector and the cellular / helper virus genome used to propagate the Ad vector is reduced so as to reduce the probability of obtaining a replication-competent Ad vector. The coat proteins of the Ad vector can be manipulated to alter the binding specificity of the resulting adenoviral particle. Suitable modifications to the coat proteins include, but are not limited to, insertions, deletions, or replacements in the adenoviral fiber, penton, pIX, pIIIa, pVI, or hexon proteins, or any suitable combination thereof, including insertions of various native or non-native ligands into portions of such coatproteins. Examples of Ad vectors with modified binding specificity are described in, e.g.,U.S. Pat. Nos.5,871,727, 5,885,808, and 5,922,315. Modified Ad vector particles include those described in, for example, Wickham et al., J. Virol., 71(10), 7663-9 (1997), Cripe et al., Cancer Res., 61(7), 2953-60 (2001), van Deutekom et al., J. Gene Med., 1(6), 393-9 (1999), McDonald et al., J. Gene Med., 1(2), 103-10 (1999), Staba etal., Cancer Gene Ther., 7(1), 13-9 (2000), Wickham, Gene Ther., 7(2), 110-4 (2000),Kibbe et al., Arch. Surg., 135(2), 191-7 (2000), Harari et al., Gene Ther., 6(5), 801-7 (2000), Bouri et al., Hum Gene Ther., 10(10), 1633-40 (1999), Wickham et al., Nat. Biotechnol., 14(11), 1570-3 (1996), Wickham et al., Cancer Immunol. Immunother., 45(3-4), 149-51 (1997), and Wickham et al., Gene Ther., 2(10), 750-6(1995), and U.S. Pat. Nos.5,559,099; 5,712,136; 5,731,190; 5,770,442; 5,801,030;5,846,782; 5,962,311; 5,965,541; 6,057,155; 6,127,525; and 6,153,435; and International Patent Applications WO 96 / 07734, WO 96 / 26281, WO 97 / 20051, WO 98 / 07865, WO 98 / 07877, WO 98 / 40509, WO 98 / 54346, WO 00 / 15823, and WO 01 / 58940. Replication-deficient Ad vectors are typically produced in complementing cell lines that provide gene functions not present in the replication-deficient Ad vectors, but required for viral propagation, at appropriate levels in order to generate high titers of viral vector stock. A cell line complements for at least one and optionally all replication- essential gene functions not present in a replication-deficient adenovirus. The complementing cell line can complement for a deficiency in at least one replication- essential gene function encoded by the early regions, late regions, viral packaging regions, virus-associated RNA regions, or combinations thereof, including all adenoviral functions (e.g., to enable propagation of adenoviral amplicons, which comprise minimal adenoviral sequences, such as only Ad ITRs and the packaging signal or only Ad ITRs and an adenoviral promoter). The complementing cell line complements for a deficiency in at least one replication-essential gene function (e.g., two or more replication-essential gene functions) of the E1 region of the adenoviral genome, particularly a deficiency in a replication-essential gene function of each of the E1A and E1B regions. In addition, the complementing cell line can complement for a deficiency in at least one replication- essential gene function of the E2 (particularly as concerns the adenoviral DNA polymerase and terminal protein) and / or E4 regions of the adenoviral genome. Desirably, a cell that complements for a deficiency in the E4 region comprises the E4- ORF6 gene sequence and produces the E4-ORF6 protein. Such a cell desirably comprises at least ORF6 and no other ORF of the E4 region of the adenoviral genome. The cell line may be further characterized in that it contains the complementing genes in a non-overlapping fashion with the adenoviral vector, which minimizes, and practically eliminates, the possibility of the vector genome recombining with the cellular DNA. Accordingly, the presence of replication-competent adenoviruses (RCA) is minimized if not avoided in the vector stock, which, therefore, is suitable for certain therapeutic purposes, especially gene therapy purposes. The lack of RCA in the vector stock avoidsthe replication of the Ad vector in non-complementing cells. The construction ofcomplementing cell lines involves standard molecular biology and cell culture techniques, such as those described by Sambrook et al. (1989), supra, and Ausubel et al. (1984), supra. Complementing cell lines for producing adenoviral vectors include, but are not limited to, 293 cells (described in, e.g., Graham et al., J. Gen. Virol., 36, 59-72(1977)), PER.C6 cells (described in, e.g., International Patent Application WO97 / 00326, and U.S. Pat. Nos.5,994,128 and 6,033,908), and 293-ORF6 cells (described in, e.g., International Patent Application WO 95 / 34671 and Brough et al., J. Virol., 71, 9206-9213 (1997)). Expression Cassettes for Nucleic Acid Based Delivery The selection of an expression construct for use in the disclosure may dependon a variety of factors such as, for example, the host, immunogenicity of the expression construct, the desired duration of protein production, the target cell, and the like. As each type of expression construct has distinct properties, a researcher has the freedom to tailor the disclosure to any particular situation. Moreover, more than one type of expression construct can be used, if desired. Accordingly, a nucleic acid molecule encoding, for example, VEGF is operably linked to regulatory sequences for expression, especially a promoter. A “promoter” is a DNA sequence that directs the binding of RNA polymerase and thereby promotes RNA synthesis. A nucleic acid sequence is “operably linked” to a promoter when the promoter is capable of directing transcription of that nucleic acid sequence. A promoter can be native or non-native to the nucleic acid sequence to which it is operably linked. Any promoter (i.e., whether isolated from nature or produced by recombinant DNA or synthetic techniques) can be used in connection with the disclosure to provide for transcription of a particular nucleic acid sequence. The promoter may be capable of directing transcription in a eukaryotic (desirably mammalian) cell. The functioning of the promoter can be altered by the presence of one or more enhancers and / or silencers present on the vector. “Enhancers” are cis-acting elements of DNA that stimulate or inhibit transcription of adjacent genes. An enhancer that inhibits transcription also is termed a “silencer.” Enhancers differ from DNA-binding sites for sequence-specific DNA binding proteins found only in the promoter (which also are termed “promoter elements”) in that enhancers can function in either orientation, and over distances of up to several kilobase pairs (kb), even from a position downstream of a transcribed region. The vector may employ a viral promoter. Suitable viral promoters are known in the art and include, for instance, cytomegalovirus (CMV) promoters, such as the CMV immediate-early promoter, promoters derived from human immunodeficiency virus (HIV), such as the HIV long terminal repeat promoter, Rous sarcoma virus (RSV) promoters, such as the RSV long terminal repeat, mouse mammary tumor virus (MMTV) promoters, HSV promoters, such as the Lap2 promoter or the herpes thymidine kinase promoter (Wagner et al., PNAS, 78, 144-145 (1981)), promoters derived from SV40 or Epstein Barr virus, an adeno-associated viral promoter, such as the p5promoter, and the like. The viral promoter may be an adenoviral promoter, such as theAd2 or Ad5 major late promoter and tripartite leader, a CMV promoter, or an RSV promoter. Many of the above-described promoters are constitutive promoters. Instead of being a constitutive promoter, the promoter can be an inducible promoter, i.e., apromoter that is up- and / or down-regulated in response to appropriate signals.Examples of suitable inducible promoter systems include, but are not limited to, the IL-8 promoter, the metallothionine inducible promoter system, the bacterial lacZYA expression system, the tetracycline expression system, and the T7 polymerase system. Further, promoters that are selectively activated at different developmental stages (e.g.,globin genes are differentially transcribed from globin-associated promoters in embryosand adults) can be employed. The promoter sequence that regulates expression of the nucleic acid sequence can contain at least one heterologous regulatory sequence responsive to regulation by an exogenous agent. The regulatory sequences may be responsive to exogenous agents such as, but not limited to, drugs, hormones, or other gene products. For example, the regulatory sequences, e.g., promoter, may be responsive to glucocorticoid receptor-hormone complexes, which, in turn, enhance the level of transcription of a therapeutic peptide or a therapeutic fragment thereof. One of ordinary skill in the art will appreciate that each promoter drives transcription, and, therefore, protein expression, differently with respect to the time and amount of protein produced. For example, the CMV promoter is characterized as having peak activity shortly after transduction, i.e., about 24 hours after transduction, then quickly tapering off. On the other hand, the RSV promoter's activity increases gradually, reaching peak activity several days after transduction, and maintains a high level of activity for several weeks. Indeed, sustained expression driven by an RSV promoter has been observed in all cell types studied, including, for instance, liver cells, lung cells, spleen cells, diaphragm cells, skeletal muscle cells, and cardiac muscle cells. Thus, a promoter can be selected for use in the disclosure by matching its particular pattern of activity with the desired pattern and level of expression of a nucleic acid sequence of interest. Alternatively, a hybrid promoter can be constructed which combines the desirable aspects of multiple promoters. For example, a CMV-RSV hybrid promoter combining the CMV promoter's initial rush of activity with the RSV promoter's high maintenance level of activity may be employed. It is also possible to select a promoter with an expression profile that can be manipulated by an investigator. With respect to promoters, nucleic acid sequences, selectable markers, and the like, located on an expression construct, such elements can be present as part of a cassette, either independently or coupled. In the context of the disclosure, a “cassette” is a particular base sequence that possesses functions, which facilitate subcloning, and recovery of nucleic acid sequences (e.g., one or more restriction sites) or expression (e.g., polyadenylation or splice sites) of particular nucleic acid sequences. Construction of a nucleic acid sequence operably linked to regulatorysequences for expression is well within the skill of the art (see, for example, Sambrooket al. (1989), supra). With respect to the expression of nucleic acid sequences according to the disclosure, the ordinary skilled artisan is aware that different genetic signals and processing events control levels of nucleic acids and proteins / peptides in a cell, such as, for instance, transcription, mRNA translation, and post-transcriptionalprocessing. Transcription of DNA into RNA requires a functional promoter, as describedherein. Protein expression is dependent on the level of RNA transcription that is regulated by DNA signals, and the levels of DNA template. Similarly, translation of mRNA requires, at the very least, an AUG initiation codon, which is usually locatedwithin 10 to 100 nucleotides of the 5′ end of the message. Sequences flanking the AUGinitiator codon have been shown to influence its recognition by eukaryotic ribosomes, with conformity to a perfect Kozak consensus sequence resulting in enhanced translation (see, e.g., Kozak, J. Mol. Biol., 196, 947-950 (1987)). Also, successful expression of an exogenous nucleic acid in a cell can require post-translational modification of a resultant protein. Thus, production of a protein can be affected by the efficiency with which DNA (or RNA) is transcribed into mRNA, the efficiency with which mRNA is translated into protein, and the ability of the cell to carry out post-translational modification. These are all factors of which the ordinary skilled artisan is aware and is capable of manipulating using standard means to achieve the desired end result. Along these lines, to enhance protein production, the nucleic acid molecule may further comprise a polyadenylation site following the coding region of the nucleic acid sequence. Also, the proper transcription signals (and translation signals, where appropriate) may be correctly arranged such that the nucleic acid sequence will be properly expressed in the cells into which it is introduced. Moreover, if the nucleic acid sequence encodes a protein or peptide, which is a processed or secreted protein or acts intracellularly, e.g., the nucleic acid sequence further comprises the appropriate sequences for processing, secretion, intracellular localization, and the like. It will be appreciated that the expression construct can comprise multiple nucleic acid molecules. For example, the expression construct can comprise multiple copies of a nucleic acid molecule, each copy operably linked to a different promoter or to identical promoters. Moreover, any nucleic acid molecule described herein can be altered from its native form to increase or decrease a desired effect (e.g., to increase its therapeutic effect). For example, a cytoplasmic form of a nucleic acid molecule can be converted to a secreted form by incorporating a signal peptide into the encoded gene product. Delivery Vehicles Delivery vehicles include, for example, viral vectors, microparticles, nanoparticles, liposomes and other lipid-containing complexes, and other macromolecular complexes capable of mediating delivery of a gene to a host cell, e.g., to provide for recombinant expression of a polypeptide encoded by the gene. Vehiclescan also comprise other components or functionalities that further modulate genedelivery and / or gene expression, or that otherwise provide beneficial properties. Such other components include, for example, components that influence binding or targeting to cells (including components that mediate cell-type or tissue-specific binding); components that influence uptake of the vector by the cell; components that influencelocalization of the transferred gene within the cell after uptake (such as agentsmediating nuclear localization); and components that influence expression of the gene. Such components also might include markers, such as detectable and / or selectable markers that can be used to detect or select for cells that have taken up and are expressing the nucleic acid delivered by the vector. Such components can be providedas a natural feature of the vector (such as the use of certain viral vectors which havecomponents or functionalities mediating binding and uptake), or vectors can be modified to provide such functionalities. Selectable markers can be positive, negative or bifunctional. Positive selectable markers allow selection for cells carrying the marker, whereas negative selectable markers allow cells carrying the marker to be selectively eliminated. A variety of such marker genes have been described, including bifunctional (i.e., positive / negative) markers (see, e.g., WO 92 / 08796; and WO 94 / 28143). Such marker genes can provide an added measure of control that can be advantageous in gene therapy contexts. A large variety of such vectors are known in the art and are generally available. Vehicles within the scope of the disclosure include, but are not limited to, isolated nucleic acid, e.g., plasmid-based vectors which may be extrachromosomally maintained, and viral vectors, e.g., recombinant adenovirus, retrovirus, lentivirus, herpesvirus, poxvirus, papilloma virus, or adeno-associated virus, including viral and non-viral vectors, which are present in for example, nanoparticles or microparticles including liposomes, e.g., neutral or cationic liposomes, such as DOSPA / DOPE, DOGS / DOPE or DMRIE / DOPE liposomes, and / or associated with other molecules such as DNA-anti-DNA antibody-cationic lipid (DOTMA / DOPE) complexes. Exemplary gene viral vectors are described below. Vectors or vehicles may be administered via any route including local administration, e.g., topical, subdermal, or subcutaneous administration. Exemplary Formulations and Dosages The vehicles can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, e.g., parenterally, or by intravenous, intramuscular, topical or subcutaneous routes. In one embodiment, a sustained release formulation comprising the nucleic acid encoding a polypeptide or portion thereof, may be administered by infusion or injection. Solutions of the nucleic acid encoding the polypeptide or portion thereof, or salts thereof, can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, andmixtures thereof and in oils. Under ordinary conditions of storage and use, thesepreparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable orinfusible solutions or dispersions, optionally encapsulated in liposomes. In all cases,the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils,nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can bemaintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it may be desirable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions are prepared by incorporating the active agent in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation include vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile- filtered solutions. Useful solid carriers may include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol / glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as antimicrobial agents can be added to modify the properties for a given use. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user. The amount of the vector required for use alone or with other agents will vary with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician. The nucleic acid encoding the polypeptide or portion thereof may be conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, or conveniently 50 to 500 mg of active ingredient per unitdosage form. A suitable dose may be in the range of from about 0.5 to about 100 mg / kg, e.g., from about 10 to about 75 mg / kg of body weight, such as 3 to about 50 mg per kilogram body weight, for example in the range of 6 to 90 mg / kg, e.g., in the range of 15 to 60 mg / kg.Exemplary Particle Formulations The nucleic acid sequence encoding a protein, e.g., RNA such as mRNA encoding VEGF, may be present in nanoparticles or microparticles. In one embodiment, the particles are biodegradable particles that may include or may be formed from biodegradable polymeric molecules which may include, but arenot limited to polylactic acid (PLA), polyglycolic acid (PGA), co-polymers of PLA and PGA (i.e., polyactic-co-glycolic acid (PLGA)), poly-ε-caprolactone (PCL), polyethylene glycol (PEG), poly(3-hydroxybutyrate), poly(p-dioxanone), polypropylene fumarate, poly(orthoesters), polyol / diketene acetals addition polymers, poly-alkyl-cyano-acrylates (PAC), poly(sebacic anhydride) (PSA), poly(carboxybiscarboxyphenoxyphenoxy hexone (PCPP) poly[bis (p-carboxypheonoxy)methane](PCPM), copolymers of PSA, PCPP and PCPM, poly(amino acids), poly(pseudo amino acids), polyphosphazenes, derivatives of poly[(dichloro)phosphazenes] and poly[(organo)phosphazenes], poly-hydroxybutyric acid, or S-caproic acid, elastin, or gelatin. (See, e.g., Kumari et al., Colloids and Surfaces B: Biointerfaces 75 (2010) 1-18; and U.S. Patent Nos.6,913,767; 6,884,435; 07; 6,090,925; 6,022,564; 5,981,719; 5,871,747; 5,723,269; 5,603,960; and 5,578,709; and U.S. Published Application No.2007 / 0081972; and International Application Publication Nos. WO 2012 / 115806; and WO 2012 / 054425; the contents of which are incorporated herein by reference in their entireties). The biodegradable particles may be prepared by methods known in the art. The size of the particles (e.g., mean effective diameter) may be assessed by known methods in the art, which may include but are not limited to transmission electron microscopy (TEM), scanning electron microscopy (SEM), Atomic Force Microscopy (AFM), Photon Correlation Spectroscopy (PCS), Nanoparticle Surface Area Monitor (NSAM), Condensation Particle Counter (CPC), Differential Mobility Analyzer (DMA), Scanning Mobility Particle Sizer (SMPS), Nanoparticle Tracking Analysis (NTA), X-Ray Diffraction (XRD), Aerosol Time of Flight Mass Spectroscopy (ATFMS), and Aerosol Particle Mass Analyzer (APM). In one embodiment, a particle comprises polymers including but not limited to poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), linear and / or branched PEI with differing molecular weights (e.g., 2, 22 and 25 kDa), dendrimers such as polyamidoamine (PAMAM) and polymethoacrylates; lipids including but not limited to cationic liposomes, cationic emulsions, DOTAP, DOTMA, DMRIE, DOSPA, distearoylphosphatidylcholine (DSPC), DOPE, or DC-cholesterol; peptide based vectorsincluding but not limited to Poly-L-lysine or protamine; or poly(β-amino ester), chitosan,PEI-polyethylene glycol, PEI-mannose-dextrose, DOTAP-cholesterol or RNAiMAX. In one embodiment, the delivery vehicle may be a glycopolymer-based delivery vehicle, poly(glycoamidoamine)s (PGAAs), that have the ability to complex with various polynucleotide types and form nanoparticles. These materials are created bypolymerizing the methylester or lactone derivatives of various carbohydrates (D-glucarate (D), meso-galactarate (G), D-mannarate (M), and L-tartarate (T)) with a series of oligoethyleneamine monomers (containing between 1-4 ethylenamines (Liu and Reineke, 2006). A subset composed of these carbohydrates and four ethyleneamines in the polymer repeat units yielded exceptional delivery efficiency. In one embodiment, the delivery vehicle may comprise polyethyleneimine (PEI),Polyamidoamine (PAMAM), PEI-PEG, PEI-PEG-mannose, dextran-PEI, OVA conjugate, PLGA microparticles, or PLGA microparticles coated with PAMAM, or any combination thereof. The disclosed cationic polymer may include, but are not limited to, polyamidoamine (PAMAM) dendrimers. Polyamidoamine dendrimers suitable for preparing the presently disclosed nanoparticles may include 3rd-, 4th-, 5th-, or at least 6th-generation dendrimers. In one embodiment, the delivery vehicle may comprise a lipid, e.g., N-[1-(2,3- dioleoyloxy)propel]-N,N,N-trimethylammonium (DOTMA), 2,3-dioleyloxy-N-[2-spermine carboxamide] ethyl-N,N-dimethyl-1-propanammonium trifluoracetate (DOSPA, Lipofectamine); 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); N-[1-(2,3- dimyristloxy) propyl]; N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide (DMRIE), 3- β-[N-(N,N'-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol); dioctadecyl amidoglyceryl spermine (DOGS, Transfectam); or imethyldioctadeclyammonium bromide (DDAB). The positively charged hydrophilic head group of cationic lipids usually consists of monoamine such as tertiary and quaternary amines, polyamine, amidinium, or guanidinium group. A series of pyridinium lipids have been developed (Zhu et al., 2008; van der Woude et al., 1997; Ilies et al., 2004). In addition to pyridinium cationic lipids, other types of heterocyclic head group include imidazole, piperizine and amino acid. The main function of cationic head groups is to condense negatively charged nucleic acids by means of electrostatic interaction to slightlypositively charged nanoparticles, leading to enhanced cellular uptake and endosomalescape. Lipids having two linear fatty acid chains, such as DOTMA, DOTAP and SAINT- 2, or DODAC, may be employed as a delivery vehicle, as well as tetraalkyl lipid chain surfactant, the dimer of N,N-dioleyl-N,N- dimethylammonium chloride (DODAC). All the trans-orientated lipids regardless of their hydrophobic chain lengths (C16:1, C18:1 and C20:1) appear to enhance the transfection efficiency compared with their cis-orientated counterparts. The structures of polymers useful as a delivery vehicle include but are not limited to linear polymers such as chitosan and linear poly(ethyleneimine), branched polymers such as branch poly(ethyleneimine) (PEI), circle-like polymers such as cyclodextrin, network (crosslinked) type polymers such as crosslinked poly(amino acid) (PAA), and dendrimers. Dendrimers consist of a central core molecule, from which several highly branched arms 'grow' to form a tree-like structure with a manner of symmetry or asymmetry. Examples of dendrimers include polyamidoamine (PAMAM)and polypropylenimine (PPI) dendrimers.DOPE and cholesterol are commonly used neutral co-lipids for preparing liposomes. Branched PEI-cholesterol water-soluble lipopolymer conjugates self- assemble into cationic micelles. Pluronic (poloxamer), a non-ionic polymer and SP1017, which is the combination of Pluronics L61 and F127, may also be used. In some embodiments, a biocompatible polymeric material is derived from abiodegradable polymeric such as collagen, e.g., hydroxylated collagen, fibrin, polylactic- polyglycolic acid, or a polyanhydride. Other examples include, without limitation, any biocompatible polymer, whether hydrophilic, hydrophobic, or amphiphilic, such as ethylene vinyl acetate copolymer (EVA), polymethyl methacrylate, polyamides,polycarbonates, polyesters, polyethylene, polypropylenes, polystyrenes, polyvinylchloride, polytetrafluoroethylene, N-isopropylacrylamide copolymers, poly(ethylene oxide) / poly(propylene oxide) block copolymers, poly(ethylene glycol) / poly(D,L-lactide- co-glycolide) block copolymers, polyglycolide, polylactides (PLLA or PDLA), poly(caprolactone) (PCL), or poly(dioxanone) (PPS). In another embodiment, the biocompatible material includes polyethyleneterephalate, polytetrafluoroethylene, copolymer of polyethylene oxide and polypropylene oxide, a combination of polyglycolic acid and polyhydroxyalkanoate, gelatin, alginate, poly-3-hydroxybutyrate, poly-4-hydroxybutyrate, and polyhydroxyoctanoate, and polyacrylonitrilepolyvinylchlorides. In one embodiment, the following polymers may be employed, e.g., natural polymers such as starch, chitin, glycosaminoglycans, e.g., hyaluronic acid, dermatan sulfate and chrondrotin sulfate, and microbial polyesters, e.g., hydroxyalkanoates such as hydroxyvalerate and hydroxybutyrate copolymers, and synthetic polymers, e.g., poly(orthoesters) and polyanhydrides, and including homo and copolymers of glycolide and lactides (e.g., poly(L-lactide, poly(L-lactide-co-D,L-lactide), poly(L-lactide-co- glycolide, polyglycolide and poly(D,L-lactide), pol(D,L-lactide-coglycolide), poly(lactic acid colysine) and polycaprolactone. In one embodiment, the biocompatible material is derived from isolated extracellular matrix (ECM). ECM may be isolated from endothelial layers of various cell populations, tissues and / or organs, e.g., any organ or tissue source including the dermis of the skin, liver, alimentary, respiratory, intestinal, urinary or genital tracks of a warm- blooded vertebrate. ECM employed in the disclosure may be from a combination of sources. Isolated ECM may be prepared as a sheet, in particulate form, gel form and the like. A biocompatible scaffold polymer may comprise silk, elastin, chitin, chitosan,poly(d-hydroxy acid), poly(anhydrides), or poly(orthoesters). More particularly, thebiocompatible polymer may be formed polyethylene glycol, poly(lactic acid), poly(glycolic acid), copolymers of lactic and glycolic acid, copolymers of lactic and glycolic acid with polyethylene glycol, poly(E-caprolactone), poly(3-hydroxybutyrate), poly(p-dioxanone), polypropylene fumarate, poly(orthoesters), polyol / diketene acetalsaddition polymers, poly(sebacic anhydride) (PSA),poly(carboxybiscarboxyphenoxyphenoxy hexone (PCPP) poly[bis (p-carboxypheonoxy) methane] (PCPM), copolymers of SA, CPP and CPM, poly(amino acids), poly(pseudo amino acids), polyphosphazenes, derivatives of poly[(dichloro)phosphazenes] or poly[(organo) phosphazenes], poly-hydroxybutyric acid, or S-caproic acid, polylactide-co-glycolide, polylactic acid, polyethylene glycol, cellulose, oxidized cellulose, alginate,gelatin or derivatives thereof. Thus, the polymer may be formed of any of a wide range of materials including polymers, including naturally occurring polymers, synthetic polymers, or a combination thereof. In one embodiment, the scaffold comprises biodegradable polymers. In one embodiment, a naturally occurring biodegradable polymer may be modified to provide for a synthetic biodegradable polymer derived from the naturally occurring polymer. In one embodiment, the polymer is a poly(lactic acid) ("PLA") or poly(lactic-co-glycolic acid) ("PLGA"). In one embodiment, the scaffold polymer includes but is not limited to alginate, chitosan, poly(2-hydroxyethylmethacrylate), xyloglucan, co-polymers of 2- methacryloyloxyethyl phosphorylcholine, poly(vinyl alcohol), silicone, hydrophobic polyesters and hydrophilic polyester, poly(lactide-co-glycolide), N-isoproylacrylamide copolymers, poly(ethylene oxide) / poly(propylene oxide), polylactic acid, poly(orthoesters), polyanhydrides, polyurethanes, copolymers of 2- hydroxyethylmethacrylate and sodium methacrylate, phosphorylcholine, cyclodextrins, polysulfone and polyvinylpyrrolidine, starch, poly-D,L-lactic acid-para-dioxanone- polyethylene glycol block copolymer, polypropylene, poly(ethylene terephthalate), poly(tetrafluoroethylene), poly-epsilon-caprolactone, or crosslinked chitosan. In one embodiment, the microparticles have a diameter of about 1 to about 100 microns. In one embodiment, the diameter is about 1 to about 15 microns. In one embodiment, the diameter is about 5 to about 10 microns. In one embodiment, the diameter is about 15 to about 50 microns. In one embodiment, the diameter is about 20 to about 50 microns. In one embodiment, the diameter is about 100 to about 150 microns. In one embodiment, the diameter is about 500 to about 750 microns. In one embodiment, the diameter is about 150 to about 500 microns. In one embodiment, the diameter is about 200 to about 500 microns. In one embodiment, the nanoparticles have a diameter of about 1 to about 100 nm. In one embodiment, the diameter is about 1 to about 15 nm. In one embodiment, the diameter is about 5 to about 10 nm. In one embodiment, the diameter is about 15 to about 50 nm. In one embodiment, the diameter is about 20 to about 50 nm. In one embodiment, the diameter is about 100 to about 150 nm. In one embodiment, thediameter is about 500 to about 750 nm. In one embodiment, the diameter is about 150to about 500 nm. In one embodiment, the diameter is about 200 to about 500 nm. In one embodiment, the nucleic acid in the microparticle is released for up to 10 days. In one embodiment, the nucleic acid in the microparticle is released for up to 14 days. In one embodiment, the nucleic acid in the microparticle is / are released for up to 7days. In one embodiment, the nucleic acid in the microparticle is released for up to 4days. In one embodiment, the nucleic acid in the microparticle begins being released at 2 hours. In one embodiment, the nucleic acid in the microparticle begins being released at 4 hours. In one embodiment, the nucleic acid in the microparticle beginsbeing released at 8 hours. In one embodiment, the nucleic acid in the microparticlebegin being released at 12 hours. Pharmaceutical Compositions The disclosure provides a composition comprising, consisting essentially of, or consisting of a gene therapy vector and optionally a pharmaceutically acceptable (e.g., physiologically acceptable) carrier. When the composition consists essentially of the gene therapy vector, additional components can be included that do not materially affect the composition (e.g., adjuvants, buffers, stabilizers, anti-inflammatory agents, solubilizers, preservatives, etc.). When the composition consists of the gene therapy vector, the composition does not comprise any additional components. Any suitable carrier can be used within the context of the disclosure, and such carriers are well known in the art. The choice of carrier will be determined, in part, by the particular site to which the composition may be administered and the particular method used to administer the composition. The composition optionally can be sterile with the exception of the gene therapy vector. The composition can be frozen or lyophilized for storage and reconstituted in a suitable sterile carrier prior to use. The compositions can be generated in accordance with conventional techniques described in, e.g., Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins, Philadelphia, PA (2001). Suitable formulations for the composition include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain anti-oxidants, buffers, and bacteriostats, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Extemporaneous solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. In one embodiment, the carrier is a buffered saline solution. In addition, one of ordinary skill in the art will appreciate that the gene therapy vector can be present in a composition with other therapeutic or biologically-active agents. For example, antibiotics, i.e., microbicides and fungicides, can be present to treat existing infection and / or reduce the risk of future infection, such as infection associated with procedures. Injectable depot forms are made by forming microencapsulated matrices withthe vector in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of vector to polymer, and the nature of the particular polymer employed, the rate of viral vector release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulationsare also prepared by entrapping the vector in liposomes or microemulsions which arecompatible with body tissue. In certain embodiments, a formulation comprises a biocompatible polymer selected from the group consisting of polyamides, polycarbonates, polyalkylenes, polymers of acrylic and methacrylic esters, polyvinyl polymers, polyglycolides,polysiloxanes, polyurethanes and co-polymers thereof, celluloses, polypropylene,polyethylenes, polystyrene, polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, poly(butic acid), poly(valeric acid), poly(lactide-co-caprolactone), polysaccharides, proteins, polyhyaluronic acids, polycyanoacrylates, and blends, mixtures, or copolymers thereof. The composition can be administered in or on a device that allows controlled or sustained release, such as a sponge, biocompatible meshwork, mechanical reservoir, or mechanical implant. Implants (see, e.g., U.S. Patent No.5,443,505), devices (see, e.g., U.S. Patent No.4,863,457), such as an implantable device, e.g., a mechanical reservoir or an implant or a device comprised of a polymeric composition, are particularly useful for administration of the gene therapy vector. The composition also can be administered in the form of sustained-release formulations (see, e.g., U.S. Patent No. 5,378,475) comprising, for example, gel foam, hyaluronic acid, gelatin, chondroitin sulfate, a polyphosphoester, such as bis-2-hydroxyethyl-terephthalate (BHET), and / or a polylactic-glycolic acid. Delivery of the compositions comprising the gene therapy vectors may be local using devices known in the art. Delivery may also be via surgical implantation of an implanted device. The dose of the gene therapy vector in the composition administered to the mammal will depend on a number of factors, including the size (mass) of the mammal, the extent of any side-effects, the particular route of administration, and the like. In one embodiment, the method comprises administering a “therapeutically effective amount” of the composition comprising the gene therapy vector described herein. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time desirable, to achieve a desired therapeutic result. The therapeutically effective amount may vary according to factors such as the extent of, for example, vascularization desired, age, sex, and weight of the individual, and the ability of the gene therapy vector to elicit a desired response in the individual. The dose of gene therapy vector in the composition required to achieve a particular therapeutic effect may be in units of vector genome copies per cell (gc / cell) or vector genome copies / per kilogram of body weight (gc / kg). One of ordinary skill in the art can readily determine anappropriate dose range for a gene therapy vector, based on factors that are well knownin the art. The therapeutically effective may be between 1 x 1010genome copies to 1 x 1013genome copies. The amount may be between 1 x 1011genome copies to 1 x 1014genome copies. The amount may be between 1 x 1012genome copies to 1 x 1015genome copies. The amount may be between 1 x 1013genome copies to 1 x 1016genome copies.In one embodiment, the composition is administered single site of the mammal. It is believed that a single administration of the composition having the gene therapy vector results in persistent and optionally time limited expression of a proteins such as VEGF in the mammal with minimal negative side effects. However, in certain cases, itmay be appropriate to administer the composition multiple times during a therapeuticperiod to ensure sufficient exposure of the composition. For example, the composition may be administered to the mammal two or more times (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more times) during a period to one or more sites in the body. The present disclosure provides pharmaceutically acceptable compositions which comprise a therapeutically-effective amount of a gene therapy vector comprising a nucleic acid sequence, e.g., one which encodes VEGF, an isoform thereof, or a portion thereof, the presence of which in the mammal, increases blood vessel formation in tissues surrounding the administration site. In particular, administration of a gene delivery vector in accordance with the present disclosure may be a singular occurrence at one body site, multiple occurrences at one body site, a singular occurrence at multiple body site or multiple occurrences at multiple body sites, depending, for example, upon the recipient's physiological condition, the desired result, and other factors known to skilled practitioners. Both local administration, e.g., at a surgery site and the like, and systemic administration, are contemplated. Any direct route of administration may be employed, e.g., injection at a site in need of therapy. One or more suitable unit dosage forms comprising the gene delivery vector(s), which may optionally be formulated for sustained release, can be administered by a variety of routes, e.g., that result in the induction of more blood vessels in the local milieu and / or the gen product(s) diffuse to induce blood vessels from surrounding tissues into the target tissue. The formulations may, where appropriate, may include the step of bringing into association the vector with liquid carriers, solid matrices, semi- solid carriers, finely divided solid carriers or combinations thereof, and then, if desirable, introducing or shaping the product into the desired delivery system. The amount of gene delivery vector(s) administered to achieve a particular outcome will vary depending on various factors including, but not limited to, the genes and promoters chosen, the condition, patient specific parameters, e.g., height, weight and age, and the desired outcome. The gene therapy vector may conveniently be provided in the form of formulations suitable for administration, e.g., via injection. A suitable administrationformat may best be determined by a medical practitioner for each patient individually,according to standard procedures. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulations treatises, e.g., Remington's Pharmaceuticals Sciences. By "pharmaceutically acceptable" it is meant a carrier, diluent, excipient, and / or salt that is compatible with the other ingredients of theformulation, and not deleterious to the recipient thereof.The gene therapy vector may be formulated in solution at neutral pH, for example, about pH 6.5 to about pH 8.5, or from about pH 7 to 8, with an excipient to bring the solution to about isotonicity, for example, 4.5% mannitol or 0.9% sodium chloride, pH buffered with art-known buffer solutions, such as sodium phosphate, thatare generally regarded as safe, together with an accepted preservative such asmetacresol 0.1% to 0.75%, or from 0.15% to 0.4% metacresol. Obtaining a desired isotonicity can be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes. Sodium chloride is useful for buffers containing sodium ions. If desired, solutions of the above compositions can also be prepared to enhance shelf life and stability. Therapeutically useful compositions of the disclosure can be prepared by mixing the ingredients following generally accepted procedures. For example, the selected components can be mixed to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water and / or a buffer to control pH or an additional solute to control tonicity. The vectors for delivery to cells can be provided in a dosage form containing an amount of a vector effective in one or multiple doses. For viral vectors, the dose may be in the range of at least about 107viral particles, e.g., about 109viral particles, or about 1011viral particles. The number of viral particles added may be up to 1014. For example, when a viral expression vector is employed, about 108to about 1016gc of viral vector can be nucleic acid or as a packaged virion. In some embodiments, about 109to about 1015copies of viral vector, e.g., per 0.5 to 10 mL, can be employed as nucleic acid or as a packaged virion. The nucleic acids or other vehicles, can be employed in dosages of at least about 0.0001 mg / kg to about 1 mg / kg, of at least about 0.001 mg / kg to about 0.5 mg / kg, at least about 0.01 mg / kg to about 0.25mg / kg or at least about 0.01 mg / kg to about 0.25 mg / kg of body weight, although other dosages may provide beneficial results. The amount will vary depending on various factors including, but not limited to, the nucleic acid or vector chosen for administration, the disease, deformity, void or defect, the weight, the physical condition, the health, and / or the age of the mammal. Such factors can be readily determined by the clinician employing animal models or other test systems that are available in the art. As noted, the exact dose of the gene therapy vector to be administered is determined by the attending clinician, but may be in 1 mL phosphate buffered saline. For delivery of plasmid DNA alone, or plasmid DNA in a complex with other macromolecules, the amount of DNA to bedelivered can vary. For example, from 0.0001 to 1 mg or more, e.g., up to 1 g, inindividual or divided doses, e.g., from 0.001 to 0.5 mg, or 0.01 to 0.1 mg, of DNA. For example, when a viral expression vector is employed, about 108to about 1060gc of viral vector can be employed as nucleic acid or as a packaged virion. In some embodiments, about 109to about 1015copies of viral vector, e.g., per 0.5 to 10mL, can be administered as nucleic acid or as a packaged virion. Alternatively, thenucleic acids or vehicles can be employed in dosages of at least about 0.0001 mg / kg to about 1mg / kg, of at least about 0.001 mg / kg to about 0.5 mg / kg, at least about 0.01 mg / kg to about 0.25 mg / kg or at least about 0.01 mg / kg to about 0.25 mg / kg of body weight, although other dosages may provide beneficial results. In one embodiment, administration may be by injection or infusion using anappropriate catheter or needle. A variety of catheters may be used to achieve delivery, as is known in the art. For example, a variety of general purpose catheters, as well as modified catheters, suitable for use in the present disclosure are available from commercial suppliers. By way of illustration, liposomes and other lipid-containing gene delivery complexes can be used to deliver one or more transgenes. The principles of the preparation and use of such complexes for gene delivery have been described in the art (see, e.g., Ledley, (1995); Miller et al., (1995); Chonn et al., (1995); Schofield et al., (1995); Brigham et al., (1993)). Pharmaceutical formulations containing the gene delivery vectors can be prepared by procedures known in the art using well known and readily available ingredients. For example, the vector can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. The vectors of the disclosure can also be formulated as elixirs or solutions appropriate for parenteral administration, for instance, by intramuscular, subcutaneous or intravenous routes.. In one embodiment, the gene therapy vector may be formulated for administration, e.g., by injection, for example, bolus injection or continuous infusion via a catheter, and may include an added preservative. These formulations can contain pharmaceutically acceptable vehicles and adjuvants which are well known in the prior art. It is possible, for example, to prepare solutions using one or more organic solvent(s) that is / are acceptable from the physiological standpoint. The local delivery of the gene therapy vector can also be by a variety of techniques which administer the vector at or near the site of disease, defect, deformity or void, e.g., using a catheter or needle Examples of site-specific or targeted local delivery techniques are not intended to be limiting but to be illustrative of the techniques available. Examples include local delivery catheters, such as an infusion or indwelling catheter, e.g., a needle infusion catheter, shunts and stents or other implantable devices, site specific carriers, direct injection, or direct applications. The formulations and compositions described herein may also contain otheringredients such as antimicrobial agents or preservatives. VEGF Formulations Suitable compositions comprising VEGF encoding vectors such as nucleic acid encoding VEGF, e.g., in a microparticle or nanoparticle, include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain anti-oxidants, buffers,bacteriostats, and solutes that render the formulation isotonic with the blood or intraocular fluid of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Extemporaneous solutions and suspensions can beprepared from sterile powders, granules, and tablets of the kind previously described.When administering a composition, the pharmaceutically acceptable carrier may be a buffered saline solution. In addition, the composition of the disclosure can comprise, or alternatively can be co-administered with, other therapeutic or biologically active agents. By “co- administration” is meant administration before, concurrently with, e.g., in combination with the composition in the same formulation or in separate formulations, or after administration of the composition as described above. For example, nucleic acid sequences, proteins, and / or other agents useful in the methods can be present and co- administered with the compositions of the disclosure. Suitable biologically active agents can include, for example, factors that control inflammation, such as ibuprofen or steroids, which can be co-administered to reduce swelling and inflammation associated with administration of the composition. Immunosuppressive agents can be co- administered to reduce inappropriate immune responses. Similarly, vitamins and minerals, anti-oxidants, and micronutrients can be co-administered. Antibiotics, e.g., microbicides and fungicides, can be co-administered to reduce the risk of infection. Administration results in the subsequent release of VEGF. Selective isoform release may allow for an improved outcome. In one aspect of the disclosure, the nucleic acid molecule can be constructed by manipulating the splice donor, branch point, and / or splice acceptor regions. For example, a nucleic acid molecule can be included in an expression construct and administered to a mammal to promote the production of VEGF189 at the expense of VEGF165 or VEGF121. Suitable methods, both invasive and noninvasive methods, of directly administering the composition are available. Although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. The composition can be appropriately formulated and administered in the form of a local injection. The composition can be applied, for example, topically. Local injections typically involve the administration of the composition by a catheter or needle. Pharmaceutically acceptable carriers for injectable compositions are well known to those of ordinary skill in the art (see Pharmaceutics and PharmacyPractice, J. B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986)). Subjects The subject may be any animal, including a human and non-human animal.Non-human animals include all vertebrates, e.g., mammals and non-mammals, such asnon-human primates, sheep, dogs, cats, cows, horses, chickens, amphibians, and reptiles, although mammals are envisioned as subjects, such as non-human primates, sheep, dogs, cats, cows and horses. The subject may also be livestock such as, cattle, swine, sheep, poultry, and horses, or pets, such as dogs and cats. In one embodiment, subjects include human subjects suffering from or at riskfor the medical diseases and disorders described herein. The subject is generally diagnosed with the condition by skilled artisans, such as a medical practitioner. The methods described herein can be employed for subjects of any species, gender, age, ethnic population, or genotype. Accordingly, the term subject includes males and females, and it includes elderly, elderly-to-adult transition age subjects, adults, adult-to-pre-adult transition age subjects, and pre-adults, including adolescents, children, and infants. Examples of human ethnic populations include Caucasians, Asians, Hispanics, Africans, African Americans, Native Americans, Semites, and Pacific Islanders. The methods may be more appropriate for some ethnic populations such as Caucasians, especially northern European populations, as well as Asian populations. The term subject also includes subjects of any genotype or phenotype as long as they are in need of treatment, as described above. In addition, the subject can have the genotype or phenotype for any hair color, eye color, skin color or any combination thereof. The term subject includes a subject of any body height, body weight, or any organ or body part size or shape. Example A: Exemplary Vector Encoding Angiogenic Mediators In one embodiment, a vector of the disclosure encodes an angiogenic mediator. An “angiogenic mediator” can be any substance that enhances the level of perfusion of blood to a location, particularly by initiating or enhancing angiogenesis (i.e., the formation of new blood vessels or neovascularization, as well as the promotion of blood vessel formation, including collateral blood vessel growth). Therefore, an angiogenic mediator is any substance that will induce the initiation of angiogenesis to a location not otherwise undergoing angiogenesis or enhance or heighten angiogenesis to a location already undergoing angiogenesis. The angiogenic mediator can be any suitable angiogenic mediator. Examples of angiogenic mediators include angiogenic peptides. More particularly, a number of peptides broadly classified as “growth factors” are known to induce angiogenesis. Suitable examples of such growth factors include Fibroblast Growth Factor (FGF) (more particularly, acidic Fibroblast Growth Factor (aFGF) and basic Fibroblast Growth Factor(bFGF)), Transforming Growth Factor (particularly, Transforming Growth Factor-Beta),Placental Growth Factor, Platelet-derived Endothelial Cell Growth Factor, and Vascular Endothelial Growth Factor (VEGF). Other angiogenic mediators include Angiogenin, and cytokines such as Tumor Necrosis Factor-alpha and Interleukin-8. The angiogenic mediator is not limited to peptides such as cytokines or growth factors, but includesother substances such as modified peptides (e.g., glycoproteins or lipoproteins),ribozymes, polynucleotides, and other substances that induce angiogenesis. Another example of a suitable angiogenic mediator is a nucleic acid encoding an angiogenic substance. Desirably, such nucleic acid will be in the form of a vector comprising a DNA encoding the angiogenic substance, in one embodiment a DNAencoding an angiogenic peptide. In one embodiment, the vector will comprise a viralvector. More in one embodiment, the vector will comprise an adenoviral vector (i.e., a viral vector being at least partially comprised of a DNA sequence of (or similar to) that of an adenovirus). Through the use of such adenoviral vectors as angiogenic mediators, it is possible to infect host cells and thereby induce the sustained, predictable, and effective production of an angiogenic peptide for about a week. After about a week, the adenoviral vector ceases to produce the angiogenic peptide, and, to that extent, the present disclosure provides a self-terminating method of inducing angiogenesis. The DNA encoding an angiogenic mediator (e.g., an angiogenic peptide such as VEGF) can be any suitable DNA molecule. The DNA desirably is operably linked to suitable expression signals. Whereas the DNA can be operably linked to any suitable set of expression signals, in one embodiment, the expression of the DNA is under the control of the cytomegalovirus (CMV) immediate early promoter. The DNA can encode any suitable angiogenic mediator. The angiogenic mediator may be an angiogenic peptide. The angiogenic peptide may be a growth factor as described above, particularly a VEGF protein. In one embodiment, the angiogenic peptide is selected from the group comprising VEGF121, VEGF145, VEGF165, and VEGF189, Other angiogenic peptides include VEGF II, VEGF-C, FGF-4, angiogenin, angiogenin-2, and P1GF. The adenoviral vector also can include a DNA encoding an angiogenic peptide receptor. Suitable angiogenic peptide receptors include, for example, FLT-1, FLK-1, and FLT-4. Indeed, in certain embodiments, the adenoviral vector can utilize a DNA encoding an angiogenic peptide receptor in place of, rather than in addition to, the DNA encoding an angiogenic peptide. The DNA can be inserted into any suitable region of the adenoviral vector as an expression cassette. In that respect, the skilled artisan will readily appreciate that there are certain advantages to using an adenoviral vector deficient in some essential gene region of the adenoviral genome inasmuch as such a deficiency will provide room in the vector for a transgene and will prevent the virus from replicating in the absence of a complementary cell line. In one embodiment, the DNA segment is inserted into the E1region of the adenoviral vector. Whereas the DNA segment can be inserted as anexpression cassette in any suitable orientation in any suitable region of the adenoviral vector, in one embodiment the orientation of the DNA segment is from right to left. By the expression cassette having an orientation from right to left, it is meant that the direction of transcription of the expression cassette is opposite that of the region of theadenoviral vector into which the expression cassette is inserted.An adenoviral vector illustrative of the present vector is deficient in the entire E1a region, at least part of the E1b region, and at least part of the E3 region of the adenoviral genome and contains the DNA encoding the angiogenic factor under the control of the CMV immediate early promoter in the E1 region of the adenoviralgenome. Such a vector supports in vivo expression of VEGF that is maximized at oneday following administration and is not detectable above baseline levels as little as one week after administration. This is ideal inasmuch as it is sufficient to provide substantial growth of new vasculature while minimizing adverse neovascularization at distal sites. In that regard, when this vector is locally administered to a target tissue, VEGF expression can be detected in blood serum using standard ELISA monitoring assays. Local administration to a target tissue of adenoviral vectors encoding one or more isoforms of human VEGF in the E1 region of the adenoviral genome are able to increase blood flow. The target and source locations to deliver the vector can be any suitable locations in a host that can be subject to administration of the angiogenic mediator within the context of the present disclosure. The target and source locations may comprise tissues (i.e., a target tissue and a source tissue), more in one embodiment the target and source locations (e.g., tissues) comprise receptors capable of binding an angiogenic peptide, such as growth factor receptors. Even more in one embodiment, the target and source tissues comprise VEGF receptors. In one embodiment, the source and target tissues comprise endothelial cells. Generally, the source and / or target locations comprise tissue(s) that is a part of, or forms, a discrete organ, e.g., a muscle, such as the heart. The source location in one embodiment is an angiogenically functional location, e.g., a location in the host that has a sufficient level of perfusion of blood, such as an area near existing blood vessels (in one embodiment with a significant amount of existing blood vessels). The target location in one embodiment is an actual or potential angiogenically dysfunctional location, e.g., a location in the host that is either undergoing or is at risk of undergoing ischemia or any other condition wherein the growth of new, or extension of existing, blood vessels is desirable. The target location (particularly an angiogenically dysfunctional location) may be suffering from or be at risk of suffering from ischemic damage, which results when the tissue is deprived of an adequate supply of oxygenated blood. The interruption of the supply of oxygenated blood is often caused by a vascular occlusion. Such vascular occlusion can be caused by arteriosclerosis, trauma, surgical procedures, disease,and / or other indications. Induction of angiogenesis in tissue affected by or at risk ofbeing affected by a vascular occlusion is an effective means of preventing and / or attenuating ischemia in such tissue. As a result, although any suitable tissue can be targeted for the induction of angiogenesis, the target tissue is in one embodiment one which is affected by or at risk of being affected by a vascular occlusion. For example, the blood supply to discrete organs (that are target locationsand / or angiogenically dysfunctional locations in the context of the present disclosure) such as the brain, heart, pancreas, limbs, or generalized areas of the body, such as a foot, can be attenuated by disease, trauma, surgery, or other events. The alleviation of such attenuated blood supply regardless of its origin is contemplated by the presentdisclosure. Thus, prevention or alleviation of damage from indications such asmyocardial ischemia and stroke are fully contemplated. Additionally, the planning of a surgical procedure can be predictive of the interruption of blood supply through a particular portion of a patient's vasculature. Prior treatment according to the present method can substantially improve the desired outcome of these surgeries. In that case, treatment in one embodiment occurs about one day to about six weeks before the surgery, and more in one embodiment about two to about fourteen days prior to surgery. The present disclosure involves establishing a gradient of an angiogenic mediator of increasing concentration from a source location in the host to a target location in the host, such that the level of perfusion of blood to the target location in the host is enhanced. While any suitable means of administering the angiogenic mediator to the target tissue that creates a gradient of increasing concentration from the source location to the target location can be used within the context of the present disclosure, such an administration to produce the gradient in the host between the source and target locations is accomplished by directly administering (e.g., injecting or topically administering) the angiogenic mediator into or near the source location or by topical administration to or near the source and target locations. By the term “injecting,” it is meant that the angiogenic mediator is forcefully introduced into the target tissue. The angiogenic mediator to be injected can be any suitable angiogenic mediator conducive to such administration, including gene transfer vectors such as the adenoviral vectors described herein. Any suitable injection device can be used within the context of the present disclosure. For example, in the context of direct injection of an angiogenic mediator that comprises an adenoviral vector comprising a DNA encoding an angiogenic substance, a suitable injection device that is capable of delivering simultaneous multiple injections is. Other suitable injection devices which can be used within the context of the present disclosure include minimally invasive injection devices. Such devices are capable of accessing a tissue (e.g., the heart) through small incisions of less than about 15 cm and are designed to provide injections through a single lumen, in contrast to the multiple injection devices described above. To allow for the need for multiple injectionswith a specific geometry, a marking system can be employed so that the sites ofprevious injections are well delineated. Minimally invasive injection devices can comprise injector tips which are flexible and steerable to allow access via small incisions to the curved outer surface of the heart, for example, which exists at varying angles with respect to the limited aperture window required with minimally invasivesurgeries.Furthermore, the angiogenic mediator can be administered to any suitable surface, either internal or external, of (or near to) the source and / or target locations. For example, with respect to directly injecting an angiogenic mediator comprising an adenoviral vector (as described herein) into cardiac tissue, it is contemplated that suchan injection can be administered from any suitable surface of the heart (i.e.,endocardially and / or epicardially). While the administration of the angiogenic mediator to form the concentration gradient can be performed in any suitable manner (including methods that may include single applications (e.g., injections) of the angiogenic mediator), the concentration gradient may be established by at least two injections of the angiogenic mediator. For example, an injection of an angiogenic mediator at a relatively lower concentration at (or near) the source location and another injection of a relatively higher concentration at the target location will produce such a gradient. Similarly, application of a relatively greater volume of a composition comprising an angiogenic mediator at a uniform concentration at (or near) the source location and a similar application of a lesser volume of a composition comprising an angiogenic mediator at (or near) the target location also will generate a suitable gradient. Alternatively, there may be multiple applications (e.g., injections), wherein each injection is of a relatively uniform volume of a composition having a relatively uniform concentration of an angiogenic mediator therein. The multiple applications can be 2, 3, 4, 5, or more applications, for example at least 10 (e.g., 10, 15, 20, 25, 30 or more) applications. The manipulation of the multiple applications (e.g., injections) to achieve a gradient can be accomplished by modifying the number and / or spacing of the multiple applications (e.g., injections). Multiple applications provide an advantage over single applications in that they can be manipulated by such parameters as a specific geometry defined by the source and / or target locations, as well as the area therebetween, where each application is administered. The administration of a single dose of the angiogenic mediator via multiple applications can be better controlled, and the effectiveness with which any given dose is administered can be maximized. Moreover, the effectiveness of generating the concentration gradient can be maximized, while the area of the host that is exposed to the angiogenic mediator can be minimized, or at least more localized. Thus, for example, with regard to the use of an adenoviral vector (comprising a DNA encoding an angiogenic substance as described herein) as the angiogenicmediator, the method of present disclosure can comprise administering differentamounts of the adenoviral vector at a uniform concentration by modifying the number of applications of the adenoviral vector to the host to produce the gradient. More particularly, such an embodiment of the disclosure comprises administering fewer applications (or doses) of the adenoviral vector at (or near) the source location than at(or near) the target location to produce a gradient.The specific geometry of the multiple applications is defined by the location on the target and / or source locations, either in two- or three-dimensional space, where each application of the angiogenic mediator is administered. The multiple applications in one embodiment are spaced such that the points of application are separated by up toabout 4 cm (e.g., about 0.5-4 cm), more in one embodiment up to about 3 cm (e.g.,about 1-3 cm), and most in one embodiment up to about 2 cm (e.g., about 1-2 cm). With respect to the specific geometry of the multiple applications in two-dimensional space, the specific geometry is defined by a plane (i.e., a cross-section of the target tissue) in which the multiple applications lie. The plane defined by the multiple applications can lie at a constant distance from the surface of source and / or target locations (i.e., substantially parallel to the surface of the source and / or target locations), the depth of the plane, or, alternatively, the plane can lie at an angle with respect to the surface of the target and / or source locations. In one embodiment, a single application will be administered for about every 0.5-15 cm2of the plane, more in one embodiment for about every 1-12 cm2of the plane, and most in one embodiment for about every 1.5-7 cm2of the plane. The depth of the plane is in one embodiment about 1-10 mm, more in one embodiment about 2-7 mm, and most in one embodiment about 3-5 mm. In three- dimensional space, a single application in one embodiment is administered for up to about 50 cm3(e.g., about 0.5-50 cm3) of source and / or target locations (e.g., source and / or target tissues), more in one embodiment for up to about 35 cm3(e.g., about 1-35 cm3) of source and / or target locations, and most in one embodiment for up to about 15 cm3(e.g., about 3-15 cm3) of source and / or target locations. Furthermore, the multiple applications can define any suitable pattern or specific geometry. Therefore, for example, in two-dimensional space, the multiple applications can define a square whereas in three-dimensional space the multiple applications can define a cube. Another parameter of the multiple applications which can be manipulated is the time differential between each application. In one embodiment, each of the multiple applications is administered within about 10 minutes (e.g., about 0.5-10 minutes) of each other, more in one embodiment within about 8 minutes (e.g., about 0.5-8 minutes) of each other, and even more in one embodiment within about 6 minutes (e.g., about 1- 6 minutes) of each other. Most in one embodiment, all of the multiple applications of the single dose are administered within the aforementioned time frames. In one embodiment, each of the multiple applications is administered substantially simultaneously. By manipulating both the specific geometry and the time differentials of themultiple applications, the induction of angiogenesis in non-targeted tissue can beminimized, while desirably causing angiogenesis to the target location. When administering the angiogenic mediator to the source and / or target locations (e.g., to source and / or target tissues) it is desirable that the administration is such that the angiogenic mediator is able to contact a region reasonably adjacent to thesource and / or target locations, as well as the area therebetween. It is not believed to benecessary to have the angiogenic mediator actually contact the precise sites of the source and the terminus for collateral blood vessel formation. However, within the context of multiple applications of the angiogenic mediator, it is desirable that the specific geometry of the multiple applications be defined to allow the angiogenicmediator to contact or reach a region including the source, the terminus, and the areatherebetween for the collateral blood vessel formation, in one embodiment to actually contact the precise sites of the source and the terminus for the collateral blood vessel formation, along with the area therebetween. Furthermore, administration of the angiogenic mediator to the source and / or target locations (which are located within or near the tissue of interest) can be accomplished either in vivo or ex vivo. Therefore, for example, the tissue of interest can be removed from the recipient of the present inventive method, can be treated with the angiogenic substance, and then can be reimplanted into the recipient. Ex vivo administration of the angiogenic mediator to the tissue of interest also helps to minimize undesirable induction of angiogenesis in non-targeted tissue. The angiogenic mediator desirably is administered to the host in a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the angiogenic mediator. Any suitable pharmaceutically acceptable carrier can be used within the context of the present disclosure, and such carriers are well known in the art. The choice of carrier will be determined, in part, by the particular site to which the composition is to be administered and the particular method used to administer the composition. Various examples of suitable pharmaceutical carriers, particularly with regards to pharmaceutically acceptable carriers in combination with adenoviral vectors comprising DNA encoding an angiogenic substance are described in International Patent Application WO 98 / 32859. The method of the disclosure can be practiced, and is useful, in a variety of contexts and can be applied to any suitable host. In one embodiment, the host is a mammalian host, more in one embodiment the host is a human host, and optimally the host is a human host suffering from either, or at risk of suffering from, ischemic conditions and / or vascular occlusion in the target location. The desired dosage (i.e., total dosage to the host) is such that angiogenesis is induced in the target location, e.g., such that there is a therapeutic and / or prophylactic effect on target location. Additionally, the dosage desirably is such that induction of angiogenesis in non-targeted tissue is minimized. The dosage also will vary depending upon the angiogenic mediator to beadministered. For example, when an adenoviral vector is used as an angiogenic mediator, the dosage will vary depending upon the particular vector and DNA encoding the angiogenic substance in the vector. A dose typically will be at least about 1×106pfu (e.g., 1×106-1×1013pfu) to the target tissue, e.g., a discrete organ, such as a humanheart. The dose in one embodiment is at least about 1×107 pfu (e.g., about 1×107-1×1013pfu), more in one embodiment at least about 1×108pfu (e.g., about 1×108- 1×1011pfu), and most in one embodiment at least about 1×109pfu (e.g., about 1×109- 1×1010pfu). The dose typically is for a volume of targeted tissue of about 100 cm3, more typically about 150 cm3. The dose is administered via multiple applications, and, assuch, is divided among the multiple applications. Thus, if the dose is administered via10 administrations, each administration involves about 1×105-1×1012pfu. In one embodiment, each application involves about 1×106-1×1012pfu, more in one embodiment about 1×107-1×1010pfu, and most in one embodiment about 1×108- 1×109pfu. For purposes of considering the dose in terms of particle units (pu), also referred to as viral particles, it can be assumed that there are 100 particles / pfu (e.g., 1×1012pfu is equivalent to 1×104pu). In a single round of vector administration, using, for example, an adenoviral vector deleted of the entire E1a region, part of the E1b region, and part of the E3 region of the adenoviral genome, wherein the vector carries human VEGF under the control of a standard CMV immediate early promoter, about 107-1013pfu, in one embodiment about 109-1011pfu, are administered to the host (e.g., to a discrete organ containing the source and / or target locations) with an estimated volume of about 150 cm3. Under these conditions, a substantial level of VEGF production is achieved in the tissue of interest without producing detectable levels of VEGF production in distal tissues. Example B: Exemplary Viral Vector Having VEGF Coding Sequences In one embodiment, a vector of the disclosure provides an isolated or purified nucleic acid molecule having a nucleotide sequence of at least 1877 contiguous nucleotides of SEQ ID NO:1, or a sequence with at least 80%, 82%, 84%, 85%, 87%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% nucleic acid sequence identity thereto which encodes an angiogenic factor, which sequence us capable of producing different isoforms of a protein, such as a vascular endothelial growth factor (VEGF). In one embodiment, the nucleic acid molecule comprises a nucleotide sequence comprising cDNA joined to genomic DNA. The disclosure also provides an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding an angiogenic factor comprising cDNA comprising exons 1-5 of a VEGF joined to genomic DNA comprising introns 5, 6, and 7 and exons 6, 7, and 8 of VEGF, wherein the nucleotide sequence may include a mutation in one or more of the splice donor, branch point, or splice acceptor regions contained in an exon selected from exons 5, 6, 7, and / or 8, wherein the mutation promotes the production of one isoform of VEGF as compared to another isoform of VEGF. In one embodiment, the production of an isoform of VEGF that binds heparin is promoted over the production of an isoform of VEGF thatdoes not bind heparin. Generally, any size nucleic acid molecule is contemplated as long as the isolated or purified nucleic acid molecule has contiguous nucleotides spanning 44% or more, 50% or more, or even 55% or more of SEQ ID NO:1. When the nucleic acid molecule of the disclosure comprises both cDNA and genomic DNA sequences, these DNA sequences are joined to one another. In thisrespect, a cDNA is “joined” to genomic DNA when genomic DNA is included in the nucleic acid molecule and is positioned in the molecule either directly 5′ or 3′ to a cDNA sequence. When multiple genomic DNAs are included in the nucleic acid molecule, such sequences can be positioned either 5′ and / or 3′ to a cDNA sequence. The nucleic acid molecule is constructed such that the production of one isoform of a particular geneis promoted at the expense of another isoform. In such instances, the nucleotide sequence comprising the splice donor, branch point, and / or the splice acceptor site is manipulated (e.g., by site-specific mutagenesis) and, in effect, determines sites within the nucleic acid molecule which are to be removed by splicing. This allows for more control over which particular isoform is to be produced by alternative splicing. In the instance where the pre-mRNA encodes a VEGF, correspondence with the consensus splicing sequences shown in Figure 3 is indicative of efficient splicing. Similarly, a discordance with the consensus sequence is indicative of inefficient splicing. Consensus splice sites in other genes can be determined through routine experimentation.. With respect to the aforementioned isolated or purified nucleic acid molecules, in one embodiment, no insertions, deletions, and / or substitutions are present in the nucleic acid molecule. Such a nucleic acid molecule will code for a “wild-type” gene product (i.e., protein). However, it is suitable for the aforementioned isolated or purified nucleic acid molecules to comprise one or more insertions, deletions, and / or substitutions. Such a nucleic acid molecule will code for a “variant” gene product. In one embodiment, the variant nucleic acid molecule will not differ functionally from the corresponding wild-type molecule. For example, any insertions, deletions, and / or substitutions contained within the nucleic acid molecule comprising a nucleotide sequence of at least 1877 contiguous nucleotides of SEQ ID NO:1 or a sequence with at least 80% nucleic acid sequence identity thereto may not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the nucleotide sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. In one embodiment, the one or more substitution(s) do(es) not result in a change in an amino acid encoded by the nucleic acid molecule. In an alternative embodiment, the one or more substitution(s) may result in the substitution of at least one amino acid with another amino acid of approximately equivalent size, shape, and / or charge (a “conservative” substitution). When desired, the nucleic acid molecule of the disclosure can be inserted intoan expression construct. A nucleic acid molecule as described above can be cloned intoany suitable expression construct and can be used to transform or transfect any suitable host. The selection of expression and methods to construct them are commonly known to persons of ordinary skill in the art. Suitable expression constructs include those designed for propagation and expansion or for expression or both. Examples of suitableexpression constructs include plasmids, phagemids, cosmids, viruses, and othervehicles derived from viral or bacterial sources. Any of these expression constructs can be manipulated to include a nucleic acid sequence having at least 1877 contiguous nucleotides of SEQ ID NO:1 or a sequence with at least 80% nucleic acid sequence identity thereto and can be prepared using standard recombinant DNA techniques. Plasmids are genetically engineered circular double-stranded DNA moleculesand can be designed to contain an expression cassette comprising a nucleic acid molecule of the disclosure. By complexing the plasmid with liposomes, the efficiency of gene transfer in general is improved. While the liposomes used for plasmid-mediated gene transfer strategies have various compositions, they are typically synthetic cationic lipids. Advantages of plasmid-liposome complexes include their ability to transfer large nucleic acid sequences and their relatively low immunogenicity. While plasmids are suitable for use in the disclosure, in one embodiment the expression construct is a viral vector. The viral vector can be any suitable viral vector. Suitable viral vectors include, but are not limited to, reoviruses, adenoviruses, adeno-associated viruses, papovaviruses, parvoviruses, picomaviruses, and enteroviruses of any suitable origin (in one embodiment of animal origin (e.g., avian or mammalian) and desirably of human origin). Other suitable viral vectors are known in the art and are well characterized. The viral vector is derived from, or based on, a virus that normally infects animals, such as mammals (most in one embodiment humans). Adenoviral (Ad) vectors based on human adenoviruses are envisioned viral vectors. The Ad vector can be deficient in replication-essential gene functions of only the early regions of the adenoviral genome, only the late regions of the adenoviral genome, and both the early and late regions of the adenoviral genome. The adenoviral vector also can have essentially the entire adenoviral genome removed, in which case it is preferred that at least either the viral (i.e., adenoviral) inverted terminal repeats (Ad ITRs) and one or more promoters or the Ad ITRs and a packaging signal are left intact (i.e., an adenoviral amplicon). The larger the region of the adenoviral genome that is removed, the larger the piece of exogenous nucleic acid sequence that can be inserted into the genome. For example, given that the adenoviral genome is 36 kb, by leaving the Ad ITRs and one or more promoters intact, the exogenous insert capacity of the adenovirus is approximately 35 kb. Alternatively, a multiply deficient Ad vector that contains only an Ad ITR and a packaging signal effectively allows insertion of an exogenous nucleic acid sequence of approximately 37-38 kb. Suitable replication- deficient Ad vectors, including multiply deficient Ad vectors, are known. It should beappreciated that the deletion of different regions of the Ad vector can alter the immuneresponse of a mammal exposed to the Ad vector. In particular, the deletion of different regions can reduce the inflammatory response generated by the Ad vector. Furthermore, the Ad vector's coat protein can be modified so as to decrease the Ad vector's ability or inability to be recognized by a neutralizing antibody directed againstthe wild-type coat protein.The Ad vector in one embodiment contains a packaging domain. The packaging domain can be located at any position in the adenoviral genome, so long as the adenoviral genome is packaged into adenoviral particles. In one embodiment, the packaging domain is located downstream of the E1 region. The coat proteins of the Ad vector can be manipulated to alter the bindingspecificity of the resulting adenoviral particle. Suitable modifications to the coat proteins include, but are not limited to, insertions, deletions, or replacements in the adenoviral fiber, penton, pIX, pIIIa, pVI, or hexon proteins, or any suitable combination thereof, including insertions of various native or non-native ligands into portions of such coat proteins. Replication-deficient Ad vectors are typically produced in complementing cell lines that provide gene functions not present in the replication-deficient Ad vectors, but required for viral propagation, at appropriate levels in order to generate high titers of viral vector stock. A cell line may complement for at least one and in one embodiment all replication-essential gene functions not present in a replication-deficient adenovirus. The complementing cell line can complement for a deficiency in at least one replication- essential gene function encoded by the early regions, late regions, viral packaging regions, virus-associated RNA regions, or combinations thereof, including all adenoviral functions (e.g., to enable propagation of adenoviral amplicons, which comprise minimal adenoviral sequences, such as only Ad ITRs and the packaging signal or only Ad ITRs and an adenoviral promoter). Most in one embodiment, the complementing cell line complements for a deficiency in at least one replication-essential gene function (e.g., two or more replication-essential gene functions) of the E1 region of the adenoviral genome, particularly a deficiency in a replication-essential gene function of each of the E1A and E1B regions. In addition, the complementing cell line can complement for a deficiency in at least one replication-essential gene function of the E2 (particularly as concerns the adenoviral DNA polymerase and terminal protein) and / or E4 regions of the adenoviral genome. Desirably, a cell that complements for a deficiency in the E4 region comprises the E4-ORF6 gene sequence and produces the E4-ORF6 protein. Such a cell desirably comprises at least ORF6 and no other ORF of the E4 region of the adenoviral genome. The cell line in one embodiment is further characterized in that it contains the complementing genes in a non-overlapping fashion with the adenoviral vector, which minimizes, and practically eliminates, the possibility of the vector genome recombining with the cellular DNA. Accordingly, the presence of replication-competent adenoviruses (RCA) is minimized if not avoided in the vector stock, which, therefore, issuitable for certain therapeutic purposes, especially gene therapy purposes.The nucleic acid molecule may be operably linked to regulatory sequences for expression, especially a promoter. A “promoter” is a DNA sequence that directs the binding of RNA polymerase and thereby promotes RNA synthesis. A nucleic acid sequence is “operably linked” to a promoter when the promoter is capable of directingtranscription of that nucleic acid sequence. A promoter can be native or non-native tothe nucleic acid sequence to which it is operably linked. Any promoter (i.e., whether isolated from nature or produced by recombinant DNA or synthetic techniques) can be used in connection with the disclosure to provide for transcription of a particular nucleic acid sequence. The promoter in one embodimentis capable of directing transcription in a eukaryotic (desirably mammalian) cell. Thefunctioning of the promoter can be altered by the presence of one or more enhancers and / or silencers present on the vector. “Enhancers” are cis-acting elements of DNA that stimulate or inhibit transcription of adjacent genes. An enhancer that inhibits transcription also is termed a “silencer.” Enhancers differ from DNA-binding sites for sequence-specific DNA binding proteins found only in the promoter (which also are termed “promoter elements”) in that enhancers can function in either orientation, and over distances of up to several kilobase pairs (kb), even from a position downstream of a transcribed region. In one embodiment, the promoter is a viral promoter. Suitable viral promoters are known in the art and include, for instance, cytomegalovirus (CMV) promoters, such as the CMV immediate-early promoter, promoters derived from human immunodeficiency virus (HIV), such as the HIV long terminal repeat promoter, Rous sarcoma virus (RSV) promoters, such as the RSV long terminal repeat, mouse mammary tumor virus (MMTV) promoters, HSV promoters, such as the Lap2 promoter or the herpes thymidine kinase promoter (Wagner et al., PNAS, 78, 144-145 (1981)), promoters derived from SV40 or Epstein Barr virus, an adeno-associated viral promoter, such as the p5 promoter, and the like. In one embodiment, the viral promoter is an adenoviral promoter, such as the Ad2 or Ad5 major late promoter and tripartite leader, a CMV promoter, or an RSV promoter. Many of the above-described promoters are constitutive promoters. Instead of being a constitutive promoter, the promoter can be an inducible promoter, i.e., a promoter that is up- and / or down-regulated in response to appropriate signals. The promoter sequence that regulates expression of the nucleic acid sequence can contain at least one heterologous regulatory sequence responsive to regulation by an exogenous agent. The regulatory sequences are in one embodiment responsive to exogenous agents such as, but not limited to, drugs, hormones, or other gene products. For example, the regulatory sequences, e.g., promoter, in one embodiment are responsive to glucocorticoid receptor-hormone complexes, which, in turn, enhance the level of transcription of a therapeutic peptide or a therapeutic fragment thereof. In one embodiment, the nucleic acid molecule further comprises apolyadenylation site following the coding region of the nucleic acid sequence. Also, inone embodiment all the proper transcription signals (and translation signals, where appropriate) will be correctly arranged such that the nucleic acid sequence will be properly expressed in the cells into which it is introduced. Moreover, if the nucleic acid sequence encodes a protein or peptide, which is a processed or secreted protein oracts intracellularly, in one embodiment the nucleic acid sequence further comprises theappropriate sequences for processing, secretion, intracellular localization, and the like. It will be appreciated that the expression construct can comprise multiple nucleic acid molecules of the disclosure. For example, the expression construct can comprise multiple copies of a nucleic acid molecule, each copy operably linked to adifferent promoter or to identical promoters. Moreover, any nucleic acid moleculedescribed herein can be altered from its native form to increase or decrease a desired effect (e.g., to increase its therapeutic effect). For example, a cytoplasmic form of a nucleic acid molecule can be converted to a secreted form by incorporating a signal peptide into the encoded gene product. The disclosure further provides a cell (i.e., a host cell) comprising an isolated or purified nucleic acid molecule or an expression construct as described herein. A nucleic acid molecule such as an expression construct can be useful to prophylactically or therapeutically treat a mammal for a pathologic state. Such treatment will involve the administration of a composition of the disclosure to a mammal, e.g., such treatment will involve the administration of an expression construct to a human. In such instances, the nucleic acid molecule, whether or not present in an expression construct, encodes a therapeutic factor that is an angiogenic factor, such as VEGF. Other suitable therapeutic factors will be apparent to those skilled in the art and can include, for example, fibroblast growth factor, fibroblast growth factor 3, fibroblast growth factor 8, VEGF B, VEGF D, hypoxia-inducible factor 1α, hepatocyte growth factor, and platelet derived growth factors. Upon administration, the nucleic acid molecule of the disclosure is expressed, resulting in the subsequent production of the therapeutic factor. Such expression and subsequent production of the therapeutic factor may allow for enhanced production of one isoform as compared to another isoform. This selective isoform production is useful to prophylactically or therapeutically treat the mammal for the pathologic state. In one embodiment, the nucleic acid molecule can be constructed by manipulating the splice donor, branch point, and / or splice acceptor regions, as described above. For example, a nucleic acid molecule, as set forth in Figure 1, can be included in an expression construct and administered to a mammal to promote the production of VEGF189 at the expense of VEGF165. Such an effect is desirable when the angiogenic signal provided by VEGF189 is more potent than that provided by VEGF165, or the safety of VEGF189 is greater than that provided by VEGF165. The production of VEGF189 also can be at the expense of production of VEGF121, in addition or in alternative to a decrease in VEGF165 production. The pathologic state can be any pathologic state. For example, the pathologicstate can be a disorder caused by an increased or decreased level of a particular geneproduct(s). By “increased level” is meant a level above that which is considered normal. Similarly, by “decreased level” is meant a level below that which is considered normal. Many angiogenic-related diseases result from an increased or a decreased level of a particular isoform of a gene. Accordingly, the pathologic state in one embodiment is anangiogenic-related disease, and the nucleic acid sequence in one embodiment encodesan angiogenic factor, which promotes the production of new blood vessels. The pathologic state can be any type of disease that can receive benefit from the growth of new blood vessels. For example, the pathologic state can be all forms of atherosclerosis (e.g., coronary artery disease), peripheral vascular disease and diffuseatherosclerosis, wound healing, tissue repair and remodeling following surgery, andcongestive heart failure. Other pathologic states also are contemplated in the context of the disclosure. For example, the pathologic state can be an inflammatory disease (e.g., arthritis), a neurodegenerative disease, a disease of an organ which is attributed to the presence of the increased or decreased level of a particular isoform(s), or any other pathologic state for which the modulation of different isoforms of a gene associated with a pathologic state will treat or prevent the pathologic state. Suitable methods, both invasive and noninvasive methods, of directly administering the composition are available. Although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. The inventive method is not dependent on the mode of administering the composition to a mammal, in one embodiment a human, to achieve the desired effect. As such, any route of administration is appropriate so long as the nucleic acid molecule is processed through RNA splicing as described herein. The composition can be appropriately formulated and administered in the form of a local injection, lotion, ointment, implant, or the like. The composition can be applied, for example, topically. The composition can be administered through multiple applications and / or multiple routes to ensure sufficient exposure of cells to the composition. The nucleic acid molecule or expression construct comprising the nucleic acid molecule may be formulated into a composition prior to administration and is administered as soon as possible after it has been determined that an animal, such as a mammal, specifically a human, is at risk for a particular pathologic state (prophylactic treatment) or has developed the pathologic state (therapeutic treatment). Treatment will depend, in part, upon the particular therapeutic factor expressed from the nucleic acid sequence, the route of administration, and the cause and extent, if any, of the pathologic state. The composition can be administered using invasive procedures, such as, for instance, local injection to a target tissue (e.g., intramuscular injection). Local injections typically involve the administration of the composition by a catheter or similar device inserted sufficiently deeply into the proximal portion of the organ- or tissue-feedingartery or arteries so that gene transfer is effected substantially only into the cells of thetarget organ or tissue. Pharmaceutically acceptable carriers for injectable compositions are well known to those of ordinary skill in the art. The composition can be non-invasively administered to a mammal. For instance, if multiple surgeries have been performed, the mammal displays low toleranceto anesthetic, or other disorders exist, topical administration of the composition may bemost appropriate. Topical formulations are well known to those of skill in the art. A composition also can be administered non-invasively using a needleless injection device. The composition may be present in or on a device that allows controlled orsustained release, such as a biocompatible polymeric matrix, meshwork, mechanicalreservoir, or mechanical implant. Implants and devices, such as an implantable device, e.g., a mechanical reservoir or an implant or a device comprised of a polymeric composition, are particularly useful for the administration of the composition. The composition also can be administered in the form of a sustained-release formulation (see, e.g., U.S. Pat. No.5,378,475) comprising, for example, gelatin, chondroitin sulfate, a polyphosphoester, such as bis-2-hydroxyethyl-terephthalate (BHET), or a polylactic- glycolic acid. When administering the composition, the appropriate dosage and route of administration can be selected to minimize loss of the nucleic acid molecule or expression construct or inactivation of the either of the foregoing due to a host's immune system. For example, for in vivo administration, it can be advantageous to administer, to a mammal being treated, an immunosuppressive agent (e.g., cyclophosphamide or FK506) or monoclonal antibody that can block a T cell receptor, prior to performing the inventive method. Prior administration of an immunosuppressive agent or monoclonal antibody can serve to decrease the amount of composition cleared by the immune system of the mammal. When practiced in vivo, any suitable organs or tissues or component cells can be targeted for delivery. In one embodiment, the organs / tissues / cells employed are of the circulatory system (i.e., heart, blood vessels or blood), respiratory system (i.e., nose, pharynx, larynx, trachea, bronchi, bronchioles, lungs), gastrointestinal system (i.e., mouth, pharynx, esophagus, stomach, intestines, salivary glands, pancreas, liver, gallbladder), urinary system (i.e., kidneys, ureters, urinary bladder, urethra), nervous system (i.e., brain and spinal cord, and special sense organs such as the eye), and integumentary system (i.e., skin). Even more in one embodiment, the cells being targeted are selected from the group consisting of heart, blood vessel, lung, liver, gallbladder, urinary bladder, and eye cells. The dose of composition administered to a mammal, particularly a human, in accordance with the disclosure should be in an amount sufficient to treat prophylactically or therapeutically a mammal for a pathologic state. Dosage will depend upon a variety of factors, including the age, species, the pathology in question, andcondition or disease state. Dosage also depends on the nucleic acid sequencescontained in an expression construct, as well as the amount of tissue about to be affected or actually affected by the disease. The size of the dose also will be determined by the route, timing, and frequency of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of aparticular composition and the desired physiological effect. It will be appreciated by oneof ordinary skill in the art that various conditions or disease states, in particular, chronic conditions or disease states, may require prolonged treatment involving multiple administrations. Suitable doses and dosage regimens can be determined by conventionalrange-finding techniques known to those of ordinary skill in the art. When administeringan expression construct, such as a viral vector, in one embodiment about 106viral particles to about 1012viral particles are delivered to the diseased tissue. In other words, a composition of the expression construct can be administered that comprises an expression construct concentration of about 106particles / ml to about 1012particles / ml (including all integers within the range of about 106particles / ml to about 1012particles / ml), in one embodiment about 1010particles / ml to about 1012particles / ml. Typically, about 0.1 μl to about 100 μl of such an expression construct composition to each affected tissue. Of course, other routes of administration may require smaller or larger doses to achieve a therapeutic effect. Any variations in dosages and routes of administration can be determined by the ordinarily skilled artisan using routine techniques known in the art. In some embodiments, it is advantageous to administer two or more (i.e., multiple) doses of the composition. The disclosure provides for multiple applications of the composition in order to achieve sufficient integration, thereby prophylactically or therapeutically treating a particular disease state. For example, at least two applications of a composition can be administered to the same tissue. In one embodiment, the targeted cells are contacted with two applications or more of the composition via direct administration to the desired tissue within about 30 days or more. More in one embodiment, two or more applications are administered to cells of the same tissue within about 90 days or more. However, three, four, five, six, or more doses can be administered in any time frame (e.g., 2, 7, 10, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 85 or more days between doses) so long as the desired prophylactic or therapeutic effect is achieved. The composition can be introduced ex vivo into cells, previously removed from the mammal, especially a human, and exposed to the composition. Such transduced autologous or homologous host cells, reintroduced into the mammal (e.g., human), will express directly the nucleic acid sequences contained therein in vivo following initiation of DN A replication. One ex vivo therapeutic option involves the encapsidation of infected cells into a biocompatible capsule, which can be implanted into a particular tissue. Such cells need not be isolated from the patient, but instead can be isolated fromanother individual and implanted into the patient.The human VEGF gene may be reconstructed as a hybrid using the cDNA for exons 1 through 5 joined to the genomic configuration for exons 6, 7, and 8 (including introns 5, 6, and 7). Exon 5 was mutated to contain a SacI restriction site, exon 6 was mutated to contain an XbaI restriction site, and exon 7 was mutated to contain an XhoIrestriction site all without changing the encoded VEGF protein sequence. A HindIIIrestriction site was created immediately following the stop codon of exon 8. Accordingly, mutations were made in each of the splice acceptor, branch point, and splice donor site of exon 6 to increase the production of VEGF189 at the expense of VEGF165 and VEGF121. By making appropriate mutations by site-specificmutagenesis, the efficiency of recognition of exon 6 was enhanced.These mutations ware outlined in the table below. The “ / ” in the splice acceptor sequences represents the end of the splice acceptor sequence and the beginning of exon 6. Similarly, the “ / ” in the splice donor sequences represents the end of exon 6 and the beginning of the splice donor sequence. Mutations are indicated in bold. Branch Point Splice Acceptor Splice Donor TT The nucleic acid molecule of can be used to increase the abundance of VEGF189 at the expense of VEGF121. The invention will be further described by the following non-limiting examples. Example 1 As part of a thorough characterization of Ad5VEGF-A116A+, the splicing pattern was assessed following infection of AC16 cardiomyocyte cells using a high dose of 5000 particle units per cell. RNA was collected after 48 hours and two methods of next generation sequencing were used to assess the mRNA profile: the PacBio technology that provide very long reads and the RNA-Seq (Illumina) method that provides a massive number of short (100 bp) reads. The sequence reads were mapped to the artificial chromosome of Ad5VEGF- A116A+ and splicing variants were quantified. While the canonical splices of VEGF121, VEGF165 and VEGF189 were observed, there was a large degree of mis-splicing. This was of two categories (1) intron inclusion; and (2) polyA read through resulting in variant forms of VEGF being expressed. The frequency of these inadvertent splicing events was determined for both sequencing platforms. It is dominated by the polyA read through, with exclusion of exon 8 and inclusion of adenovirus E1B sequences. Table 2. Comparison of VEGF Isoforms Identified by PacBio (long) and RNA-seq PacBio RNA-seq* Isoform % Total Reads (59,022) % Total Reads (15,636,285) VEGF121 0.003 0.01 VEGF165 0.04 4.40 VEGF189 1.60 2.70 Variant VEGF125 4.80 0.01 Variant VEGF169 10.40 27.70 Variant VEGF193 78.00 60.10 Intron 5 inclusion 0.02 0.80 Intron 6 inclusion 0.02 0.40 Intron 7 inclusion 7 3.90 * Illumina reads do not cover whole cDNA so are calculated from junction frequency. Intron retention is a common observation for many alternately spliced genes and is widely observed in RNA-seq data (Zheng 2020). Some intron-containing transcripts are rapidly degraded due to nonsense mediated decay. The frequency ofintron retention increases in some disease sates such as cellular transformation / cancer(Monteuuis 2020). Polyadenylation. The process of polyadenylation at the 3’ end of nascent primary RNA is one step in formation of a mature mRNA. The process is co- transcriptional and is mediated by a large enzyme complex including factors thatrecognize the correct site based on certain RNA sequences. It requires two steps withRNA cleavage followed by the template-free addition of 30-200 adenyl residues. Polyadenylation depends on the interactions of specific sequences and trans- acting polyadenylation factors. The fundamental process depends on recognition of the sequence AAUAAA by cleavage and polyadenylation factor complex (CPSF) and an upstream sequence GUUGUGGU by cleavage stimulation factor complex (CSTF). The cleavage and polyA addition site lies between these two recognition sequences. However, there is a wide range of efficiency and it is estimated that 60% of genes have multiple polyadenylation sites Therefore, readthrough of polyA sites is a common occurrence. In some cases, there are tissue specific read throughs that result in variant functions from the same gene (Gruber 2019). AdVEGF-A116A+ contains the poly-adenylation signal from SV40. This is a complex but compact entity which can be effective in either orientation since it includes signals for polyadenylation of convergent transcripts from early and late SV40 genes. In the Ad5VEGFA116A+ construct, the polyA is in the early configuration that polyadenylates T antigen. In the next generation sequencing data, 80% - 90% of transcripts did not terminate as expected at the SV40 polyA site and read through to the flanking adenoviral genome until encountering the truncated adenoviral E1B gene. This gene includes a splice acceptor followed by a polyadenylation site. In the absence of efficient polyadenylation at the SV40 site, nascent transcripts spliced onto the E1B gene instead of the VEGF exon 8. Exon 8 of VEGF encodes the last 7 amino acids of VEGF while the splice into AdE1B encodes 11 different amino acids followed by a stop codon.Therefore, the canonical VEGFs 121, 165 and 189 are instead expressed as variants129, 169 and 193 (Figure 5). While the VEGF variants are evidently biologically active, they create a potential neo-antigen of sequence SRRRHEHQLV – a very basic peptide sequence. The human protein database was searched for similar sequences. The top match was 7 / 11 in thelamin B2 gene.The splicing patterns (Table 1) show that all 3 splice donors at the end of exons 5, 6A and 7 spliced into the AdE1B gene. The specificity approximately matched that of the splicing into exon 8 of E7>E6A>E5. It is unclear if this polyA read-through and mis-splicing are specific to AdVGEG-A116A+ or if it would be present in other Ad vectors. All first generation Ad genetransfer vectors have a similar configuration with a partial deletion of the AdE1A and E1B genes. Depending on the presence of overt or cryptic splice donors in the expression cassette, the consequences may differ. In the simplest case it would be an unspliced transcript (for example when a cDNA is in the expression cassette) and therefore translation termination would happen at the correct site even if transcription terminated at the E1B polyA. Example 2 As discussed above, the read through of the SV40 polyA site in Ad5VEGF- A116A+ has unintended consequences. Below are described exemplary methods to circumvent this issue. Method 1. Use of stronger polyadenylation site(s). The first method to eliminate the nonnative forms for VEGF is to use a stronger polyadenylation site so that read- through into the adenoviral sequence flanking the VEGF expression cassette is decreased or eliminated. This can be achieved by using alternate polyA signals. Examples that have been used in gene therapy are derived from the rabbit beta globin gene (531bp) and the human growth hormone genes (477bp). Both of these are longer than SV40 and include potential binding sites for additional proteins of the termination complex. Alternate polyA signals can be chosen from genes that a have a single polyadenylation site such as GAPDH or RPL3. These may be further mutagenized to 10 promote recognition by multiple termination factors to increase overall efficiency of termination. As needed, multiple polyA sites may be screened to identify one that is efficient in the context of Ad5VEGF-A116A+, in one embodiment in multiple cell types. If the desired level of termination cannot be achieved, serial polyA sites may be utilized. Exemplary PolyA sequences 15 GAPDH polyA (500 bp) GGGCTGGCATTGCCCTCAACGACCACTTTGTCAAGCTCATTTCCTGGTATGTGGCT GGGGCCAGAGACTGGCTCTTAAAAAGTGCAGGGTCTGGCGCCCTCTGGTGGCTG GCTCAGAAAAAGGGCCCTGACAACTCTTTTCATCTTCTAGGTATGACAACGAATTT GGCTACAGCAACAGGGTGGTGGACCTCATGGCCCACATGGCCTCCAAGGAGTAA 20GACCCCTGGACCACCAGCCCCAGCAAGAGCACAAGAGGAAGAGAGAGACCCTCACTGCTGGGGAGTCCCTGCCACACTCAGTCCCCCACCACACTGAATCTCCCCTCCT CACAGTTGCCATGTAGACCCCTTGAAGAGGGGAGGGGCCTAGGGAGCCGCACCT TGTCATGTACCATCAATAAAGTACCCTGTGCTCAACCAGTTACTTGTCCTGTCTTAT TCTAGGGTCTGGGGCAGAGGGGAGGGAAGCTGGGCTTGTGTCAAGGTGAGACAT 25TCTTGC (SEQ ID NO:41)TUBB polyA (330 bp) GTCCCCAGAGGAGAGGGGAACCCTCCTCCATCTTTTTTGCAACATCTCATTTCTTC CTTTTGCTGTTGCTTCCCCCCTCACACACTTGGTTTTGTTCTATCCTACATTTGAGA TTTCTATTTTATGTTGAACTTGCTGCTTTTTTTCATATTGAAAAGATGACATCGCCCC 30AAGAGCCAAAAATAAATGGGAATTGAAAAAAGCTGCGAGATGTGTGCTTATTTAGGGAAACACGGCTGGCTGATGGAGGCATGGGGCCTGAGTTCAGTTGCACTGCTCTCC TTAAATTGACACTTAATATTGAGTCCCTGTCCTACGGATTCAACCAAC (SEQ ID NO:42) RPL3 polya (540 bp) 35 CCCTGTCTCCTTCTCGTCTCCACAGCACTGGCATCACCCAAGCTGTGCAAACAGCA GAGACCCAGCTGCCTCACCCTGGTGACAAACATTTGCACAATGCCCACTGCTCCA GGCTGGATTTCTACAGCTCAGCTGCAGAACCAGGCCCAGCTTTTACCTCCCTCCA GGGACTGAGGGTGGGGGACAGAGTGGGAGGCCAGAAGGCAAACCCAGCGAAGC TACAGAAAGGAGGGCAGTGGCCTTGGGGAGCACAAGGCACCTCAAGGGCCCCCA 40 TCTGCCTCCCCAGTCCCAGCCTCTCTCCTGAAGAAAGAGGCAAGATGTCAGTGGA AAATAACTTTTATTGAGACCCCACCAACTGCAAAATCTGTTCCTGGCATTAAGCTCC TTCTTCCTTTGCAATTCGGTCTTTCTTCAGTGGTCCCTGTGGGGAGAGAGGCAGTG GTCAGAGGTAGAAGATGACAGGTGACAGCAGATGCCCACTCTAGAGGAGACCAAG ACTCTGGGCCAGTCTCCACAGCCACAAGAGAGGCCTAAGGCATC (SEQ ID NO:43) rabbit beta globin polyA (531 bp) AATTCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAA TGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGG ACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCA TTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGG GCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCC CATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGAA ACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGA TTTTTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTAC ATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCC CTCTTCTCTTATGGAGATCCC (SEQ ID NO:44) hGH polyA (477 bp) GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCA CTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACT AGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCA AGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGT GCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCT CCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGC TAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCC AACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACA GGCGTGAACCACTGCTCCCTTCCCTGTCCTT (SEQ ID NO:45)

[0002] Method 2. Eliminate E1 B splice acceptor from vectors. First generation adenoviral vectors are produced in the 293 cell line where the adenoviral E1 A and E1 B functions are provided by the packaging cell line in cis. Therefore, the E1 B sequences in the AdVEGF-AII6A+ vector are not required and can be eliminated from the construct without impacting function or production. This may have an added benefit of reducing the production of replication competent adenovirus during vector production. In that way the splice acceptor for E1 B would be eliminated and any read through could terminate the polyA site of AdE1 B.

[0003] Method 3. Enhance splice acceptor of VEGF exon 8. There is a consensus splice acceptor sequence of both the actual junction and the upstream branch site, typically about 40 nt upstream of the acceptor. Generally efficient splicing is promoted by matching this consensus closely. The exon 7 branch site could be enhanced to promote the usage of exon 8 of the VEGF gene essentially competing more effectively with the AdE1 B acceptor for splice donors of exon 5, 6A and 7. Compone | Goal | Exon 8 in VEGF-AII6A+ | Updated design Method 4. Reverse orientation of VEGF A116A expression cassette with respect to adenoviral genome. If the orientation of the expression cassette was reversed, then the read through would enter the inverted terminal repeats of the adenovirus and therefore not hit a potential splice acceptor or polyA site. In the event that polyadenylation was inefficient, the primary transcript would run off the left hand end of the adenoviral template and not be properly processed resulting in rapid degradation in the nucleus. There is a large amount to turnover of improperly processed mRNA in the nucleus of all cells and this a normal cellular process (Wang 2020). Method 5. In the event that none of the above alone are sufficient to completely eliminate read through and mis-splicing, they may be combined and show multiplicative effects for additional benefit. Example 3 There is extensive evidence that AdVEGF-All6A+ functions and is safe (XyloCor). However, in sequencing studies (see above) of the VEGF isoforms expressed by Ad5VEGF-All6A+ in the human AC16 cardiomyocyte cell line, it was discovered that most of the VEGF isoforms expressed by Ad5VEGF-All6A+ deleted exon 8a and included 11 amino acids coded by out-of-frame sequences in adenovirus serotype 5 E1b region. The analysis demonstrated that there was readthough of the relatively weak SV40 polyA sequence and that most of the VEGF isoforms expressed used their 3’ splice donor to join with an E1B splice acceptor. This finding was unpredictable and unexpected. The VEGF-IFa and VEGF-IFb expression cassettes described herein are designed to eliminate this problem, creating potent expression cassettes that generate the correct VEGF isoforms. Inappropriate splicing with Ad5VEGF-All6A+ To understand the relative abundance of the different VEGF isoforms produced from cell infected with by AdVAEG-All6A+, next generation mRNA sequence was performed with the PacBio technology that provide long reads. This provided an unexpected observation that the SV40 polyadenylation site that should terminatetranscription of VEGF-All6A+ was inefficient in the context of Ad5VEGF-All6A+ (Figure 3). Subsequent to the development of VEGF-All and VEGF-All6A+ expression cassettes, multiple inhibitory isoforms of VEGF were discovered with an alternate C- terminus generated by an alternate exon 8 called exon 8b. The most abundant isoform was designated as VEGF165b isoform which has an alternate 6 amino acid C-terminus of SLTRKD compared to CDKPRR In the canonical angiogenic VEGF. VEGF165b is both an antagonist of the angiogenic isoforms and also attenuates angiogenic processes. Exon 8b is absent from the VEGF-ALL and VEGF-ALL6A+ expression cassettes. VEGF-IFa and VEGF-IFb The following is a description of “VEGF-IFa” (human vascular endothelial growth factor version a) and “VEGF-IFb” (human vascular endothelial growth factor isoform version b), gene therapy expression cassettes designed to express the major isoforms of vascular endothelial growth factor (VEGF) delivered by an adenovirus gene transfer vector. The examples shown are with adenovirus serotype 5, but the adenovirus could be of any serotype, human or nonhuman. The expression cassette of VEGF-IFa is designed to express VEGF isoforms 189>165>121 by an adenovirus gene transfer vector and all isoforms expressed include exon 8a, exclude exon 8b and do not result in any aberrant splicing to adenovirus genes. The expression cassette of VEGF-IFb is designed to express 189, 165, 121 in normal ratios and includes exon 8a, exclude exon 8b and do not result in any aberrant splicing to adenovirus genes. VEGF-IFa is based on the expression cassette used in Ad5VEGF-All6+ (US Patent No.7,368,553). Based on sequencing studies of the expression product of Ad5VEGF-All6A+, the SV40 polyA sequence in Ad5VEGF-All6A+ allows readthrough toa splice acceptor in adenovirus serotype 5 E1B gene, resulting in deletion of exon 8a inthe majority of VEGF sequences, and inclusion of 11 C-terminal amino acids resulting from transcription of 33 out-of-frame E1B sequences. VEGF-IFa corrects this to include, in all VEGF isoforms expressed, exon 8a as the C-terminal amino acids of the VEGF- IFa product, and elimination of any readthrough of E1B sequences. This has beenaccomplished by adding more powerful poly A sequences and reverse orientation of theVEGF-IFa expression cassette in the adenovirus vector. VEGF-IFb is based on the expression cassette used in Ad5VEGF-All. The expression cassette in Ad5VEGF-All is similar to that to VEGF-All6A+ except the splice donor and acceptor sequences in “All” generate 189, 165, and 121 in similar ratioswhereas the splicing sequences in “All6A+” are designed to generate 189>165>121isoforms. The sequence changes in VEGF-IFb are identical to that in VEGF-IFa, but based on the Ad5VEGF-All expression cassette. There are a number of methods that may be used to create VEGF-All6A+ and VEGF-All derivatives that do not splice into the adenoviral AdE1B gene, see, e.g., Figure 7. In the first variant, the previously designed VEGF-All and the VEGF-All6A+ genes are used to express either all isoform equally or to produce a preponderance of VEGF 189 respectively. But the weak SV40 ploy A site is replaced by a more effective poly A site to prevent read-through. Poly A sites widely used in gene therapy are derived from the rabbit beta globin gene (531bp) and the human growth hormone genes (477bp). Both of these are longer than SV40 and include potential binding sites for additional proteins of the termination complex. Many genes have multiple polyA signals implying these are weak or conditional and are to be avoided. Alternate polyA signals can be chosen from human genes that a have a single polyadenylation site such as GAPDH, TUBB (tubulin), RPL3 (ribosomal protein large 3), or ITGA1 (Integrin A1). These may be further mutagenized to promote recognition by multiple termination factors to increase overall efficiency of termination. As needed, multiple polyA sites may be screened to identify one that is efficient in the context of Ad5VEGF-All6A+ and AdVEGF-All, in one embodiment in multiple cell types. If the desired level of termination is not sufficient, serial polyA sites may be utilized. In the second variant, the orientation of the VEGF expression cassette with respect to the adenoviral genome is reversed. Therefore, even if there is a weak polyA site such as SV40, the consequence of polyA site read-through would be run off at the terminus of adenovirus. If that was the case, the transcript would not be polyadenylated and therefore would be rapidly degraded. Note that variants 1 and 2 can readily be combined. Example 4 Exemplary Sequences of Vector Designed to suppress VEGF mis-splicing SEQ ID NO: 48 ADVEGFALL-6A+VARIANT #5 (35,648 BP) CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGG AGTTTGTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGG CGGAAGTGTGATGTTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAA AAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGG TTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTC GCGGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGC GCGTAATACTGTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGG AGTTCCGCGGGATCTCCATAAGAGAAGAGGGACAGCTATGACTGGGAGTAGTCAG GAGAGGAGGAAAAATCTGGCTAGTAAAACATGTAAGGAAAATTTTAGGGATGTTAA AGAAAAAAATAACACAAAACAAAATATAAAAAAAATCTAACCTCAAGTCAAGGCTTTT CTATGGAATAAGGAATGGACAGCAGGGGGCTGTTTCATATACTGATGACCTCTTTA TAGCCAACCTTTGTTCATGGCAGCCAGCATATGGGCATATGTTGCCAAACTCTAAA CCAAATACTCATTCTGATGTTTTAAATGATTTGCCCTCCCATATGTCCTTCCGAGTG AGAGACACAAAAAATTCCAACACACTATTGCAATGAAAATAAATTTCCTTTATTAGC CAGAAGTCAGATGCTCAAGGGGCTTCATGATGTCCCCATAATTTTTGGCAGAGGGA AAAAGATCTCAGTGGTATTTGTGAGCCAGGGCATTGGCCACACCAGCCACCACCTT CTGATAGGCAGCCTGCACCCGGTGGATCGGATATCTTATCTAGAAGCTTTCACCGC CTCGGCTTGTCACATCTGAGGGAAATGGAAAACAAAGGCTGGGGTTAGGGCCAAG TGAGGAGGCCTGGCGATGAGGCAGGCGGCCTCCCCATTCCTGGGGGCCCCTGG GTCACTGCAGCCTCCGGCACCATAAGAGCAGAGGGGACAGGAAGGTGTGGTCCT GGGGCAGAAAGCCCCAGTATGAGAACAGCCCCAGCCCTGCCCTCAGGGAGCCCC GGCCTGAGCAGCAGCTCCACTCAGGGGCTCCCAGTCTACCCTCCTGAGCTTGCAA TCTACTTGAGACAAGACAAGGACATGGGAACACTTTACAAAGCAACAAATGAACGG ATACCAAAGAACAGTCCCCACTTGACATTTTAAGAGCTGATGGGTGACCAGAGCTG GATGAAGTTAATCAGAAGAGGCTCCCTGCTGAGGAGGGTTTTCAGTTCAGTCTCTA GGGGCTGGTGTGGGGAAGAGAGTGGGCAGATCCACTAGTAACGGCCGCCAGTGT GCTGGAATTCGCCCTTCGCAGATCTCAGGCAGGCAGCTAGAAACTGAGCAAGCAG CTGGCCCCTCTCAGGCGCTCTCCCGCTCGCTCGCTCGCTCACTCTCTTTCTCTCTC TCTCTCCCCATCTCTGTGTGATGCCCCTCTCTGACTTGCTTGCCCTCTGGGAACCA ACCTGCAAGTACGTTCGTTTAACTCAAGCTGCCTCGCCTTGCATCTCGAGTCTGTG TTTTTGCAGGAACATTTACACGTCTGCGGATCTTGTACAAACAAATGCTTTCTCCGC TCTGAGCAAGGCCCACAGGGACTGCAAAAAGGCAAAAGGAAAGACATCTAAGCTA GAGCATCAGCAGAGAGAGAGAAAAAAAATCACCATGCAACACCCCCTAACATGTCC GCAGCTGCACCCCCACCCAGCCGGTCAGCCCCCAGGCCCTGGAAGGATCCGAGC GCTACAGCAAAAGACAGAGAGAGCGGCGGAAAGAGGCAGCACTGGCTAGGACAC CTGCCGCAGGAAGAGGCGGGCACAGACGGGCAGAGAGTGCAGGGAGAGGCTGC CATAAGGGGCAATGCTGTGTCTCTGGGAGACAAGGGTGAGTCTCAGGCCACAGG GACCCAACTGCTGTTGCCCCCATCGGAGCACGCCTTGACTCTTCACCTGCTGGGG ATGGCAATCAGGGGCCACCTTCTCCCCGTGCAAGGCTCATGTCCAGGCCCTTCCA CCAAGGTGGGCTAAAGTAGGGTGTGATGGGAGGCTAAGCCCGGAGGCAGTGTCC CCAGGCCAGGCCGCTGGTGGCCAGAGGGCCCAGGGCAGGGCCCACCACAGCCT CCGACCCGGAGGAAGAGGCTGCCCTGCAAGGAGGCCTCTGTGGGTGCCATGGGT TGGGCCAGAATAGGGGGCTCCCCTCCAGAGGCCCCACCTCCGTGAGGAGCCAGG GCACTTCCACCAGATGAAGGGAGGCCGCCACATGGTGTCTGATCCCACCCAAGCT CCTCCTTCAGCCAAGGAGTCATTCAGCAAGCTGCCTCCAGTCATTCACAGCCCTTC TTGGGCCATGTCTGCCCTCCCCACCACCCTCAGCTTCCAGACGAGTGCAGAAGCC TAGAGCAATGGAAACCAGTTGGGTGAGCAGGCACCTGTGCCAACATGGGCCTGCC ACCAGTGCCCAGTGGGTGAGAGAAAATCGGTGCCCAGCCAAGCCAGGGTCCCCT CCCTTAATCCTCCAGGCCAAGTCGGCACCCCCATTCACCCCAACCCTGGACCAGC AATGCCACCACCAAATCTACCCGTTGGTGCCAATTAGTGGAGTGAGAGAGTGAGA GAGAGACACGGGCCAGGAGGATGAGAGCCAGGGAGGGACCAGGGGAGGGAGGC AGGGTTACAGGGAATGGCAGGCGGAGGTTGTACTGGGGGCCAGGGAGGCTCCAG GGCATTAGACAGCAGCGGGCACCAACTTACACGCTCCAGGACTTATATCTAGATTT CTTGCGCTTTCGTTTTTGCCCCTTTCCCTTTCCTCGAACTGATTTTCTGGAAAAGAAAAAAACAGAGACAGAGAAAGAGCGGGGGCGGTGGGGGGAGTAAAAGAAGTGCTCAGGGGGGCAGGGATGGGGGAACGACCAAAGCAAAGCCACACAGGGCCGCTTCCC GGAGGAAGTGTCAGGAGGCAGGTGGTCTCTGGGGAGGCATGCGCGGGCGCACA CAGGCGTGTCTGGGCAGCAAGCACTCGATGGCTCTTTCTTCTCCTCACGCTGCCC ACCATGGGATGGCAAACCCAGCCCCTGACAAGGCTTTGGTGGGAAGCCGAGACTGGGTGGAGGGCACAGGACCCAAAGGTCTCCACACTCACAGTGGCTCCCAGTCCCCGGCAGGGGGCAAAGCCTGAGGGAAGGCTCTTTGCCCAGCAGCCCTGTCCAAGT CTGACCCTGAAGGTCCGGGGGTGATAAAAGGTAGGCCAGACTTTGGGGAGAAGG TCAGAGACCTGCCTGGATGGGGAGCAGGAGTGGGAGGGAGGGCTGTGTATCAGG CCTTGTGCCTTCATTTGCAACTGCGACAGAACCTCTGGGAATCCCGGTGTGGGGGAAGCGGCTACCTTGGGAGCTGGCACGGAACCAAGAGCAACACCAGCCTGCTCAGCACGACCTGGACTGGGAGGCAGGGCTGGGTGTCCTGGAGCCCTGGGCAGGCAG CAGGATGGGGTGGGAGTTAAGGAGGTCTGGGGAGGAGAGGCTTGGGCGGTACTT GGCAGGGAGTTCTCTCCCCAGCCTGTCAAAGCCTGCTACACCATCTCACCAGACA CTCTTCCGAGCCCAGGCGAGCCCCCTACTCTCCCCATGGCAGAGCAGTCATTTGG GGAAACAGGAAGGGGGGCAGGCTGTAGCCTGTCCCCTTCAAGAGAACCAGAGCT CTCCATGCCTGCCAAGCCCAAGAGAACACACCTCAGGATGTCTGTCACAGGGAAG AAAGGAGGGGGAGAAGGGACCAGAGAGGGCAAGTCTGTCCCCCTTAGGAGAAAG CACCAAAGGGTGGAAGGAAGGTTTCCGCATCCCCTCGCTCTGGAAGCTGGGAGCT GAGGGAAGAGGCAAGGGGTTGAGGCCTGGTGGGGGCTTCAATGTCCGCACAGCA CTGGAGGCAGACAAGATGGTGTGGGGGAAAGGGCAGGGCACAGGTGCTCTCTCT CAGTCTCTCTTTCCCTGCAAGCTCTTGCTGATGCCAGCCGCCCACCCTGTCTTGAA GGGTTACTGCCGCCAAACCTTGTCCCCCACCCCATCCTACCTGCCCCTTAACACG GAGCACTCACAAGCCTCTGAAAATGACCAACATTCAACTTTTTCTCCCTGGCCAAG AGGGCTGTGTGTCTGCCGCCTGCCGCCTACAGGAGGGCATGCACTGAGAAACCA CCCTCCAGCCGGCCTCGCATCCAACTGCACCGTCACAGCAGCCACCAAAAGAGGC CATTTCCTCTGACACACAAAAGCTGGCCTCTCTGCCACCCACTCCCTCTCCCCACT GTGGGTGTCCTAGAGCAAGCCAGTGAGCCAGTGTCCACAGTGCCCCCTGACACAC CGAAACAGCAAGTCCTGGTCAGAAATGATCTGGAGACCCAGAAGGCATTGTCCCT TCCAAAGGAAGTGCCAGGCTCCTGGCTATGTTTTCTCACTAGCCCTAGAGCCATCA TCCTGGAGTTGGCTCCATCCCATTGTTGCTGCCACCACAAGTCCCCCACAAGACCA AGTCCCTGACCCAGGGAGGCTATGGGAGCCCCCAACAGAGGTAGCCAAGAGCCC CAAACCAAGACAACCGGCCATGGAGAGGGAGAAGTGCTAAAGTCAGGGCCACTTA CTTTTCTTGTCGAGCTCTATCTTTCTTTGGTCTGCATTCACATTTGTTGTGCTGTAG GAAGCTCATCTCTCCTATGTGCTGGCCTTGGTGAGGTTTGATCCGCATAATCTGCA TGGTGATGTTGGACTCCTCAGTGGGCACACACTCCAGGCCCTCGTCATTGCAGCA GCCCCCGCATCGCATCAGGGGCACACAGGATGGCTTGAAGATGTACTCGATCTCA TCAGGGTACTCCTGGAAGATGTCCACCAGGGTCTCGATCGGATGGCAGTAGCTGC GCTGATAGACATCCATGAACTTCACCACTTCGTGATGATTCTGCCCTCCTCCTTCT GCCATGGGTGCAGCCTGGGACCACTTGGCATGGTGGAGGTAGAGCAGCAAGGCA AGGCTCCAATGCACCCAAGACAGCAGAAAGTTCATGGTTTCGGAGGCCCGACCGGAATTCGATATCAAGCTTATCGATACCGTCGACGACGGTGACTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCAGATCTCTAGC GGATCTGACGGTTCACTAAACCAGCTCTGCTTATATAGACCTCCCACCGTACACGC CTACCGCCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGAAAGTCCC GTTGATTTTGGTGCCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCACCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCC ATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCA ATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTA CCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACACGCGGATCTGGGCGTGGTTAAGGGTGG GAAAGAATATATAAGGTGGGGGTCTTATGTAGTTTTGTATCTGTTTTGCAGCAGCC GCCGCCGCCATGAGCACCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGAC AACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCAT TGATGGTCGCCCCGTCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTG TCTGGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCC ACCGCCCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTG CAGCTTCCCGTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGGCACAATTG GATTCTTTGACCCGGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCA GCAGGTTTCTGCCCTGAAGGCTTCCTCCCCTCCCAATGCGGTTTAAAACATAAATA AAAAACCAGACTCTGTTTGGATTTGGATCAAGCAAGTGTCTTGCTGTCTTTATTTAG GGGTTTTGCGCGCGCGGTAGGCCCGGGACCAGCGGTCTCGGTCGTTGAGGGTCC TGTGTATTTTTTCCAGGACGTGGTAAAGGTGACTCTGGATGTTCAGATACATGGGC ATAAGCCCGTCTCTGGGGTGGAGGTAGCACCACTGCAGAGCTTCATGCTGCGGG GTGGTGTTGTAGATGATCCAGTCGTAGCAGGAGCGCTGGGCGTGGTGCCTAAAAA TGTCTTTCAGTAGCAAGCTGATTGCCAGGGGCAGGCCCTTGGTGTAAGTGTTTACA AAGCGGTTAAGCTGGGATGGGTGCATACGTGGGGATATGAGATGCATCTTGGACT GTATTTTTAGGTTGGCTATGTTCCCAGCCATATCCCTCCGGGGATTCATGTTGTGC AGAACCACCAGCACAGTGTATCCGGTGCACTTGGGAAATTTGTCATGTAGCTTAGA AGGAAATGCGTGGAAGAACTTGGAGACGCCCTTGTGACCTCCAAGATTTTCCATGC ATTCGTCCATAATGATGGCAATGGGCCCACGGGCGGCGGCCTGGGCGAAGATATT TCTGGGATCACTAACGTCATAGTTGTGTTCCAGGATGAGATCGTCATAGGCCATTT TTACAAAGCGCGGGCGGAGGGTGCCAGACTGCGGTATAATGGTTCCATCCGGCC CAGGGGCGTAGTTACCCTCACAGATTTGCATTTCCCACGCTTTGAGTTCAGATGGG GGGATCATGTCTACCTGCGGGGCGATGAAGAAAACGGTTTCCGGGGTAGGGGAG ATCAGCTGGGAAGAAAGCAGGTTCCTGAGCAGCTGCGACTTACCGCAGCCGGTG GGCCCGTAAATCACACCTATTACCGGCTGCAACTGGTAGTTAAGAGAGCTGCAGC TGCCGTCATCCCTGAGCAGGGGGGCCACTTCGTTAAGCATGTCCCTGACTCGCAT GTTTTCCCTGACCAAATCCGCCAGAAGGCGCTCGCCGCCCAGCGATAGCAGTTCT TGCAAGGAAGCAAAGTTTTTCAACGGTTTGAGACCGTCCGCCGTAGGCATGCTTTTGAGCGTTTGACCAAGCAGTTCCAGGCGGTCCCACAGCTCGGTCACCTGCTCTACGGCATCTCGATCCAGCATATCTCCTCGTTTCGCGGGTTGGGGCGGCTTTCGCTGTA CGGCAGTAGTCGGTGCTCGTCCAGACGGGCCAGGGTCATGTCTTTCCACGGGCG CAGGGTCCTCGTCAGCGTAGTCTGGGTCACGGTGAAGGGGTGCGCTCCGGGCTG CGCGCTGGCCAGGGTGCGCTTGAGGCTGGTCCTGCTGGTGCTGAAGCGCTGCCGGTCTTCGCCCTGCGCGTCGGCCAGGTAGCATTTGACCATGGTGTCATAGTCCAGCCCCTCCGCGGCGTGGCCCTTGGCGCGCAGCTTGCCCTTGGAGGAGGCGCCGCAC GAGGGGCAGTGCAGACTTTTGAGGGCGTAGAGCTTGGGCGCGAGAAATACCGATT CCGGGGAGTAGGCATCCGCGCCGCAGGCCCCGCAGACGGTCTCGCATTCCACGA GCCAGGTGAGCTCTGGCCGTTCGGGGTCAAAAACCAGGTTTCCCCCATGCTTTTTGATGCGTTTCTTACCTCTGGTTTCCATGAGCCGGTGTCCACGCTCGGTGACGAAAAGGCTGTCCGTGTCCCCGTATACAGACTTGAGAGGCCTGTCCTCGAGCGGTGTTCC GCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACAAAGGCTCGCGTCCAG GCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGG TCCACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGG TGATTGGTTTGTAGGTGTAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATA AAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAG GGCCAGCTGTTGGGGTGAGTACTCCCTCTGAAAAGCGGGCATGACTTCTGCGCTA AGATTGTCAGTTTCCAAAAACGAGGAGGATTTGATATTCACCTGGCCCGCGGTGAT GCCTTTGAGGGTGGCCGCATCCATCTGGTCAGAAAAGACAATCTTTTTGTTGTCAA GCTTGGTGGCAAACGACCCGTAGAGGGCGTTGGACAGCAACTTGGCGATGGAGC GCAGGGTTTGGTTTTTGTCGCGATCGGCGCGCTCCTTGGCCGCGATGTTTAGCTG CACGTATTCGCGCGCAACGCACCGCCATTCGGGAAAGACGGTGGTGCGCTCGTC GGGCACCAGGTGCACGCGCCAACCGCGGTTGTGCAGGGTGACAAGGTCAACGCT GGTGGCTACCTCTCCGCGTAGGCGCTCGTTGGTCCAGCAGAGGCGGCCGCCCTT GCGCGAGCAGAATGGCGGTAGGGGGTCTAGCTGCGTCTCGTCCGGGGGGTCTGC GTCCACGGTAAAGACCCCGGGCAGCAGGCGCGCGTCGAAGTAGTCTATCTTGCAT CCTTGCAAGTCTAGCGCCTGCTGCCATGCGCGGGCGGCAAGCGCGCGCTCGTAT GGGTTGAGTGGGGGACCCCATGGCATGGGGTGGGTGAGCGCGGAGGCGTACAT GCCGCAAATGTCGTAAACGTAGAGGGGCTCTCTGAGTATTCCAAGATATGTAGGGT AGCATCTTCCACCGCGGATGCTGGCGCGCACGTAATCGTATAGTTCGTGCGAGGG AGCGAGGAGGTCGGGACCGAGGTTGCTACGGGCGGGCTGCTCTGCTCGGAAGAC TATCTGCCTGAAGATGGCATGTGAGTTGGATGATATGGTTGGACGCTGGAAGACG TTGAAGCTGGCGTCTGTGAGACCTACCGCGTCACGCACGAAGGAGGCGTAGGAG TCGCGCAGCTTGTTGACCAGCTCGGCGGTGACCTGCACGTCTAGGGCGCAGTAGT CCAGGGTTTCCTTGATGATGTCATACTTATCCTGTCCCTTTTTTTTCCACAGCTCGC GGTTGAGGACAAACTCTTCGCGGTCTTTCCAGTACTCTTGGATCGGAAACCCGTCG GCCTCCGAACGGTAAGAGCCTAGCATGTAGAACTGGTTGACGGCCTGGTAGGCGC AGCATCCCTTTTCTACGGGTAGCGCGTATGCCTGCGCGGCCTTCCGGAGCGAGGT GTGGGTGAGCGCAAAGGTGTCCCTGACCATGACTTTGAGGTACTGGTATTTGAAG TCAGTGTCGTCGCATCCGCCCTGCTCCCAGAGCAAAAAGTCCGTGCGCTTTTTGGAACGCGGATTTGGCAGGGCGAAGGTGACATCGTTGAAGAGTATCTTTCCCGCGCGAGGCATAAAGTTGCGTGTGATGCGGAAGGGTCCCGGCACCTCGGAACGGTTGTTA ATTACCTGGGCGGCGAGCACGATCTCGTCAAAGCCGTTGATGTTGTGGCCCACAA TGTAAAGTTCCAAGAAGCGCGGGATGCCCTTGATGGAAGGCAATTTTTTAAGTTCC TCGTAGGTGAGCTCTTCAGGGGAGCTGAGCCCGTGCTCTGAAAGGGCCCAGTCTGCAAGATGAGGGTTGGAAGCGACGAATGAGCTCCACAGGTCACGGGCCATTAGCATTTGCAGGTGGTCGCGAAAGGTCCTAAACTGGCGACCTATGGCCATTTTTTCTGGG GTGATGCAGTAGAAGGTAAGCGGGTCTTGTTCCCAGCGGTCCCATCCAAGGTTCG CGGCTAGGTCTCGCGCGGCAGTCACTAGAGGCTCATCTCCGCCGAACTTCATGAC CAGCATGAAGGGCACGAGCTGCTTCCCAAAGGCCCCCATCCAAGTATAGGTCTCTACATCGTAGGTGACAAAGAGACGCTCGGTGCGAGGATGCGAGCCGATCGGGAAGAACTGGATCTCCCGCCACCAATTGGAGGAGTGGCTATTGATGTGGTGAAAGTAGA AGTCCCTGCGACGGGCCGAACACTCGTGCTGGCTTTTGTAAAAACGTGCGCAGTA CTGGCAGCGGTGCACGGGCTGTACATCCTGCACGAGGTTGACCTGACGACCGCG CACAAGGAAGCAGAGTGGGAATTTGAGCCCCTCGCCTGGCGGGTTTGGCTGGTG GTCTTCTACTTCGGCTGCTTGTCCTTGACCGTCTGGCTGCTCGAGGGGAGTTACG GTGGATCGGACCACCACGCCGCGCGAGCCCAAAGTCCAGATGTCCGCGCGCGGC GGTCGGAGCTTGATGACAACATCGCGCAGATGGGAGCTGTCCATGGTCTGGAGCT CCCGCGGCGTCAGGTCAGGCGGGAGCTCCTGCAGGTTTACCTCGCATAGACGGG TCAGGGCGCGGGCTAGATCCAGGTGATACCTAATTTCCAGGGGCTGGTTGGTGGC GGCGTCGATGGCTTGCAAGAGGCCGCATCCCCGCGGCGCGACTACGGTACCGCG CGGCGGGCGGTGGGCCGCGGGGGTGTCCTTGGATGATGCATCTAAAAGCGGTGA CGCGGGCGAGCCCCCGGAGGTAGGGGGGGCTCCGGACCCGCCGGGAGAGGGG GCAGGGGCACGTCGGCGCCGCGCGCGGGCAGGAGCTGGTGCTGCGCGCGTAGG TTGCTGGCGAACGCGACGACGCGGCGGTTGATCTCCTGAATCTGGCGCCTCTGC GTGAAGACGACGGGCCCGGTGAGCTTGAACCTGAAAGAGAGTTCGACAGAATCAA TTTCGGTGTCGTTGACGGCGGCCTGGCGCAAAATCTCCTGCACGTCTCCTGAGTT GTCTTGATAGGCGATCTCGGCCATGAACTGCTCGATCTCTTCCTCCTGGAGATCTC CGCGTCCGGCTCGCTCCACGGTGGCGGCGAGGTCGTTGGAAATGCGGGCCATGA GCTGCGAGAAGGCGTTGAGGCCTCCCTCGTTCCAGACGCGGCTGTAGACCACGC CCCCTTCGGCATCGCGGGCGCGCATGACCACCTGCGCGAGATTGAGCTCCACGT GCCGGGCGAAGACGGCGTAGTTTCGCAGGCGCTGAAAGAGGTAGTTGAGGGTGG TGGCGGTGTGTTCTGCCACGAAGAAGTACATAACCCAGCGTCGCAACGTGGATTC GTTGATATCCCCCAAGGCCTCAAGGCGCTCCATGGCCTCGTAGAAGTCCACGGCG AAGTTGAAAAACTGGGAGTTGCGCGCCGACACGGTTAACTCCTCCTCCAGAAGAC GGATGAGCTCGGCGACAGTGTCGCGCACCTCGCGCTCAAAGGCTACAGGGGCCT CTTCTTCTTCTTCAATCTCCTCTTCCATAAGGGCCTCCCCTTCTTCTTCTTCTGGCG GCGGTGGGGGAGGGGGGACACGGCGGCGACGACGGCGCACCGGGAGGCGGTC GACAAAGCGCTCGATCATCTCCCCGCGGCGACGGCGCATGGTCTCGGTGACGGC GCGGCCGTTCTCGCGGGGGCGCAGTTGGAAGACGCCGCCCGTCATGTCCCGGTT ATGGGTTGGCGGGGGGCTGCCATGCGGCAGGGATACGGCGCTAACGATGCATCTCAACAATTGTTGTGTAGGTACTCCGCCGCCGAGGGACCTGAGCGAGTCCGCATCGACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTA GGCTGAGCACCGTGGCGGGCGGCAGCGGGCGGCGGTCGGGGTTGTTTCTGGCG GAGGTGCTGCTGATGATGTAATTAAAGTAGGCGGTCTTGAGACGGCGGATGGTCG ACAGAAGCACCATGTCCTTGGGTCCGGCCTGCTGAATGCGCAGGCGGTCGGCCATGCCCCAGGCTTCGTTTTGACATCGGCGCAGGTCTTTGTAGTAGTCTTGCATGAGCCTTTCTACCGGCACTTCTTCTTCTCCTTCCTCTTGTCCTGCATCTCTTGCATCTATC GCTGCGGCGGCGGCGGAGTTTGGCCGTAGGTGGCGCCCTCTTCCTCCCATGCGT GTGACCCCGAAGCCCCTCATCGGCTGAAGCAGGGCTAGGTCGGCGACAACGCGC TCGGCTAATATGGCCTGCTGCACCTGCGTGAGGGTAGACTGGAAGTCATCCATGTCCACAAAGCGGTGGTATGCGCCCGTGTTGATGGTGTAAGTGCAGTTGGCCATAACGGACCAGTTAACGGTCTGGTGACCCGGCTGCGAGAGCTCGGTGTACCTGAGACG CGAGTAAGCCCTCGAGTCAAATACGTAGTCGTTGCAAGTCCGCACCAGGTACTGG TATCCCACCAAAAAGTGCGGCGGCGGCTGGCGGTAGAGGGGCCAGCGTAGGGTG GCCGGGGCTCCGGGGGCGAGATCTTCCAACATAAGGCGATGATATCCGTAGATGT ACCTGGACATCCAGGTGATGCCGGCGGCGGTGGTGGAGGCGCGCGGAAAGTCG CGGACGCGGTTCCAGATGTTGCGCAGCGGCAAAAAGTGCTCCATGGTCGGGACG CTCTGGCCGGTCAGGCGCGCGCAATCGTTGACGCTCTAGCGTGCAAAAGGAGAG CCTGTAAGCGGGCACTCTTCCGTGGTCTGGTGGATAAATTCGCAAGGGTATCATG GCGGACGACCGGGGTTCGAGCCCCGTATCCGGCCGTCCGCCGTGATCCATGCGG TTACCGCCCGCGTGTCGAACCCAGGTGTGCGACGTCAGACAACGGGGGAGTGCT CCTTTTGGCTTCCTTCCAGGCGCGGCGGCTGCTGCGCTAGCTTTTTTGGCCACTG GCCGCGCGCAGCGTAAGCGGTTAGGCTGGAAAGCGAAAGCATTAAGTGGCTCGC TCCCTGTAGCCGGAGGGTTATTTTCCAAGGGTTGAGTCGCGGGACCCCCGGTTCG AGTCTCGGACCGGCCGGACTGCGGCGAACGGGGGTTTGCCTCCCCGTCATGCAA GACCCCGCTTGCAAATTCCTCCGGAAACAGGGACGAGCCCCTTTTTTGCTTTTCCC AGATGCATCCGGTGCTGCGGCAGATGCGCCCCCCTCCTCAGCAGCGGCAAGAGC AAGAGCAGCGGCAGACATGCAGGGCACCCTCCCCTCCTCCTACCGCGTCAGGAG GGGCGACATCCGCGGTTGACGCGGCAGCAGATGGTGATTACGAACCCCCGCGGC GCCGGGCCCGGCACTACCTGGACTTGGAGGAGGGCGAGGGCCTGGCGCGGCTA GGAGCGCCCTCTCCTGAGCGGCACCCAAGGGTGCAGCTGAAGCGTGATACGCGT GAGGCGTACGTGCCGCGGCAGAACCTGTTTCGCGACCGCGAGGGAGAGGAGCCC GAGGAGATGCGGGATCGAAAGTTCCACGCAGGGCGCGAGCTGCGGCATGGCCTG AATCGCGAGCGGTTGCTGCGCGAGGAGGACTTTGAGCCCGACGCGCGAACCGGG ATTAGTCCCGCGCGCGCACACGTGGCGGCCGCCGACCTGGTAACCGCATACGAG CAGACGGTGAACCAGGAGATTAACTTTCAAAAAAGCTTTAACAACCACGTGCGTAC GCTTGTGGCGCGCGAGGAGGTGGCTATAGGACTGATGCATCTGTGGGACTTTGTA AGCGCGCTGGAGCAAAACCCAAATAGCAAGCCGCTCATGGCGCAGCTGTTCCTTA TAGTGCAGCACAGCAGGGACAACGAGGCATTCAGGGATGCGCTGCTAAACATAGT AGAGCCCGAGGGCCGCTGGCTGCTCGATTTGATAAACATCCTGCAGAGCATAGTG GTGCAGGAGCGCAGCTTGAGCCTGGCTGACAAGGTGGCCGCCATCAACTATTCCATGCTTAGCCTGGGCAAGTTTTACGCCCGCAAGATATACCATACCCCTTACGTTCCCATAGACAAGGAGGTAAAGATCGAGGGGTTCTACATGCGCATGGCGCTGAAGGTGC TTACCTTGAGCGACGACCTGGGCGTTTATCGCAACGAGCGCATCCACAAGGCCGT GAGCGTGAGCCGGCGGCGCGAGCTCAGCGACCGCGAGCTGATGCACAGCCTGC AAAGGGCCCTGGCTGGCACGGGCAGCGGCGATAGAGAGGCCGAGTCCTACTTTGACGCGGGCGCTGACCTGCGCTGGGCCCCAAGCCGACGCGCCCTGGAGGCAGCTGGGGCCGGACCTGGGCTGGCGGTGGCACCCGCGCGCGCTGGCAACGTCGGCGG CGTGGAGGAATATGACGAGGACGATGAGTACGAGCCAGAGGACGGCGAGTACTA AGCGGTGATGTTTCTGATCAGATGATGCAAGACGCAACGGACCCGGCGGTGCGG GCGGCGCTGCAGAGCCAGCCGTCCGGCCTTAACTCCACGGACGACTGGCGCCAGGTCATGGACCGCATCATGTCGCTGACTGCGCGCAATCCTGACGCGTTCCGGCAGCAGCCGCAGGCCAACCGGCTCTCCGCAATTCTGGAAGCGGTGGTCCCGGCGCGCG CAAACCCCACGCACGAGAAGGTGCTGGCGATCGTAAACGCGCTGGCCGAAAACA GGGCCATCCGGCCCGACGAGGCCGGCCTGGTCTACGACGCGCTGCTTCAGCGCG TGGCTCGTTACAACAGCGGCAACGTGCAGACCAACCTGGACCGGCTGGTGGGGG ATGTGCGCGAGGCCGTGGCGCAGCGTGAGCGCGCGCAGCAGCAGGGCAACCTG GGCTCCATGGTTGCACTAAACGCCTTCCTGAGTACACAGCCCGCCAACGTGCCGC GGGGACAGGAGGACTACACCAACTTTGTGAGCGCACTGCGGCTAATGGTGACTGA GACACCGCAAAGTGAGGTGTACCAGTCTGGGCCAGACTATTTTTTCCAGACCAGTA GACAAGGCCTGCAGACCGTAAACCTGAGCCAGGCTTTCAAAAACTTGCAGGGGCT GTGGGGGGTGCGGGCTCCCACAGGCGACCGCGCGACCGTGTCTAGCTTGCTGAC GCCCAACTCGCGCCTGTTGCTGCTGCTAATAGCGCCCTTCACGGACAGTGGCAGC GTGTCCCGGGACACATACCTAGGTCACTTGCTGACACTGTACCGCGAGGCCATAG GTCAGGCGCATGTGGACGAGCATACTTTCCAGGAGATTACAAGTGTCAGCCGCGC GCTGGGGCAGGAGGACACGGGCAGCCTGGAGGCAACCCTAAACTACCTGCTGAC CAACCGGCGGCAGAAGATCCCCTCGTTGCACAGTTTAAACAGCGAGGAGGAGCG CATTTTGCGCTACGTGCAGCAGAGCGTGAGCCTTAACCTGATGCGCGACGGGGTA ACGCCCAGCGTGGCGCTGGACATGACCGCGCGCAACATGGAACCGGGCATGTAT GCCTCAAACCGGCCGTTTATCAACCGCCTAATGGACTACTTGCATCGCGCGGCCG CCGTGAACCCCGAGTATTTCACCAATGCCATCTTGAACCCGCACTGGCTACCGCC CCCTGGTTTCTACACCGGGGGATTCGAGGTGCCCGAGGGTAACGATGGATTCCTC TGGGACGACATAGACGACAGCGTGTTTTCCCCGCAACCGCAGACCCTGCTAGAGT TGCAACAGCGCGAGCAGGCAGAGGCGGCGCTGCGAAAGGAAAGCTTCCGCAGGC CAAGCAGCTTGTCCGATCTAGGCGCTGCGGCCCCGCGGTCAGATGCTAGTAGCC CATTTCCAAGCTTGATAGGGTCTCTTACCAGCACTCGCACCACCCGCCCGCGCCT GCTGGGCGAGGAGGAGTACCTAAACAACTCGCTGCTGCAGCCGCAGCGCGAAAA AAACCTGCCTCCGGCATTTCCCAACAACGGGATAGAGAGCCTAGTGGACAAGATG AGTAGATGGAAGACGTACGCGCAGGAGCACAGGGACGTGCCAGGCCCGCGCCCG CCCACCCGTCGTCAAAGGCACGACCGTCAGCGGGGTCTGGTGTGGGAGGACGAT GACTCGGCAGACGACAGCAGCGTCCTGGATTTGGGAGGGAGTGGCAACCCGTTT GCGCACCTTCGCCCCAGGCTGGGGAGAATGTTTTAAAAAAAAAAAAGCATGATGCAAAATAAAAAACTCACCAAGGCCATGGCACCGAGCGTTGGTTTTCTTGTATTCCCCTTAGTATGCGGCGCGCGGCGATGTATGAGGAAGGTCCTCCTCCCTCCTACGAGAGT GTGGTGAGCGCGGCGCCAGTGGCGGCGGCGCTGGGTTCTCCCTTCGATGCTCCC CTGGACCCGCCGTTTGTGCCTCCGCGGTACCTGCGGCCTACCGGGGGGAGAAAC AGCATCCGTTACTCTGAGTTGGCACCCCTATTCGACACCACCCGTGTGTACCTGGTGGACAACAAGTCAACGGATGTGGCATCCCTGAACTACCAGAACGACCACAGCAACTTTCTGACCACGGTCATTCAAAACAATGACTACAGCCCGGGGGAGGCAAGCACAC AGACCATCAATCTTGACGACCGGTCGCACTGGGGCGGCGACCTGAAAACCATCCT GCATACCAACATGCCAAATGTGAACGAGTTCATGTTTACCAATAAGTTTAAGGCGC GGGTGATGGTGTCGCGCTTGCCTACTAAGGACAATCAGGTGGAGCTGAAATACGAGTGGGTGGAGTTCACGCTGCCCGAGGGCAACTACTCCGAGACCATGACCATAGACCTTATGAACAACGCGATCGTGGAGCACTACTTGAAAGTGGGCAGACAGAACGGGG TTCTGGAAAGCGACATCGGGGTAAAGTTTGACACCCGCAACTTCAGACTGGGGTTT GACCCCGTCACTGGTCTTGTCATGCCTGGGGTATATACAAACGAAGCCTTCCATCC AGACATCATTTTGCTGCCAGGATGCGGGGTGGACTTCACCCACAGCCGCCTGAGC AACTTGTTGGGCATCCGCAAGCGGCAACCCTTCCAGGAGGGCTTTAGGATCACCT ACGATGATCTGGAGGGTGGTAACATTCCCGCACTGTTGGATGTGGACGCCTACCA GGCGAGCTTGAAAGATGACACCGAACAGGGCGGGGGTGGCGCAGGCGGCAGCA ACAGCAGTGGCAGCGGCGCGGAAGAGAACTCCAACGCGGCAGCCGCGGCAATGC AGCCGGTGGAGGACATGAACGATCATGCCATTCGCGGCGACACCTTTGCCACACG GGCTGAGGAGAAGCGCGCTGAGGCCGAAGCAGCGGCCGAAGCTGCCGCCCCCG CTGCGCAACCCGAGGTCGAGAAGCCTCAGAAGAAACCGGTGATCAAACCCCTGAC AGAGGACAGCAAGAAACGCAGTTACAACCTAATAAGCAATGACAGCACCTTCACCC AGTACCGCAGCTGGTACCTTGCATACAACTACGGCGACCCTCAGACCGGAATCCG CTCATGGACCCTGCTTTGCACTCCTGACGTAACCTGCGGCTCGGAGCAGGTCTAC TGGTCGTTGCCAGACATGATGCAAGACCCCGTGACCTTCCGCTCCACGCGCCAGA TCAGCAACTTTCCGGTGGTGGGCGCCGAGCTGTTGCCCGTGCACTCCAAGAGCTT CTACAACGACCAGGCCGTCTACTCCCAACTCATCCGCCAGTTTACCTCTCTGACCC ACGTGTTCAATCGCTTTCCCGAGAACCAGATTTTGGCGCGCCCGCCAGCCCCCAC CATCACCACCGTCAGTGAAAACGTTCCTGCTCTCACAGATCACGGGACGCTACCG CTGCGCAACAGCATCGGAGGAGTCCAGCGAGTGACCATTACTGACGCCAGACGC CGCACCTGCCCCTACGTTTACAAGGCCCTGGGCATAGTCTCGCCGCGCGTCCTAT CGAGCCGCACTTTTTGAGCAAGCATGTCCATCCTTATATCGCCCAGCAATAACACA GGCTGGGGCCTGCGCTTCCCAAGCAAGATGTTTGGCGGGGCCAAGAAGCGCTCC GACCAACACCCAGTGCGCGTGCGCGGGCACTACCGCGCGCCCTGGGGCGCGCA CAAACGCGGCCGCACTGGGCGCACCACCGTCGATGACGCCATCGACGCGGTGGT GGAGGAGGCGCGCAACTACACGCCCACGCCGCCACCAGTGTCCACAGTGGACGC GGCCATTCAGACCGTGGTGCGCGGAGCCCGGCGCTATGCTAAAATGAAGAGACG GCGGAGGCGCGTAGCACGTCGCCACCGCCGCCGACCCGGCACTGCCGCCCAAC GCGCGGCGGCGGCCCTGCTTAACCGCGCACGTCGCACCGGCCGACGGGCGGCC ATGCGGGCCGCTCGAAGGCTGGCCGCGGGTATTGTCACTGTGCCCCCCAGGTCCAGGCGACGAGCGGCCGCCGCAGCAGCCGCGGCCATTAGTGCTATGACTCAGGGTCGCAGGGGCAACGTGTATTGGGTGCGCGACTCGGTTAGCGGCCTGCGCGTGCCC GTGCGCACCCGCCCCCCGCGCAACTAGATTGCAAGAAAAAACTACTTAGACTCGT ACTGTTGTATGTATCCAGCGGCGGCGGCGCGCAACGAAGCTATGTCCAAGCGCAA AATCAAAGAAGAGATGCTCCAGGTCATCGCGCCGGAGATCTATGGCCCCCCGAAGAAGGAAGAGCAGGATTACAAGCCCCGAAAGCTAAAGCGGGTCAAAAAGAAAAAGAAAGATGATGATGATGAACTTGACGACGAGGTGGAACTGCTGCACGCTACCGCGCC CAGGCGACGGGTACAGTGGAAAGGTCGACGCGTAAAACGTGTTTTGCGACCCGG CACCACCGTAGTCTTTACGCCCGGTGAGCGCTCCACCCGCACCTACAAGCGCGTG TATGATGAGGTGTACGGCGACGAGGACCTGCTTGAGCAGGCCAACGAGCGCCTCGGGGAGTTTGCCTACGGAAAGCGGCATAAGGACATGCTGGCGTTGCCGCTGGACGAGGGCAACCCAACACCTAGCCTAAAGCCCGTAACACTGCAGCAGGTGCTGCCCG CGCTTGCACCGTCCGAAGAAAAGCGCGGCCTAAAGCGCGAGTCTGGTGACTTGG CACCCACCGTGCAGCTGATGGTACCCAAGCGCCAGCGACTGGAAGATGTCTTGGA AAAAATGACCGTGGAACCTGGGCTGGAGCCCGAGGTCCGCGTGCGGCCAATCAA GCAGGTGGCGCCGGGACTGGGCGTGCAGACCGTGGACGTTCAGATACCCACTAC CAGTAGCACCAGTATTGCCACCGCCACAGAGGGCATGGAGACACAAACGTCCCCG GTTGCCTCAGCGGTGGCGGATGCCGCGGTGCAGGCGGTCGCTGCGGCCGCGTC CAAGACCTCTACGGAGGTGCAAACGGACCCGTGGATGTTTCGCGTTTCAGCCCCC CGGCGCCCGCGCCGTTCGAGGAAGTACGGCGCCGCCAGCGCGCTACTGCCCGA ATATGCCCTACATCCTTCCATTGCGCCTACCCCCGGCTATCGTGGCTACACCTACC GCCCCAGAAGACGAGCAACTACCCGACGCCGAACCACCACTGGAACCCGCCGCC GCCGTCGCCGTCGCCAGCCCGTGCTGGCCCCGATTTCCGTGCGCAGGGTGGCTC GCGAAGGAGGCAGGACCCTGGTGCTGCCAACAGCGCGCTACCACCCCAGCATCG TTTAAAAGCCGGTCTTTGTGGTTCTTGCAGATATGGCCCTCACCTGCCGCCTCCGT TTCCCGGTGCCGGGATTCCGAGGAAGAATGCACCGTAGGAGGGGCATGGCCGGC CACGGCCTGACGGGCGGCATGCGTCGTGCGCACCACCGGCGGCGGCGCGCGTC GCACCGTCGCATGCGCGGCGGTATCCTGCCCCTCCTTATTCCACTGATCGCCGCG GCGATTGGCGCCGTGCCCGGAATTGCATCCGTGGCCTTGCAGGCGCAGAGACAC TGATTAAAAACAAGTTGCATGTGGAAAAATCAAAATAAAAAGTCTGGACTCTCACGC TCGCTTGGTCCTGTAACTATTTTGTAGAATGGAAGACATCAACTTTGCGTCTCTGGC CCCGCGACACGGCTCGCGCCCGTTCATGGGAAACTGGCAAGATATCGGCACCAG CAATATGAGCGGTGGCGCCTTCAGCTGGGGCTCGCTGTGGAGCGGCATTAAAAAT TTCGGTTCCACCGTTAAGAACTATGGCAGCAAGGCCTGGAACAGCAGCACAGGCC AGATGCTGAGGGATAAGTTGAAAGAGCAAAATTTCCAACAAAAGGTGGTAGATGGC CTGGCCTCTGGCATTAGCGGGGTGGTGGACCTGGCCAACCAGGCAGTGCAAAATA AGATTAACAGTAAGCTTGATCCCCGCCCTCCCGTAGAGGAGCCTCCACCGGCCGT GGAGACAGTGTCTCCAGAGGGGCGTGGCGAAAAGCGTCCGCGCCCCGACAGGGA AGAAACTCTGGTGACGCAAATAGACGAGCCTCCCTCGTACGAGGAGGCACTAAAG CAAGGCCTGCCCACCACCCGTCCCATCGCGCCCATGGCTACCGGAGTGCTGGGC CAGCACACACCCGTAACGCTGGACCTGCCTCCCCCCGCCGACACCCAGCAGAAACCTGTGCTGCCAGGCCCGACCGCCGTTGTTGTAACCCGTCCTAGCCGCGCGTCCCTGCGCCGCGCCGCCAGCGGTCCGCGATCGTTGCGGCCCGTAGCCAGTGGCAAC TGGCAAAGCACACTGAACAGCATCGTGGGTCTGGGGGTGCAATCCCTGAAGCGCC GACGATGCTTCTGATAGCTAACGTGTCGTATGTGTGTCATGTATGCGTCCATGTCG CCGCCAGAGGAGCTGCTGAGCCGCCGCGCGCCCGCTTTCCAAGATGGCTACCCCTTCGATGATGCCGCAGTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGGGCTGGTGCAGTTTGCCCGCGCCACCGAGACGTACTTCAGC CTGAATAACAAGTTTAGAAACCCCACGGTGGCGCCTACGCACGACGTGACCACAG ACCGGTCCCAGCGTTTGACGCTGCGGTTCATCCCTGTGGACCGTGAGGATACTGC GTACTCGTACAAGGCGCGGTTCACCCTAGCTGTGGGTGATAACCGTGTGCTGGACATGGCTTCCACGTACTTTGACATCCGCGGCGTGCTGGACAGGGGCCCTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCCCTGGCTCCCAAGGGTGCCCCAAATCC TTGCGAATGGGATGAAGCTGCTACTGCTCTTGAAATAAACCTAGAAGAAGAGGACG ATGACAACGAAGACGAAGTAGACGAGCAAGCTGAGCAGCAAAAAACTCACGTATTT GGGCAGGCGCCTTATTCTGGTATAAATATTACAAAGGAGGGTATTCAAATAGGTGT CGAAGGTCAAACACCTAAATATGCCGATAAAACATTTCAACCTGAACCTCAAATAG GAGAATCTCAGTGGTACGAAACAGAAATTAATCATGCAGCTGGGAGAGTCCTAAAA AAGACTACCCCAATGAAACCATGTTACGGTTCATATGCAAAACCCACAAATGAAAAT GGAGGGCAAGGCATTCTTGTAAAGCAACAAAATGGAAAGCTAGAAAGTCAAGTGG AAATGCAATTTTTCTCAACTACTGAGGCAGCCGCAGGCAATGGTGATAACTTGACT CCTAAAGTGGTATTGTACAGTGAAGATGTAGATATAGAAACCCCAGACACTCATATT TCTTACATGCCCACTATTAAGGAAGGTAACTCACGAGAACTAATGGGCCAACAATC TATGCCCAACAGGCCTAATTACATTGCTTTTAGGGACAATTTTATTGGTCTAATGTA TTACAACAGCACGGGTAATATGGGTGTTCTGGCGGGCCAAGCATCGCAGTTGAAT GCTGTTGTAGATTTGCAAGACAGAAACACAGAGCTTTCATACCAGCTTTTGCTTGAT TCCATTGGTGATAGAACCAGGTACTTTTCTATGTGGAATCAGGCTGTTGACAGCTA TGATCCAGATGTTAGAATTATTGAAAATCATGGAACTGAAGATGAACTTCCAAATTA CTGCTTTCCACTGGGAGGTGTGATTAATACAGAGACTCTTACCAAGGTAAAACCTA AAACAGGTCAGGAAAATGGATGGGAAAAAGATGCTACAGAATTTTCAGATAAAAAT GAAATAAGAGTTGGAAATAATTTTGCCATGGAAATCAATCTAAATGCCAACCTGTGG AGAAATTTCCTGTACTCCAACATAGCGCTGTATTTGCCCGACAAGCTAAAGTACAG TCCTTCCAACGTAAAAATTTCTGATAACCCAAACACCTACGACTACATGAACAAGCG AGTGGTGGCTCCCGGGCTAGTGGACTGCTACATTAACCTTGGAGCACGCTGGTCC CTTGACTATATGGACAACGTCAACCCATTTAACCACCACCGCAATGCTGGCCTGCG CTACCGCTCAATGTTGCTGGGCAATGGTCGCTATGTGCCCTTCCACATCCAGGTG CCTCAGAAGTTCTTTGCCATTAAAAACCTCCTTCTCCTGCCGGGCTCATACACCTA CGAGTGGAACTTCAGGAAGGATGTTAACATGGTTCTGCAGAGCTCCCTAGGAAAT GACCTAAGGGTTGACGGAGCCAGCATTAAGTTTGATAGCATTTGCCTTTACGCCAC CTTCTTCCCCATGGCCCACAACACCGCCTCCACGCTTGAGGCCATGCTTAGAAAC GACACCAACGACCAGTCCTTTAACGACTATCTCTCCGCCGCCAACATGCTCTACCC TATACCCGCCAACGCTACCAACGTGCCCATATCCATCCCCTCCCGCAACTGGGCGGCTTTCCGCGGCTGGGCCTTCACGCGCCTTAAGACTAAGGAAACCCCATCACTGGGCTCGGGCTACGACCCTTATTACACCTACTCTGGCTCTATACCCTACCTAGATGGA ACCTTTTACCTCAACCACACCTTTAAGAAGGTGGCCATTACCTTTGACTCTTCTGTC AGCTGGCCTGGCAATGACCGCCTGCTTACCCCCAACGAGTTTGAAATTAAGCGCT CAGTTGACGGGGAGGGTTACAACGTTGCCCAGTGTAACATGACCAAAGACTGGTTCCTGGTACAAATGCTAGCTAACTATAACATTGGCTACCAGGGCTTCTATATCCCAGAGAGCTACAAGGACCGCATGTACTCCTTCTTTAGAAACTTCCAGCCCATGAGCCGT CAGGTGGTGGATGATACTAAATACAAGGACTACCAACAGGTGGGCATCCTACACC AACACAACAACTCTGGATTTGTTGGCTACCTTGCCCCCACCATGCGCGAAGGACA GGCCTACCCTGCTAACTTCCCCTATCCGCTTATAGGCAAGACCGCAGTTGACAGCATTACCCAGAAAAAGTTTCTTTGCGATCGCACCCTTTGGCGCATCCCATTCTCCAGTAACTTTATGTCCATGGGCGCACTCACAGACCTGGGCCAAAACCTTCTCTACGCCAA CTCCGCCCACGCGCTAGACATGACTTTTGAGGTGGATCCCATGGACGAGCCCACC CTTCTTTATGTTTTGTTTGAAGTCTTTGACGTGGTCCGTGTGCACCAGCCGCACCG CGGCGTCATCGAAACCGTGTACCTGCGCACGCCCTTCTCGGCCGGCAACGCCAC AACATAAAGAAGCAAGCAACATCAACAACAGCTGCCGCCATGGGCTCCAGTGAGC AGGAACTGAAAGCCATTGTCAAAGATCTTGGTTGTGGGCCATATTTTTTGGGCACC TATGACAAGCGCTTTCCAGGCTTTGTTTCTCCACACAAGCTCGCCTGCGCCATAGT CAATACGGCCGGTCGCGAGACTGGGGGCGTACACTGGATGGCCTTTGCCTGGAA CCCGCACTCAAAAACATGCTACCTCTTTGAGCCCTTTGGCTTTTCTGACCAGCGAC TCAAGCAGGTTTACCAGTTTGAGTACGAGTCACTCCTGCGCCGTAGCGCCATTGCT TCTTCCCCCGACCGCTGTATAACGCTGGAAAAGTCCACCCAAAGCGTACAGGGGC CCAACTCGGCCGCCTGTGGACTATTCTGCTGCATGTTTCTCCACGCCTTTGCCAAC TGGCCCCAAACTCCCATGGATCACAACCCCACCATGAACCTTATTACCGGGGTACC CAACTCCATGCTCAACAGTCCCCAGGTACAGCCCACCCTGCGTCGCAACCAGGAA CAGCTCTACAGCTTCCTGGAGCGCCACTCGCCCTACTTCCGCAGCCACAGTGCGC AGATTAGGAGCGCCACTTCTTTTTGTCACTTGAAAAACATGTAAAAATAATGTACTA GAGACACTTTCAATAAAGGCAAATGCTTTTATTTGTACACTCTCGGGTGATTATTTA CCCCCACCCTTGCCGTCTGCGCCGTTTAAAAATCAAAGGGGTTCTGCCGCGCATC GCTATGCGCCACTGGCAGGGACACGTTGCGATACTGGTGTTTAGTGCTCCACTTA AACTCAGGCACAACCATCCGCGGCAGCTCGGTGAAGTTTTCACTCCACAGGCTGC GCACCATCACCAACGCGTTTAGCAGGTCGGGCGCCGATATCTTGAAGTCGCAGTT GGGGCCTCCGCCCTGCGCGCGCGAGTTGCGATACACAGGGTTGCAGCACTGGAA CACTATCAGCGCCGGGTGGTGCACGCTGGCCAGCACGCTCTTGTCGGAGATCAG ATCCGCGTCCAGGTCCTCCGCGTTGCTCAGGGCGAACGGAGTCAACTTTGGTAGC TGCCTTCCCAAAAAGGGCGCGTGCCCAGGCTTTGAGTTGCACTCGCACCGTAGTG GCATCAAAAGGTGACCGTGCCCGGTCTGGGCGTTAGGATACAGCGCCTGCATAAA AGCCTTGATCTGCTTAAAAGCCACCTGAGCCTTTGCGCCTTCAGAGAAGAACATGC CGCAAGACTTGCCGGAAAACTGATTGGCCGGACAGGCCGCGTCGTGCACGCAGC ACCTTGCGTCGGTGTTGGAGATCTGCACCACATTTCGGCCCCACCGGTTCTTCAC GATCTTGGCCTTGCTAGACTGCTCCTTCAGCGCGCGCTGCCCGTTTTCGCTCGTCACATCCATTTCAATCACGTGCTCCTTATTTATCATAATGCTTCCGTGTAGACACTTAAGCTCGCCTTCGATCTCAGCGCAGCGGTGCAGCCACAACGCGCAGCCCGTGGGCT CGTGATGCTTGTAGGTCACCTCTGCAAACGACTGCAGGTACGCCTGCAGGAATCG CCCCATCATCGTCACAAAGGTCTTGTTGCTGGTGAAGGTCAGCTGCAACCCGCGG TGCTCCTCGTTCAGCCAGGTCTTGCATACGGCCGCCAGAGCTTCCACTTGGTCAGGCAGTAGTTTGAAGTTCGCCTTTAGATCGTTATCCACGTGGTACTTGTCCATCAGCGCGCGCGCAGCCTCCATGCCCTTCTCCCACGCAGACACGATCGGCACACTCAGC GGGTTCATCACCGTAATTTCACTTTCCGCTTCGCTGGGCTCTTCCTCTTCCTCTTGC GTCCGCATACCACGCGCCACTGGGTCGTCTTCATTCAGCCGCCGCACTGTGCGCT TACCTCCTTTGCCATGCTTGATTAGCACCGGTGGGTTGCTGAAACCCACCATTTGTAGCGCCACATCTTCTCTTTCTTCCTCGCTGTCCACGATTACCTCTGGTGATGGCGGGCGCTCGGGCTTGGGAGAAGGGCGCTTCTTTTTCTTCTTGGGCGCAATGGCCAAA TCCGCCGCCGAGGTCGATGGCCGCGGGCTGGGTGTGCGCGGCACCAGCGCGTC TTGTGATGAGTCTTCCTCGTCCTCGGACTCGATACGCCGCCTCATCCGCTTTTTTG GGGGCGCCCGGGGAGGCGGCGGCGACGGGGACGGGGACGACACGTCCTCCAT GGTTGGGGGACGTCGCGCCGCACCGCGTCCGCGCTCGGGGGTGGTTTCGCGCT GCTCCTCTTCCCGACTGGCCATTTCCTTCTCCTATAGGCAGAAAAAGATCATGGAG TCAGTCGAGAAGAAGGACAGCCTAACCGCCCCCTCTGAGTTCGCCACCACCGCCT CCACCGATGCCGCCAACGCGCCTACCACCTTCCCCGTCGAGGCACCCCCGCTTG AGGAGGAGGAAGTGATTATCGAGCAGGACCCAGGTTTTGTAAGCGAAGACGACGA GGACCGCTCAGTACCAACAGAGGATAAAAAGCAAGACCAGGACAACGCAGAGGCA AACGAGGAACAAGTCGGGCGGGGGGACGAAAGGCATGGCGACTACCTAGATGTG GGAGACGACGTGCTGTTGAAGCATCTGCAGCGCCAGTGCGCCATTATCTGCGACG CGTTGCAAGAGCGCAGCGATGTGCCCCTCGCCATAGCGGATGTCAGCCTTGCCTA CGAACGCCACCTATTCTCACCGCGCGTACCCCCCAAACGCCAAGAAAACGGCACA TGCGAGCCCAACCCGCGCCTCAACTTCTACCCCGTATTTGCCGTGCCAGAGGTGC TTGCCACCTATCACATCTTTTTCCAAAACTGCAAGATACCCCTATCCTGCCGTGCCA ACCGCAGCCGAGCGGACAAGCAGCTGGCCTTGCGGCAGGGCGCTGTCATACCTG ATATCGCCTCGCTCAACGAAGTGCCAAAAATCTTTGAGGGTCTTGGACGCGACGA GAAGCGCGCGGCAAACGCTCTGCAACAGGAAAACAGCGAAAATGAAAGTCACTCT GGAGTGTTGGTGGAACTCGAGGGTGACAACGCGCGCCTAGCCGTACTAAAACGCA GCATCGAGGTCACCCACTTTGCCTACCCGGCACTTAACCTACCCCCCAAGGTCAT GAGCACAGTCATGAGTGAGCTGATCGTGCGCCGTGCGCAGCCCCTGGAGAGGGA TGCAAATTTGCAAGAACAAACAGAGGAGGGCCTACCCGCAGTTGGCGACGAGCAG CTAGCGCGCTGGCTTCAAACGCGCGAGCCTGCCGACTTGGAGGAGCGACGCAAA CTAATGATGGCCGCAGTGCTCGTTACCGTGGAGCTTGAGTGCATGCAGCGGTTCT TTGCTGACCCGGAGATGCAGCGCAAGCTAGAGGAAACATTGCACTACACCTTTCG ACAGGGCTACGTACGCCAGGCCTGCAAGATCTCCAACGTGGAGCTCTGCAACCTG GTCTCCTACCTTGGAATTTTGCACGAAAACCGCCTTGGGCAAAACGTGCTTCATTC CACGCTCAAGGGCGAGGCGCGCCGCGACTACGTCCGCGACTGCGTTTACTTATTT CTATGCTACACCTGGCAGACGGCCATGGGCGTTTGGCAGCAGTGCTTGGAGGAGTGCAACCTCAAGGAGCTGCAGAAACTGCTAAAGCAAAACTTGAAGGACCTATGGACGGCCTTCAACGAGCGCTCCGTGGCCGCGCACCTGGCGGACATCATTTTCCCCGAA CGCCTGCTTAAAACCCTGCAACAGGGTCTGCCAGACTTCACCAGTCAAAGCATGTT GCAGAACTTTAGGAACTTTATCCTAGAGCGCTCAGGAATCTTGCCCGCCACCTGCT GTGCACTTCCTAGCGACTTTGTGCCCATTAAGTACCGCGAATGCCCTCCGCCGCTTTGGGGCCACTGCTACCTTCTGCAGCTAGCCAACTACCTTGCCTACCACTCTGACATAATGGAAGACGTGAGCGGTGACGGTCTACTGGAGTGTCACTGTCGCTGCAACCTA TGCACCCCGCACCGCTCCCTGGTTTGCAATTCGCAGCTGCTTAACGAAAGTCAAAT TATCGGTACCTTTGAGCTGCAGGGTCCCTCGCCTGACGAAAAGTCCGCGGCTCCG GGGTTGAAACTCACTCCGGGGCTGTGGACGTCGGCTTACCTTCGCAAATTTGTACCTGAGGACTACCACGCCCACGAGATTAGGTTCTACGAAGACCAATCCCGCCCGCCTAATGCGGAGCTTACCGCCTGCGTCATTACCCAGGGCCACATTCTTGGCCAATTGC AAGCCATCAACAAAGCCCGCCAAGAGTTTCTGCTACGAAAGGGACGGGGGGTTTA CTTGGACCCCCAGTCCGGCGAGGAGCTCAACCCAATCCCCCCGCCGCCGCAGCC CTATCAGCAGCAGCCGCGGGCCCTTGCTTCCCAGGATGGCACCCAAAAAGAAGCT GCAGCTGCCGCCGCCACCCACGGACGAGGAGGAATACTGGGACAGTCAGGCAGA GGAGGTTTTGGACGAGGAGGAGGAGGACATGATGGAAGACTGGGAGAGCCTAGA CGAGGAAGCTTCCGAGGTCGAAGAGGTGTCAGACGAAACACCGTCACCCTCGGTC GCATTCCCCTCGCCGGCGCCCCAGAAATCGGCAACCGGTTCCAGCATGGCTACAA CCTCCGCTCCTCAGGCGCCGCCGGCACTGCCCGTTCGCCGACCCAACCGTAGAT GGGACACCACTGGAACCAGGGCCGGTAAGTCCAAGCAGCCGCCGCCGTTAGCCC AAGAGCAACAACAGCGCCAAGGCTACCGCTCATGGCGCGGGCACAAGAACGCCA TAGTTGCTTGCTTGCAAGACTGTGGGGGCAACATCTCCTTCGCCCGCCGCTTTCTT CTCTACCATCACGGCGTGGCCTTCCCCCGTAACATCCTGCATTACTACCGTCATCT CTACAGCCCATACTGCACCGGCGGCAGCGGCAGCAACAGCAGCGGCCACACAGA AGCAAAGGCGACCGGATAGCAAGACTCTGACAAAGCCCAAGAAATCCACAGCGGC GGCAGCAGCAGGAGGAGGAGCGCTGCGTCTGGCGCCCAACGAACCCGTATCGAC CCGCGAGCTTAGAAACAGGATTTTTCCCACTCTGTATGCTATATTTCAACAGAGCA GGGGCCAAGAACAAGAGCTGAAAATAAAAAACAGGTCTCTGCGATCCCTCACCCG CAGCTGCCTGTATCACAAAAGCGAAGATCAGCTTCGGCGCACGCTGGAAGACGCG GAGGCTCTCTTCAGTAAATACTGCGCGCTGACTCTTAAGGACTAGTTTCGCGCCCT TTCTCAAATTTAAGCGCGAAAACTACGTCATCTCCAGCGGCCACACCCGGCGCCA GCACCTGTTGTCAGCGCCATTATGAGCAAGGAAATTCCCACGCCCTACATGTGGA GTTACCAGCCACAAATGGGACTTGCGGCTGGAGCTGCCCAAGACTACTCAACCCG AATAAACTACATGAGCGCGGGACCCCACATGATATCCCGGGTCAACGGAATACGC GCCCACCGAAACCGAATTCTCCTGGAACAGGCGGCTATTACCACCACACCTCGTA ATAACCTTAATCCCCGTAGTTGGCCCGCTGCCCTGGTGTACCAGGAAAGTCCCGC TCCCACCACTGTGGTACTTCCCAGAGACGCCCAGGCCGAAGTTCAGATGACTAAC TCAGGGGCGCAGCTTGCGGGCGGCTTTCGTCACAGGGTGCGGTCGCCCGGGCA GGGTATAACTCACCTGACAATCAGAGGGCGAGGTATTCAGCTCAACGACGAGTCG GTGAGCTCCTCGCTTGGTCTCCGTCCGGACGGGACATTTCAGATCGGCGGCGCCGGCCGCTCTTCATTCACGCCTCGTCAGGCAATCCTAACTCTGCAGACCTCGTCCTCTGAGCCGCGCTCTGGAGGCATTGGAACTCTGCAATTTATTGAGGAGTTTGTGCCAT CGGTCTACTTTAACCCCTTCTCGGGACCTCCCGGCCACTATCCGGATCAATTTATT CCTAACTTTGACGCGGTAAAGGACTCGGCGGACGGCTACGACTGAATGTTAAGTG GAGAGGCAGAGCAACTGCGCCTGAAACACCTGGTCCACTGTCGCCGCCACAAGTGCTTTGCCCGCGACTCCGGTGAGTTTTGCTACTTTGAATTGCCCGAGGATCATATCGAGGGCCCGGCGCACGGCGTCCGGCTTACCGCCCAGGGAGAGCTTGCCCGTAG CCTGATTCGGGAGTTTACCCAGCGCCCCCTGCTAGTTGAGCGGGACAGGGGACC CTGTGTTCTCACTGTGATTTGCAACTGTCCTAACCCTGGATTACATCAAGATCCTCT AGTTAATGTCAGGTCGCCTAAGTCGATTAACTAGAGTACCCGGGGATCTTATTCCCTTTAACTAATAAAAAAAAATAATAAAGCATCACTTACTTAAAATCAGTTAGCAAATTTCTGTCCAGTTTATTCAGCAGCACCTCCTTGCCCTCCTCCCAGCTCTGGTATTGCAG CTTCCTCCTGGCTGCAAACTTTCTCCACAATCTAAATGGAATGTCAGTTTCCTCCTG TTCCTGTCCATCCGCACCCACTATCTTCATGTTGTTGCAGATGAAGCGCGCAAGAC CGTCTGAAGATACCTTCAACCCCGTGTATCCATATGACACGGAAACCGGTCCTCCA ACTGTGCCTTTTCTTACTCCTCCCTTTGTATCCCCCAATGGGTTTCAAGAGAGTCCC CCTGGGGTACTCTCTTTGCGCCTATCCGAACCTCTAGTTACCTCCAATGGCATGCT TGCGCTCAAAATGGGCAACGGCCTCTCTCTGGACGAGGCCGGCAACCTTACCTCC CAAAATGTAACCACTGTGAGCCCACCTCTCAAAAAAACCAAGTCAAACATAAACCT GGAAATATCTGCACCCCTCACAGTTACCTCAGAAGCCCTAACTGTGGCTGCCGCC GCACCTCTAATGGTCGCGGGCAACACACTCACCATGCAATCACAGGCCCCGCTAA CCGTGCACGACTCCAAACTTAGCATTGCCACCCAAGGACCCCTCACAGTGTCAGA AGGAAAGCTAGCCCTGCAAACATCAGGCCCCCTCACCACCACCGATAGCAGTACC CTTACTATCACTGCCTCACCCCCTCTAACTACTGCCACTGGTAGCTTGGGCATTGA CTTGAAAGAGCCCATTTATACACAAAATGGAAAACTAGGACTAAAGTACGGGGCTC CTTTGCATGTAACAGACGACCTAAACACTTTGACCGTAGCAACTGGTCCAGGTGTG ACTATTAATAATACTTCCTTGCAAACTAAAGTTACTGGAGCCTTGGGTTTTGATTCA CAAGGCAATATGCAACTTAATGTAGCAGGAGGACTAAGGATTGATTCTCAAAACAG ACGCCTTATACTTGATGTTAGTTATCCGTTTGATGCTCAAAACCAACTAAATCTAAG ACTAGGACAGGGCCCTCTTTTTATAAACTCAGCCCACAACTTGGATATTAACTACAA CAAAGGCCTTTACTTGTTTACAGCTTCAAACAATTCCAAAAAGCTTGAGGTTAACCT AAGCACTGCCAAGGGGTTGATGTTTGACGCTACAGCCATAGCCATTAATGCAGGA GATGGGCTTGAATTTGGTTCACCTAATGCACCAAACACAAATCCCCTCAAAACAAA AATTGGCCATGGCCTAGAATTTGATTCAAACAAGGCTATGGTTCCTAAACTAGGAA CTGGCCTTAGTTTTGACAGCACAGGTGCCATTACAGTAGGAAACAAAAATAATGAT AAGCTAACTTTGTGGACCACACCAGCTCCATCTCCTAACTGTAGACTAAATGCAGA GAAAGATGCTAAACTCACTTTGGTCTTAACAAAATGTGGCAGTCAAATACTTGCTAC AGTTTCAGTTTTGGCTGTTAAAGGCAGTTTGGCTCCAATATCTGGAACAGTTCAAAG TGCTCATCTTATTATAAGATTTGACGAAAATGGAGTGCTACTAAACAATTCCTTCCT GGACCCAGAATATTGGAACTTTAGAAATGGAGATCTTACTGAAGGCACAGCCTATA CAAACGCTGTTGGATTTATGCCTAACCTATCAGCTTATCCAAAATCTCACGGTAAAACTGCCAAAAGTAACATTGTCAGTCAAGTTTACTTAAACGGAGACAAAACTAAACCTGTAACACTAACCATTACACTAAACGGTACACAGGAAACAGGAGACACAACTCCAAGT GCATACTCTATGTCATTTTCATGGGACTGGTCTGGCCACAACTACATTAATGAAATA TTTGCCACATCCTCTTACACTTTTTCATACATTGCCCAAGAATAAAGAATCGTTTGT GTTATGTTTCAACGTGTTTATTTTTCAATTGCAGAAAATTTCAAGTCATTTTTCATTCAGTAGTATAGCCCCACCACCACATAGCTTATACAGATCACCGTACCTTAATCAAACTCACAGAACCCTAGTATTCAACCTGCCACCTCCCTCCCAACACACAGAGTACACAGTC CTTTCTCCCCGGCTGGCCTTAAAAAGCATCATATCATGGGTAACAGACATATTCTTA GGTGTTATATTCCACACGGTTTCCTGTCGAGCCAAACGCTCATCAGTGATATTAATA AACTCCCCGGGCAGCTCACTTAAGTTCATGTCGCTGTCCAGCTGCTGAGCCACAGGCTGCTGTCCAACTTGCGGTTGCTTAACGGGCGGCGAAGGAGAAGTCCACGCCTACATGGGGGTAGAGTCATAATCGTGCATCAGGATAGGGCGGTGGTGCTGCAGCAG CGCGCGAATAAACTGCTGCCGCCGCCGCTCCGTCCTGCAGGAATACAACATGGCA GTGGTCTCCTCAGCGATGATTCGCACCGCCCGCAGCATAAGGCGCCTTGTCCTCC GGGCACAGCAGCGCACCCTGATCTCACTTAAATCAGCACAGTAACTGCAGCACAG CACCACAATATTGTTCAAAATCCCACAGTGCAAGGCGCTGTATCCAAAGCTCATGG CGGGGACCACAGAACCCACGTGGCCATCATACCACAAGCGCAGGTAGATTAAGTG GCGACCCCTCATAAACACGCTGGACATAAACATTACCTCTTTTGGCATGTTGTAATT CACCACCTCCCGGTACCATATAAACCTCTGATTAAACATGGCGCCATCCACCACCA TCCTAAACCAGCTGGCCAAAACCTGCCCGCCGGCTATACACTGCAGGGAACCGGG ACTGGAACAATGACAGTGGAGAGCCCAGGACTCGTAACCATGGATCATCATGCTC GTCATGATATCAATGTTGGCACAACACAGGCACACGTGCATACACTTCCTCAGGAT TACAAGCTCCTCCCGCGTTAGAACCATATCCCAGGGAACAACCCATTCCTGAATCA GCGTAAATCCCACACTGCAGGGAAGACCTCGCACGTAACTCACGTTGTGCATTGT CAAAGTGTTACATTCGGGCAGCAGCGGATGATCCTCCAGTATGGTAGCGCGGGTT TCTGTCTCAAAAGGAGGTAGACGATCCCTACTGTACGGAGTGCGCCGAGACAACC GAGATCGTGTTGGTCGTAGTGTCATGCCAAATGGAACGCCGGACGTAGTCATATTT CCTGAAGCAAAACCAGGTGCGGGCGTGACAAACAGATCTGCGTCTCCGGTCTCGC CGCTTAGATCGCTCTGTGTAGTAGTTGTAGTATATCCACTCTCTCAAAGCATCCAG GCGCCCCCTGGCTTCGGGTTCTATGTAAACTCCTTCATGCGCCGCTGCCCTGATA ACATCCACCACCGCAGAATAAGCCACACCCAGCCAACCTACACATTCGTTCTGCGA GTCACACACGGGAGGAGCGGGAAGAGCTGGAAGAACCATGTTTTTTTTTTTATTCC AAAAGATTATCCAAAACCTCAAAATGAAGATCTATTAAGTGAACGCGCTCCCCTCC GGTGGCGTGGTCAAACTCTACAGCCAAAGAACAGATAATGGCATTTGTAAGATGTT GCACAATGGCTTCCAAAAGGCAAACGGCCCTCACGTCCAAGTGGACGTAAAGGCT AAACCCTTCAGGGTGAATCTCCTCTATAAACATTCCAGCACCTTCAACCATGCCCA AATAATTCTCATCTCGCCACCTTCTCAATATATCTCTAAGCAAATCCCGAATATTAAG TCCGGCCATTGTAAAAATCTGCTCCAGAGCGCCCTCCACCTTCAGCCTCAAGCAG CGAATCATGATTGCAAAAATTCAGGTTCCTCACAGACCTGTATAAGATTCAAAAGCG GAACATTAACAAAAATACCGCGATCCCGTAGGTCCCTTCGCAGGGCCAGCTGAAC ATAATCGTGCAGGTCTGCACGGACCAGCGCGGCCACTTCCCCGCCAGGAACCATGACAAAAGAACCCACACTGATTATGACACGCATACTCGGAGCTATGCTAACCAGCGTAGCCCCGATGTAAGCTTGTTGCATGGGCGGCGATATAAAATGCAAGGTGCTGCTC AAAAAATCAGGCAAAGCCTCGCGCAAAAAAGAAAGCACATCGTAGTCATGCTCATG CAGATAAAGGCAGGTAAGCTCCGGAACCACCACAGAAAAAGACACCATTTTTCTCT CAAACATGTCTGCGGGTTTCTGCATAAACACAAAATAAAATAACAAAAAAACATTTAAACATTAGAAGCCTGTCTTACAACAGGAAAAACAACCCTTATAAGCATAAGACGGACTACGGCCATGCCGGCGTGACCGTAAAAAAACTGGTCACCGTGATTAAAAAGCAC CACCGACAGCTCCTCGGTCATGTCCGGAGTCATAATGTAAGACTCGGTAAACACAT CAGGTTGATTCACATCGGTCAGTGCTAAAAAGCGACCGAAATAGCCCGGGGGAAT ACATACCCGCAGGCGTAGAGACAACATTACAGCCCCCATAGGAGGTATAACAAAATTAATAGGAGAGAAAAACACATAAACACCTGAAAAACCCTCCTGCCTAGGCAAAATAGCACCCTCCCGCTCCAGAACAACATACAGCGCTTCCACAGCGGCAGCCATAACAG TCAGCCTTACCAGTAAAAAAGAAAACCTATTAAAAAAACACCACTCGACACGGCAC CAGCTCAATCAGTCACAGTGTAAAAAAGGGCCAAGTGCAGAGCGAGTATATATAGG ACTAAAAAATGACGTAACGGTTAAAGTCCACAAAAAACACCCAGAAAACCGCACGC GAACCTACGCCCAGAAACGAAAGCCAAAAAACCCACAACTTCCTCAAATCGTCACT TCCGTTTTCCCACGTTACGTCACTTCCCATTTTAAGAAAACTACAATTCCCAACACA TACAAGTTACTCCGCCCTAAAACCTACGTCACCCGCCCCGTTCCCACGCCCCGCG CCACGTCACAAACTCCACCCCCTCATTATCATATTGGCTTCAATCCAAAATAAGGTA TATTATTGATGATG SEQ ID NO: 49 ADVEGFALL-6A+VARIANT #6 (35,371 BP) CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGG AGTTTGTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGG CGGAAGTGTGATGTTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAA AAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGG TTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTC GCGGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGC GCGTAATACTGTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGG AGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGA CCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGA CTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTA CATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATG GCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGT ACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCA ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGA CGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTA ACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTA TATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGAGATCTGGTACCGGG CCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCCTGCAGTCACC GTCGTCGACGGTATCGATAAGCTTGATATCGAATTCCGGTCGGGCCTCCGAAACCATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCACCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCA TCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCGATCG AGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAG CCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTGGAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGA ATGCAGACCAAAGAAAGATAGAGCTCGACAAGAAAAGTAAGTGGCCCTGACTTTAG CACTTCTCCCTCTCCATGGCCGGTTGTCTTGGTTTGGGGCTCTTGGCTACCTCTGT TGGGGGCTCCCATAGCCTCCCTGGGTCAGGGACTTGGTCTTGTGGGGGACTTGTGGTGGCAGCAACAATGGGATGGAGCCAACTCCAGGATGATGGCTCTAGGGCTAGTGAGAAAACATAGCCAGGAGCCTGGCACTTCCTTTGGAAGGGACAATGCCTTCTGGG TCTCCAGATCATTTCTGACCAGGACTTGCTGTTTCGGTGTGTCAGGGGGCACTGTG GACACTGGCTCACTGGCTTGCTCTAGGACACCCACAGTGGGGAGAGGGAGTGGG TGGCAGAGAGGCCAGCTTTTGTGTGTCAGAGGAAATGGCCTCTTTTGGTGGCTGC TGTGACGGTGCAGTTGGATGCGAGGCCGGCTGGAGGGTGGTTTCTCAGTGCATG CCCTCCTGTAGGCGGCAGGCGGCAGACACACAGCCCTCTTGGCCAGGGAGAAAA AGTTGAATGTTGGTCATTTTCAGAGGCTTGTGAGTGCTCCGTGTTAAGGGGCAGGT AGGATGGGGTGGGGGACAAGGTTTGGCGGCAGTAACCCTTCAAGACAGGGTGGG CGGCTGGCATCAGCAAGAGCTTGCAGGGAAAGAGAGACTGAGAGAGAGCACCTG TGCCCTGCCCTTTCCCCCACACCATCTTGTCTGCCTCCAGTGCTGTGCGGACATTG AAGCCCCCACCAGGCCTCAACCCCTTGCCTCTTCCCTCAGCTCCCAGCTTCCAGA GCGAGGGGATGCGGAAACCTTCCTTCCACCCTTTGGTGCTTTCTCCTAAGGGGGA CAGACTTGCCCTCTCTGGTCCCTTCTCCCCCTCCTTTCTTCCCTGTGACAGACATC CTGAGGTGTGTTCTCTTGGGCTTGGCAGGCATGGAGAGCTCTGGTTCTCTTGAAG GGGACAGGCTACAGCCTGCCCCCCTTCCTGTTTCCCCAAATGACTGCTCTGCCAT GGGGAGAGTAGGGGGCTCGCCTGGGCTCGGAAGAGTGTCTGGTGAGATGGTGTA GCAGGCTTTGACAGGCTGGGGAGAGAACTCCCTGCCAAGTACCGCCCAAGCCTCT CCTCCCCAGACCTCCTTAACTCCCACCCCATCCTGCTGCCTGCCCAGGGCTCCAG GACACCCAGCCCTGCCTCCCAGTCCAGGTCGTGCTGAGCAGGCTGGTGTTGCTCT TGGTTCCGTGCCAGCTCCCAAGGTAGCCGCTTCCCCCACACCGGGATTCCCAGAG GTTCTGTCGCAGTTGCAAATGAAGGCACAAGGCCTGATACACAGCCCTCCCTCCC ACTCCTGCTCCCCATCCAGGCAGGTCTCTGACCTTCTCCCCAAAGTCTGGCCTACC TTTTATCACCCCCGGACCTTCAGGGTCAGACTTGGACAGGGCTGCTGGGCAAAGA GCCTTCCCTCAGGCTTTGCCCCCTGCCGGGGACTGGGAGCCACTGTGAGTGTGG AGACCTTTGGGTCCTGTGCCCTCCACCCAGTCTCGGCTTCCCACCAAAGCCTTGT CAGGGGCTGGGTTTGCCATCCCATGGTGGGCAGCGTGAGGAGAAGAAAGAGCCA TCGAGTGCTTGCTGCCCAGACACGCCTGTGTGCGCCCGCGCATGCCTCCCCAGA GACCACCTGCCTCCTGACACTTCCTCCGGGAAGCGGCCCTGTGTGGCTTTGCTTT GGTCGTTCCCCCATCCCTGCCCCCCTGAGCACTTCTTTTACTCCCCCCACCGCCC CCGCTCTTTCTCTGTCTCTGTTTTTTTCTTTTCCAGAAAATCAGTTCGAGGAAAGGGAAAGGGGCAAAAACGAAAGCGCAAGAAATCTAGATATAAGTCCTGGAGCGTGTAAGTTGGTGCCCGCTGCTGTCTAATGCCCTGGAGCCTCCCTGGCCCCCAGTACAACC TCCGCCTGCCATTCCCTGTAACCCTGCCTCCCTCCCCTGGTCCCTCCCTGGCTCT CATCCTCCTGGCCCGTGTCTCTCTCTCACTCTCTCACTCCACTAATTGGCACCAAC GGGTAGATTTGGTGGTGGCATTGCTGGTCCAGGGTTGGGGTGAATGGGGGTGCCGACTTGGCCTGGAGGATTAAGGGAGGGGACCCTGGCTTGGCTGGGCACCGATTTTCTCTCACCCACTGGGCACTGGTGGCAGGCCCATGTTGGCACAGGTGCCTGCTCAC CCAACTGGTTTCCATTGCTCTAGGCTTCTGCACTCGTCTGGAAGCTGAGGGTGGT GGGGAGGGCAGACATGGCCCAAGAAGGGCTGTGAATGACTGGAGGCAGCTTGCT GAATGACTCCTTGGCTGAAGGAGGAGCTTGGGTGGGATCAGACACCATGTGGCGGCCTCCCTTCATCTGGTGGAAGTGCCCTGGCTCCTCACGGAGGTGGGGCCTCTGGAGGGGAGCCCCCTATTCTGGCCCAACCCATGGCACCCACAGAGGCCTCCTTGCA GGGCAGCCTCTTCCTCCGGGTCGGAGGCTGTGGTGGGCCCTGCCCTGGGCCCTC TGGCCACCAGCGGCCTGGCCTGGGGACACTGCCTCCGGGCTTAGCCTCCCATCA CACCCTACTTTAGCCCACCTTGGTGGAAGGGCCTGGACATGAGCCTTGCACGGGG AGAAGGTGGCCCCTGATTGCCATCCCCAGCAGGTGAAGAGTCAAGGCGTGCTCC GATGGGGGCAACAGCAGTTGGGTCCCTGTGGCCTGAGACTCACCCTTGTCTCCCA GAGACACAGCATTGCCCCTTATGGCAGCCTCTCCCTGCACTCTCTGCCCGTCTGT GCCCGCCTCTTCCTGCGGCAGGTGTCCTAGCCAGTGCTGCCTCTTTCCGCCGCTC TCTCTGTCTTTTGCTGTAGCGCTCGGATCCTTCCAGGGCCTGGGGGCTGACCGGC TGGGTGGGGGTGCAGCTGCGGACATGTTAGGGGGTGTTGCATGGTGATTTTTTTT CTCTCTCTCTGCTGATGCTCTAGCTTAGATGTCTTTCCTTTTGCCTTTTTGCAGTCC CTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACG TGTAAATGTTCCTGCAAAAACACAGACTCGAGATGCAAGGCGAGGCAGCTTGAGTT AAACGAACGTACTTGCAGGTTGGTTCCCAGAGGGCAAGCAAGTCAGAGAGGGGCA TCACACAGAGATGGGGAGAGAGAGAGAGAAAGAGAGTGAGCGAGCGAGCGAGCG GGAGAGCGCCTGAGAGGGGCCAGCTGCTTGCTCAGTTTCTAGCTGCCTGCCTGA GATCTGCGAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCTGCCC ACTCTCTTCCCCACACCAGCCCCTAGAGACTGAACTGAAAACCCTCCTCAGCAGG GAGCCTCTTCTGATTAACTTCATCCAGCTCTGGTCACCCATCAGCTCTTAAAATGTC AAGTGGGGACTGTTCTTTGGTATCCGTTCATTTGTTGCTTTGTAAAGTGTTCCCATG TCCTTGTCTTGTCTCAAGTAGATTGCAAGCTCAGGAGGGTAGACTGGGAGCCCCT GAGTGGAGCTGCTGCTCAGGCCGGGGCTCCCTGAGGGCAGGGCTGGGGCTGTTC TCATACTGGGGCTTTCTGCCCCAGGACCACACCTTCCTGTCCCCTCTGCTCTTATG GTGCCGGAGGCTGCAGTGACCCAGGGGCCCCCAGGAATGGGGAGGCCGCCTGC CTCATCGCCAGGCCTCCTCACTTGGCCCTGACCCCAGCCTTTGTTTTCCCTTTCCC TCAGGTGTGACAAGCCGAGGCGGTGAAAGCTTCTAGATAAGATATCCGATCCACC GGATCTAGATAACTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCT TTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTT GTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAA ATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAACGCGGATCTGGGCGTGGTTAAGGGTGGGAAAGAATATATAAGGTGGGGGTCTTATGTAGTTTTGTATCTGTTTTGCAGCAGCCGCCGCCGCCATGAGCA CCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCA TGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGTC CTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCC GCCCGCGATGACAAGTTGACGGCTCTTTTGGCACAATTGGATTCTTTGACCCGGG AACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTG AAGGCTTCCTCCCCTCCCAATGCGGTTTAAAACATAAATAAAAAACCAGACTCTGTTTGGATTTGGATCAAGCAAGTGTCTTGCTGTCTTTATTTAGGGGTTTTGCGCGCGCGGTAGGCCCGGGACCAGCGGTCTCGGTCGTTGAGGGTCCTGTGTATTTTTTCCAGG ACGTGGTAAAGGTGACTCTGGATGTTCAGATACATGGGCATAAGCCCGTCTCTGG GGTGGAGGTAGCACCACTGCAGAGCTTCATGCTGCGGGGTGGTGTTGTAGATGAT CCAGTCGTAGCAGGAGCGCTGGGCGTGGTGCCTAAAAATGTCTTTCAGTAGCAAG CTGATTGCCAGGGGCAGGCCCTTGGTGTAAGTGTTTACAAAGCGGTTAAGCTGGG ATGGGTGCATACGTGGGGATATGAGATGCATCTTGGACTGTATTTTTAGGTTGGCT ATGTTCCCAGCCATATCCCTCCGGGGATTCATGTTGTGCAGAACCACCAGCACAGT GTATCCGGTGCACTTGGGAAATTTGTCATGTAGCTTAGAAGGAAATGCGTGGAAGA ACTTGGAGACGCCCTTGTGACCTCCAAGATTTTCCATGCATTCGTCCATAATGATG GCAATGGGCCCACGGGCGGCGGCCTGGGCGAAGATATTTCTGGGATCACTAACG TCATAGTTGTGTTCCAGGATGAGATCGTCATAGGCCATTTTTACAAAGCGCGGGCG GAGGGTGCCAGACTGCGGTATAATGGTTCCATCCGGCCCAGGGGCGTAGTTACCC TCACAGATTTGCATTTCCCACGCTTTGAGTTCAGATGGGGGGATCATGTCTACCTG CGGGGCGATGAAGAAAACGGTTTCCGGGGTAGGGGAGATCAGCTGGGAAGAAAG CAGGTTCCTGAGCAGCTGCGACTTACCGCAGCCGGTGGGCCCGTAAATCACACCT ATTACCGGCTGCAACTGGTAGTTAAGAGAGCTGCAGCTGCCGTCATCCCTGAGCA GGGGGGCCACTTCGTTAAGCATGTCCCTGACTCGCATGTTTTCCCTGACCAAATCC GCCAGAAGGCGCTCGCCGCCCAGCGATAGCAGTTCTTGCAAGGAAGCAAAGTTTT TCAACGGTTTGAGACCGTCCGCCGTAGGCATGCTTTTGAGCGTTTGACCAAGCAG TTCCAGGCGGTCCCACAGCTCGGTCACCTGCTCTACGGCATCTCGATCCAGCATA TCTCCTCGTTTCGCGGGTTGGGGCGGCTTTCGCTGTACGGCAGTAGTCGGTGCTC GTCCAGACGGGCCAGGGTCATGTCTTTCCACGGGCGCAGGGTCCTCGTCAGCGT AGTCTGGGTCACGGTGAAGGGGTGCGCTCCGGGCTGCGCGCTGGCCAGGGTGC GCTTGAGGCTGGTCCTGCTGGTGCTGAAGCGCTGCCGGTCTTCGCCCTGCGCGT CGGCCAGGTAGCATTTGACCATGGTGTCATAGTCCAGCCCCTCCGCGGCGTGGCC CTTGGCGCGCAGCTTGCCCTTGGAGGAGGCGCCGCACGAGGGGCAGTGCAGACT TTTGAGGGCGTAGAGCTTGGGCGCGAGAAATACCGATTCCGGGGAGTAGGCATCC GCGCCGCAGGCCCCGCAGACGGTCTCGCATTCCACGAGCCAGGTGAGCTCTGGC CGTTCGGGGTCAAAAACCAGGTTTCCCCCATGCTTTTTGATGCGTTTCTTACCTCT GGTTTCCATGAGCCGGTGTCCACGCTCGGTGACGAAAAGGCTGTCCGTGTCCCCGTATACAGACTTGAGAGGCCTGTCCTCGAGCGGTGTTCCGCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACAAAGGCTCGCGTCCAGGCCAGCACGAAGGAGG CTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTCCACTCGCTCCAGGG TGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTGTAGGTG TAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGGTGAGTACTCCCTCTGAAAAGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAA AACGAGGAGGATTTGATATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCG CATCCATCTGGTCAGAAAAGACAATCTTTTTGTTGTCAAGCTTGGTGGCAAACGAC CCGTAGAGGGCGTTGGACAGCAACTTGGCGATGGAGCGCAGGGTTTGGTTTTTGTCGCGATCGGCGCGCTCCTTGGCCGCGATGTTTAGCTGCACGTATTCGCGCGCAACGCACCGCCATTCGGGAAAGACGGTGGTGCGCTCGTCGGGCACCAGGTGCACGCG CCAACCGCGGTTGTGCAGGGTGACAAGGTCAACGCTGGTGGCTACCTCTCCGCGT AGGCGCTCGTTGGTCCAGCAGAGGCGGCCGCCCTTGCGCGAGCAGAATGGCGGT AGGGGGTCTAGCTGCGTCTCGTCCGGGGGGTCTGCGTCCACGGTAAAGACCCCG GGCAGCAGGCGCGCGTCGAAGTAGTCTATCTTGCATCCTTGCAAGTCTAGCGCCT GCTGCCATGCGCGGGCGGCAAGCGCGCGCTCGTATGGGTTGAGTGGGGGACCC CATGGCATGGGGTGGGTGAGCGCGGAGGCGTACATGCCGCAAATGTCGTAAACG TAGAGGGGCTCTCTGAGTATTCCAAGATATGTAGGGTAGCATCTTCCACCGCGGAT GCTGGCGCGCACGTAATCGTATAGTTCGTGCGAGGGAGCGAGGAGGTCGGGACC GAGGTTGCTACGGGCGGGCTGCTCTGCTCGGAAGACTATCTGCCTGAAGATGGCA TGTGAGTTGGATGATATGGTTGGACGCTGGAAGACGTTGAAGCTGGCGTCTGTGA GACCTACCGCGTCACGCACGAAGGAGGCGTAGGAGTCGCGCAGCTTGTTGACCA GCTCGGCGGTGACCTGCACGTCTAGGGCGCAGTAGTCCAGGGTTTCCTTGATGAT GTCATACTTATCCTGTCCCTTTTTTTTCCACAGCTCGCGGTTGAGGACAAACTCTTC GCGGTCTTTCCAGTACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGGTAAGAG CCTAGCATGTAGAACTGGTTGACGGCCTGGTAGGCGCAGCATCCCTTTTCTACGG GTAGCGCGTATGCCTGCGCGGCCTTCCGGAGCGAGGTGTGGGTGAGCGCAAAGG TGTCCCTGACCATGACTTTGAGGTACTGGTATTTGAAGTCAGTGTCGTCGCATCCG CCCTGCTCCCAGAGCAAAAAGTCCGTGCGCTTTTTGGAACGCGGATTTGGCAGGG CGAAGGTGACATCGTTGAAGAGTATCTTTCCCGCGCGAGGCATAAAGTTGCGTGT GATGCGGAAGGGTCCCGGCACCTCGGAACGGTTGTTAATTACCTGGGCGGCGAG CACGATCTCGTCAAAGCCGTTGATGTTGTGGCCCACAATGTAAAGTTCCAAGAAGC GCGGGATGCCCTTGATGGAAGGCAATTTTTTAAGTTCCTCGTAGGTGAGCTCTTCA GGGGAGCTGAGCCCGTGCTCTGAAAGGGCCCAGTCTGCAAGATGAGGGTTGGAA GCGACGAATGAGCTCCACAGGTCACGGGCCATTAGCATTTGCAGGTGGTCGCGAA AGGTCCTAAACTGGCGACCTATGGCCATTTTTTCTGGGGTGATGCAGTAGAAGGTA AGCGGGTCTTGTTCCCAGCGGTCCCATCCAAGGTTCGCGGCTAGGTCTCGCGCG GCAGTCACTAGAGGCTCATCTCCGCCGAACTTCATGACCAGCATGAAGGGCACGA GCTGCTTCCCAAAGGCCCCCATCCAAGTATAGGTCTCTACATCGTAGGTGACAAAG AGACGCTCGGTGCGAGGATGCGAGCCGATCGGGAAGAACTGGATCTCCCGCCACCAATTGGAGGAGTGGCTATTGATGTGGTGAAAGTAGAAGTCCCTGCGACGGGCCGAACACTCGTGCTGGCTTTTGTAAAAACGTGCGCAGTACTGGCAGCGGTGCACGGG CTGTACATCCTGCACGAGGTTGACCTGACGACCGCGCACAAGGAAGCAGAGTGG GAATTTGAGCCCCTCGCCTGGCGGGTTTGGCTGGTGGTCTTCTACTTCGGCTGCT TGTCCTTGACCGTCTGGCTGCTCGAGGGGAGTTACGGTGGATCGGACCACCACGCCGCGCGAGCCCAAAGTCCAGATGTCCGCGCGCGGCGGTCGGAGCTTGATGACAACATCGCGCAGATGGGAGCTGTCCATGGTCTGGAGCTCCCGCGGCGTCAGGTCAG GCGGGAGCTCCTGCAGGTTTACCTCGCATAGACGGGTCAGGGCGCGGGCTAGAT CCAGGTGATACCTAATTTCCAGGGGCTGGTTGGTGGCGGCGTCGATGGCTTGCAA GAGGCCGCATCCCCGCGGCGCGACTACGGTACCGCGCGGCGGGCGGTGGGCCGCGGGGGTGTCCTTGGATGATGCATCTAAAAGCGGTGACGCGGGCGAGCCCCCGGAGGTAGGGGGGGCTCCGGACCCGCCGGGAGAGGGGGCAGGGGCACGTCGGCG CCGCGCGCGGGCAGGAGCTGGTGCTGCGCGCGTAGGTTGCTGGCGAACGCGAC GACGCGGCGGTTGATCTCCTGAATCTGGCGCCTCTGCGTGAAGACGACGGGCCC GGTGAGCTTGAACCTGAAAGAGAGTTCGACAGAATCAATTTCGGTGTCGTTGACG GCGGCCTGGCGCAAAATCTCCTGCACGTCTCCTGAGTTGTCTTGATAGGCGATCT CGGCCATGAACTGCTCGATCTCTTCCTCCTGGAGATCTCCGCGTCCGGCTCGCTC CACGGTGGCGGCGAGGTCGTTGGAAATGCGGGCCATGAGCTGCGAGAAGGCGTT GAGGCCTCCCTCGTTCCAGACGCGGCTGTAGACCACGCCCCCTTCGGCATCGCG GGCGCGCATGACCACCTGCGCGAGATTGAGCTCCACGTGCCGGGCGAAGACGGC GTAGTTTCGCAGGCGCTGAAAGAGGTAGTTGAGGGTGGTGGCGGTGTGTTCTGCC ACGAAGAAGTACATAACCCAGCGTCGCAACGTGGATTCGTTGATATCCCCCAAGG CCTCAAGGCGCTCCATGGCCTCGTAGAAGTCCACGGCGAAGTTGAAAAACTGGGA GTTGCGCGCCGACACGGTTAACTCCTCCTCCAGAAGACGGATGAGCTCGGCGACA GTGTCGCGCACCTCGCGCTCAAAGGCTACAGGGGCCTCTTCTTCTTCTTCAATCTC CTCTTCCATAAGGGCCTCCCCTTCTTCTTCTTCTGGCGGCGGTGGGGGAGGGGGG ACACGGCGGCGACGACGGCGCACCGGGAGGCGGTCGACAAAGCGCTCGATCATC TCCCCGCGGCGACGGCGCATGGTCTCGGTGACGGCGCGGCCGTTCTCGCGGGG GCGCAGTTGGAAGACGCCGCCCGTCATGTCCCGGTTATGGGTTGGCGGGGGGCT GCCATGCGGCAGGGATACGGCGCTAACGATGCATCTCAACAATTGTTGTGTAGGT ACTCCGCCGCCGAGGGACCTGAGCGAGTCCGCATCGACCGGATCGGAAAACCTC TCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCACCGTGGCG GGCGGCAGCGGGCGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATG TAATTAAAGTAGGCGGTCTTGAGACGGCGGATGGTCGACAGAAGCACCATGTCCT TGGGTCCGGCCTGCTGAATGCGCAGGCGGTCGGCCATGCCCCAGGCTTCGTTTT GACATCGGCGCAGGTCTTTGTAGTAGTCTTGCATGAGCCTTTCTACCGGCACTTCT TCTTCTCCTTCCTCTTGTCCTGCATCTCTTGCATCTATCGCTGCGGCGGCGGCGGA GTTTGGCCGTAGGTGGCGCCCTCTTCCTCCCATGCGTGTGACCCCGAAGCCCCTC ATCGGCTGAAGCAGGGCTAGGTCGGCGACAACGCGCTCGGCTAATATGGCCTGC TGCACCTGCGTGAGGGTAGACTGGAAGTCATCCATGTCCACAAAGCGGTGGTATG CGCCCGTGTTGATGGTGTAAGTGCAGTTGGCCATAACGGACCAGTTAACGGTCTGGTGACCCGGCTGCGAGAGCTCGGTGTACCTGAGACGCGAGTAAGCCCTCGAGTCAAATACGTAGTCGTTGCAAGTCCGCACCAGGTACTGGTATCCCACCAAAAAGTGCG GCGGCGGCTGGCGGTAGAGGGGCCAGCGTAGGGTGGCCGGGGCTCCGGGGGC GAGATCTTCCAACATAAGGCGATGATATCCGTAGATGTACCTGGACATCCAGGTGA TGCCGGCGGCGGTGGTGGAGGCGCGCGGAAAGTCGCGGACGCGGTTCCAGATGTTGCGCAGCGGCAAAAAGTGCTCCATGGTCGGGACGCTCTGGCCGGTCAGGCGCGCGCAATCGTTGACGCTCTAGCGTGCAAAAGGAGAGCCTGTAAGCGGGCACTCTT CCGTGGTCTGGTGGATAAATTCGCAAGGGTATCATGGCGGACGACCGGGGTTCGA GCCCCGTATCCGGCCGTCCGCCGTGATCCATGCGGTTACCGCCCGCGTGTCGAA CCCAGGTGTGCGACGTCAGACAACGGGGGAGTGCTCCTTTTGGCTTCCTTCCAGGCGCGGCGGCTGCTGCGCTAGCTTTTTTGGCCACTGGCCGCGCGCAGCGTAAGCGGTTAGGCTGGAAAGCGAAAGCATTAAGTGGCTCGCTCCCTGTAGCCGGAGGGTTA TTTTCCAAGGGTTGAGTCGCGGGACCCCCGGTTCGAGTCTCGGACCGGCCGGAC TGCGGCGAACGGGGGTTTGCCTCCCCGTCATGCAAGACCCCGCTTGCAAATTCCT CCGGAAACAGGGACGAGCCCCTTTTTTGCTTTTCCCAGATGCATCCGGTGCTGCG GCAGATGCGCCCCCCTCCTCAGCAGCGGCAAGAGCAAGAGCAGCGGCAGACATG CAGGGCACCCTCCCCTCCTCCTACCGCGTCAGGAGGGGCGACATCCGCGGTTGA CGCGGCAGCAGATGGTGATTACGAACCCCCGCGGCGCCGGGCCCGGCACTACCT GGACTTGGAGGAGGGCGAGGGCCTGGCGCGGCTAGGAGCGCCCTCTCCTGAGC GGCACCCAAGGGTGCAGCTGAAGCGTGATACGCGTGAGGCGTACGTGCCGCGGC AGAACCTGTTTCGCGACCGCGAGGGAGAGGAGCCCGAGGAGATGCGGGATCGAA AGTTCCACGCAGGGCGCGAGCTGCGGCATGGCCTGAATCGCGAGCGGTTGCTGC GCGAGGAGGACTTTGAGCCCGACGCGCGAACCGGGATTAGTCCCGCGCGCGCAC ACGTGGCGGCCGCCGACCTGGTAACCGCATACGAGCAGACGGTGAACCAGGAGA TTAACTTTCAAAAAAGCTTTAACAACCACGTGCGTACGCTTGTGGCGCGCGAGGAG GTGGCTATAGGACTGATGCATCTGTGGGACTTTGTAAGCGCGCTGGAGCAAAACC CAAATAGCAAGCCGCTCATGGCGCAGCTGTTCCTTATAGTGCAGCACAGCAGGGA CAACGAGGCATTCAGGGATGCGCTGCTAAACATAGTAGAGCCCGAGGGCCGCTG GCTGCTCGATTTGATAAACATCCTGCAGAGCATAGTGGTGCAGGAGCGCAGCTTG AGCCTGGCTGACAAGGTGGCCGCCATCAACTATTCCATGCTTAGCCTGGGCAAGT TTTACGCCCGCAAGATATACCATACCCCTTACGTTCCCATAGACAAGGAGGTAAAG ATCGAGGGGTTCTACATGCGCATGGCGCTGAAGGTGCTTACCTTGAGCGACGACC TGGGCGTTTATCGCAACGAGCGCATCCACAAGGCCGTGAGCGTGAGCCGGCGGC GCGAGCTCAGCGACCGCGAGCTGATGCACAGCCTGCAAAGGGCCCTGGCTGGCA CGGGCAGCGGCGATAGAGAGGCCGAGTCCTACTTTGACGCGGGCGCTGACCTGC GCTGGGCCCCAAGCCGACGCGCCCTGGAGGCAGCTGGGGCCGGACCTGGGCTG GCGGTGGCACCCGCGCGCGCTGGCAACGTCGGCGGCGTGGAGGAATATGACGA GGACGATGAGTACGAGCCAGAGGACGGCGAGTACTAAGCGGTGATGTTTCTGATC AGATGATGCAAGACGCAACGGACCCGGCGGTGCGGGCGGCGCTGCAGAGCCAG CCGTCCGGCCTTAACTCCACGGACGACTGGCGCCAGGTCATGGACCGCATCATGT CGCTGACTGCGCGCAATCCTGACGCGTTCCGGCAGCAGCCGCAGGCCAACCGGCTCTCCGCAATTCTGGAAGCGGTGGTCCCGGCGCGCGCAAACCCCACGCACGAGAAGGTGCTGGCGATCGTAAACGCGCTGGCCGAAAACAGGGCCATCCGGCCCGACG AGGCCGGCCTGGTCTACGACGCGCTGCTTCAGCGCGTGGCTCGTTACAACAGCG GCAACGTGCAGACCAACCTGGACCGGCTGGTGGGGGATGTGCGCGAGGCCGTG GCGCAGCGTGAGCGCGCGCAGCAGCAGGGCAACCTGGGCTCCATGGTTGCACTAAACGCCTTCCTGAGTACACAGCCCGCCAACGTGCCGCGGGGACAGGAGGACTACACCAACTTTGTGAGCGCACTGCGGCTAATGGTGACTGAGACACCGCAAAGTGAGG TGTACCAGTCTGGGCCAGACTATTTTTTCCAGACCAGTAGACAAGGCCTGCAGACC GTAAACCTGAGCCAGGCTTTCAAAAACTTGCAGGGGCTGTGGGGGGTGCGGGCT CCCACAGGCGACCGCGCGACCGTGTCTAGCTTGCTGACGCCCAACTCGCGCCTGTTGCTGCTGCTAATAGCGCCCTTCACGGACAGTGGCAGCGTGTCCCGGGACACATACCTAGGTCACTTGCTGACACTGTACCGCGAGGCCATAGGTCAGGCGCATGTGGA CGAGCATACTTTCCAGGAGATTACAAGTGTCAGCCGCGCGCTGGGGCAGGAGGA CACGGGCAGCCTGGAGGCAACCCTAAACTACCTGCTGACCAACCGGCGGCAGAA GATCCCCTCGTTGCACAGTTTAAACAGCGAGGAGGAGCGCATTTTGCGCTACGTG CAGCAGAGCGTGAGCCTTAACCTGATGCGCGACGGGGTAACGCCCAGCGTGGCG CTGGACATGACCGCGCGCAACATGGAACCGGGCATGTATGCCTCAAACCGGCCGT TTATCAACCGCCTAATGGACTACTTGCATCGCGCGGCCGCCGTGAACCCCGAGTA TTTCACCAATGCCATCTTGAACCCGCACTGGCTACCGCCCCCTGGTTTCTACACCG GGGGATTCGAGGTGCCCGAGGGTAACGATGGATTCCTCTGGGACGACATAGACG ACAGCGTGTTTTCCCCGCAACCGCAGACCCTGCTAGAGTTGCAACAGCGCGAGCA GGCAGAGGCGGCGCTGCGAAAGGAAAGCTTCCGCAGGCCAAGCAGCTTGTCCGA TCTAGGCGCTGCGGCCCCGCGGTCAGATGCTAGTAGCCCATTTCCAAGCTTGATA GGGTCTCTTACCAGCACTCGCACCACCCGCCCGCGCCTGCTGGGCGAGGAGGAG TACCTAAACAACTCGCTGCTGCAGCCGCAGCGCGAAAAAAACCTGCCTCCGGCAT TTCCCAACAACGGGATAGAGAGCCTAGTGGACAAGATGAGTAGATGGAAGACGTA CGCGCAGGAGCACAGGGACGTGCCAGGCCCGCGCCCGCCCACCCGTCGTCAAA GGCACGACCGTCAGCGGGGTCTGGTGTGGGAGGACGATGACTCGGCAGACGACA GCAGCGTCCTGGATTTGGGAGGGAGTGGCAACCCGTTTGCGCACCTTCGCCCCA GGCTGGGGAGAATGTTTTAAAAAAAAAAAAGCATGATGCAAAATAAAAAACTCACC AAGGCCATGGCACCGAGCGTTGGTTTTCTTGTATTCCCCTTAGTATGCGGCGCGC GGCGATGTATGAGGAAGGTCCTCCTCCCTCCTACGAGAGTGTGGTGAGCGCGGC GCCAGTGGCGGCGGCGCTGGGTTCTCCCTTCGATGCTCCCCTGGACCCGCCGTT TGTGCCTCCGCGGTACCTGCGGCCTACCGGGGGGAGAAACAGCATCCGTTACTCT GAGTTGGCACCCCTATTCGACACCACCCGTGTGTACCTGGTGGACAACAAGTCAA CGGATGTGGCATCCCTGAACTACCAGAACGACCACAGCAACTTTCTGACCACGGT CATTCAAAACAATGACTACAGCCCGGGGGAGGCAAGCACACAGACCATCAATCTT GACGACCGGTCGCACTGGGGCGGCGACCTGAAAACCATCCTGCATACCAACATGC CAAATGTGAACGAGTTCATGTTTACCAATAAGTTTAAGGCGCGGGTGATGGTGTCG CGCTTGCCTACTAAGGACAATCAGGTGGAGCTGAAATACGAGTGGGTGGAGTTCA CGCTGCCCGAGGGCAACTACTCCGAGACCATGACCATAGACCTTATGAACAACGCGATCGTGGAGCACTACTTGAAAGTGGGCAGACAGAACGGGGTTCTGGAAAGCGACATCGGGGTAAAGTTTGACACCCGCAACTTCAGACTGGGGTTTGACCCCGTCACTG GTCTTGTCATGCCTGGGGTATATACAAACGAAGCCTTCCATCCAGACATCATTTTG CTGCCAGGATGCGGGGTGGACTTCACCCACAGCCGCCTGAGCAACTTGTTGGGC ATCCGCAAGCGGCAACCCTTCCAGGAGGGCTTTAGGATCACCTACGATGATCTGGAGGGTGGTAACATTCCCGCACTGTTGGATGTGGACGCCTACCAGGCGAGCTTGAAAGATGACACCGAACAGGGCGGGGGTGGCGCAGGCGGCAGCAACAGCAGTGGCA GCGGCGCGGAAGAGAACTCCAACGCGGCAGCCGCGGCAATGCAGCCGGTGGAG GACATGAACGATCATGCCATTCGCGGCGACACCTTTGCCACACGGGCTGAGGAGA AGCGCGCTGAGGCCGAAGCAGCGGCCGAAGCTGCCGCCCCCGCTGCGCAACCCGAGGTCGAGAAGCCTCAGAAGAAACCGGTGATCAAACCCCTGACAGAGGACAGCAAGAAACGCAGTTACAACCTAATAAGCAATGACAGCACCTTCACCCAGTACCGCAGC TGGTACCTTGCATACAACTACGGCGACCCTCAGACCGGAATCCGCTCATGGACCC TGCTTTGCACTCCTGACGTAACCTGCGGCTCGGAGCAGGTCTACTGGTCGTTGCC AGACATGATGCAAGACCCCGTGACCTTCCGCTCCACGCGCCAGATCAGCAACTTT CCGGTGGTGGGCGCCGAGCTGTTGCCCGTGCACTCCAAGAGCTTCTACAACGAC CAGGCCGTCTACTCCCAACTCATCCGCCAGTTTACCTCTCTGACCCACGTGTTCAA TCGCTTTCCCGAGAACCAGATTTTGGCGCGCCCGCCAGCCCCCACCATCACCACC GTCAGTGAAAACGTTCCTGCTCTCACAGATCACGGGACGCTACCGCTGCGCAACA GCATCGGAGGAGTCCAGCGAGTGACCATTACTGACGCCAGACGCCGCACCTGCC CCTACGTTTACAAGGCCCTGGGCATAGTCTCGCCGCGCGTCCTATCGAGCCGCAC TTTTTGAGCAAGCATGTCCATCCTTATATCGCCCAGCAATAACACAGGCTGGGGCC TGCGCTTCCCAAGCAAGATGTTTGGCGGGGCCAAGAAGCGCTCCGACCAACACCC AGTGCGCGTGCGCGGGCACTACCGCGCGCCCTGGGGCGCGCACAAACGCGGCC GCACTGGGCGCACCACCGTCGATGACGCCATCGACGCGGTGGTGGAGGAGGCG CGCAACTACACGCCCACGCCGCCACCAGTGTCCACAGTGGACGCGGCCATTCAG ACCGTGGTGCGCGGAGCCCGGCGCTATGCTAAAATGAAGAGACGGCGGAGGCGC GTAGCACGTCGCCACCGCCGCCGACCCGGCACTGCCGCCCAACGCGCGGCGGC GGCCCTGCTTAACCGCGCACGTCGCACCGGCCGACGGGCGGCCATGCGGGCCG CTCGAAGGCTGGCCGCGGGTATTGTCACTGTGCCCCCCAGGTCCAGGCGACGAG CGGCCGCCGCAGCAGCCGCGGCCATTAGTGCTATGACTCAGGGTCGCAGGGGCA ACGTGTATTGGGTGCGCGACTCGGTTAGCGGCCTGCGCGTGCCCGTGCGCACCC GCCCCCCGCGCAACTAGATTGCAAGAAAAAACTACTTAGACTCGTACTGTTGTATG TATCCAGCGGCGGCGGCGCGCAACGAAGCTATGTCCAAGCGCAAAATCAAAGAAG AGATGCTCCAGGTCATCGCGCCGGAGATCTATGGCCCCCCGAAGAAGGAAGAGC AGGATTACAAGCCCCGAAAGCTAAAGCGGGTCAAAAAGAAAAAGAAAGATGATGAT GATGAACTTGACGACGAGGTGGAACTGCTGCACGCTACCGCGCCCAGGCGACGG GTACAGTGGAAAGGTCGACGCGTAAAACGTGTTTTGCGACCCGGCACCACCGTAG TCTTTACGCCCGGTGAGCGCTCCACCCGCACCTACAAGCGCGTGTATGATGAGGT GTACGGCGACGAGGACCTGCTTGAGCAGGCCAACGAGCGCCTCGGGGAGTTTGC CTACGGAAAGCGGCATAAGGACATGCTGGCGTTGCCGCTGGACGAGGGCAACCCAACACCTAGCCTAAAGCCCGTAACACTGCAGCAGGTGCTGCCCGCGCTTGCACCGTCCGAAGAAAAGCGCGGCCTAAAGCGCGAGTCTGGTGACTTGGCACCCACCGTG CAGCTGATGGTACCCAAGCGCCAGCGACTGGAAGATGTCTTGGAAAAAATGACCG TGGAACCTGGGCTGGAGCCCGAGGTCCGCGTGCGGCCAATCAAGCAGGTGGCGC CGGGACTGGGCGTGCAGACCGTGGACGTTCAGATACCCACTACCAGTAGCACCAGTATTGCCACCGCCACAGAGGGCATGGAGACACAAACGTCCCCGGTTGCCTCAGCGGTGGCGGATGCCGCGGTGCAGGCGGTCGCTGCGGCCGCGTCCAAGACCTCTAC GGAGGTGCAAACGGACCCGTGGATGTTTCGCGTTTCAGCCCCCCGGCGCCCGCG CCGTTCGAGGAAGTACGGCGCCGCCAGCGCGCTACTGCCCGAATATGCCCTACAT CCTTCCATTGCGCCTACCCCCGGCTATCGTGGCTACACCTACCGCCCCAGAAGACGAGCAACTACCCGACGCCGAACCACCACTGGAACCCGCCGCCGCCGTCGCCGTCGCCAGCCCGTGCTGGCCCCGATTTCCGTGCGCAGGGTGGCTCGCGAAGGAGGCA GGACCCTGGTGCTGCCAACAGCGCGCTACCACCCCAGCATCGTTTAAAAGCCGGT CTTTGTGGTTCTTGCAGATATGGCCCTCACCTGCCGCCTCCGTTTCCCGGTGCCG GGATTCCGAGGAAGAATGCACCGTAGGAGGGGCATGGCCGGCCACGGCCTGACG GGCGGCATGCGTCGTGCGCACCACCGGCGGCGGCGCGCGTCGCACCGTCGCAT GCGCGGCGGTATCCTGCCCCTCCTTATTCCACTGATCGCCGCGGCGATTGGCGCC GTGCCCGGAATTGCATCCGTGGCCTTGCAGGCGCAGAGACACTGATTAAAAACAA GTTGCATGTGGAAAAATCAAAATAAAAAGTCTGGACTCTCACGCTCGCTTGGTCCT GTAACTATTTTGTAGAATGGAAGACATCAACTTTGCGTCTCTGGCCCCGCGACACG GCTCGCGCCCGTTCATGGGAAACTGGCAAGATATCGGCACCAGCAATATGAGCGG TGGCGCCTTCAGCTGGGGCTCGCTGTGGAGCGGCATTAAAAATTTCGGTTCCACC GTTAAGAACTATGGCAGCAAGGCCTGGAACAGCAGCACAGGCCAGATGCTGAGG GATAAGTTGAAAGAGCAAAATTTCCAACAAAAGGTGGTAGATGGCCTGGCCTCTGG CATTAGCGGGGTGGTGGACCTGGCCAACCAGGCAGTGCAAAATAAGATTAACAGT AAGCTTGATCCCCGCCCTCCCGTAGAGGAGCCTCCACCGGCCGTGGAGACAGTG TCTCCAGAGGGGCGTGGCGAAAAGCGTCCGCGCCCCGACAGGGAAGAAACTCTG GTGACGCAAATAGACGAGCCTCCCTCGTACGAGGAGGCACTAAAGCAAGGCCTGC CCACCACCCGTCCCATCGCGCCCATGGCTACCGGAGTGCTGGGCCAGCACACAC CCGTAACGCTGGACCTGCCTCCCCCCGCCGACACCCAGCAGAAACCTGTGCTGC CAGGCCCGACCGCCGTTGTTGTAACCCGTCCTAGCCGCGCGTCCCTGCGCCGCG CCGCCAGCGGTCCGCGATCGTTGCGGCCCGTAGCCAGTGGCAACTGGCAAAGCA CACTGAACAGCATCGTGGGTCTGGGGGTGCAATCCCTGAAGCGCCGACGATGCTT CTGATAGCTAACGTGTCGTATGTGTGTCATGTATGCGTCCATGTCGCCGCCAGAG GAGCTGCTGAGCCGCCGCGCGCCCGCTTTCCAAGATGGCTACCCCTTCGATGATG CCGCAGTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCC CCGGGCTGGTGCAGTTTGCCCGCGCCACCGAGACGTACTTCAGCCTGAATAACAA GTTTAGAAACCCCACGGTGGCGCCTACGCACGACGTGACCACAGACCGGTCCCA GCGTTTGACGCTGCGGTTCATCCCTGTGGACCGTGAGGATACTGCGTACTCGTAC AAGGCGCGGTTCACCCTAGCTGTGGGTGATAACCGTGTGCTGGACATGGCTTCCA CGTACTTTGACATCCGCGGCGTGCTGGACAGGGGCCCTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCCCTGGCTCCCAAGGGTGCCCCAAATCCTTGCGAATGGGATGAAGCTGCTACTGCTCTTGAAATAAACCTAGAAGAAGAGGACGATGACAACGA AGACGAAGTAGACGAGCAAGCTGAGCAGCAAAAAACTCACGTATTTGGGCAGGCG CCTTATTCTGGTATAAATATTACAAAGGAGGGTATTCAAATAGGTGTCGAAGGTCAA ACACCTAAATATGCCGATAAAACATTTCAACCTGAACCTCAAATAGGAGAATCTCAGTGGTACGAAACAGAAATTAATCATGCAGCTGGGAGAGTCCTAAAAAAGACTACCCCAATGAAACCATGTTACGGTTCATATGCAAAACCCACAAATGAAAATGGAGGGCAAG GCATTCTTGTAAAGCAACAAAATGGAAAGCTAGAAAGTCAAGTGGAAATGCAATTTT TCTCAACTACTGAGGCAGCCGCAGGCAATGGTGATAACTTGACTCCTAAAGTGGTA TTGTACAGTGAAGATGTAGATATAGAAACCCCAGACACTCATATTTCTTACATGCCCACTATTAAGGAAGGTAACTCACGAGAACTAATGGGCCAACAATCTATGCCCAACAGGCCTAATTACATTGCTTTTAGGGACAATTTTATTGGTCTAATGTATTACAACAGCAC GGGTAATATGGGTGTTCTGGCGGGCCAAGCATCGCAGTTGAATGCTGTTGTAGAT TTGCAAGACAGAAACACAGAGCTTTCATACCAGCTTTTGCTTGATTCCATTGGTGAT AGAACCAGGTACTTTTCTATGTGGAATCAGGCTGTTGACAGCTATGATCCAGATGT TAGAATTATTGAAAATCATGGAACTGAAGATGAACTTCCAAATTACTGCTTTCCACT GGGAGGTGTGATTAATACAGAGACTCTTACCAAGGTAAAACCTAAAACAGGTCAGG AAAATGGATGGGAAAAAGATGCTACAGAATTTTCAGATAAAAATGAAATAAGAGTTG GAAATAATTTTGCCATGGAAATCAATCTAAATGCCAACCTGTGGAGAAATTTCCTGT ACTCCAACATAGCGCTGTATTTGCCCGACAAGCTAAAGTACAGTCCTTCCAACGTA AAAATTTCTGATAACCCAAACACCTACGACTACATGAACAAGCGAGTGGTGGCTCC CGGGCTAGTGGACTGCTACATTAACCTTGGAGCACGCTGGTCCCTTGACTATATG GACAACGTCAACCCATTTAACCACCACCGCAATGCTGGCCTGCGCTACCGCTCAAT GTTGCTGGGCAATGGTCGCTATGTGCCCTTCCACATCCAGGTGCCTCAGAAGTTCT TTGCCATTAAAAACCTCCTTCTCCTGCCGGGCTCATACACCTACGAGTGGAACTTC AGGAAGGATGTTAACATGGTTCTGCAGAGCTCCCTAGGAAATGACCTAAGGGTTGA CGGAGCCAGCATTAAGTTTGATAGCATTTGCCTTTACGCCACCTTCTTCCCCATGG CCCACAACACCGCCTCCACGCTTGAGGCCATGCTTAGAAACGACACCAACGACCA GTCCTTTAACGACTATCTCTCCGCCGCCAACATGCTCTACCCTATACCCGCCAACG CTACCAACGTGCCCATATCCATCCCCTCCCGCAACTGGGCGGCTTTCCGCGGCTG GGCCTTCACGCGCCTTAAGACTAAGGAAACCCCATCACTGGGCTCGGGCTACGAC CCTTATTACACCTACTCTGGCTCTATACCCTACCTAGATGGAACCTTTTACCTCAAC CACACCTTTAAGAAGGTGGCCATTACCTTTGACTCTTCTGTCAGCTGGCCTGGCAA TGACCGCCTGCTTACCCCCAACGAGTTTGAAATTAAGCGCTCAGTTGACGGGGAG GGTTACAACGTTGCCCAGTGTAACATGACCAAAGACTGGTTCCTGGTACAAATGCT AGCTAACTATAACATTGGCTACCAGGGCTTCTATATCCCAGAGAGCTACAAGGACC GCATGTACTCCTTCTTTAGAAACTTCCAGCCCATGAGCCGTCAGGTGGTGGATGAT ACTAAATACAAGGACTACCAACAGGTGGGCATCCTACACCAACACAACAACTCTGG ATTTGTTGGCTACCTTGCCCCCACCATGCGCGAAGGACAGGCCTACCCTGCTAAC TTCCCCTATCCGCTTATAGGCAAGACCGCAGTTGACAGCATTACCCAGAAAAAGTT TCTTTGCGATCGCACCCTTTGGCGCATCCCATTCTCCAGTAACTTTATGTCCATGGGCGCACTCACAGACCTGGGCCAAAACCTTCTCTACGCCAACTCCGCCCACGCGCTAGACATGACTTTTGAGGTGGATCCCATGGACGAGCCCACCCTTCTTTATGTTTTGT TTGAAGTCTTTGACGTGGTCCGTGTGCACCAGCCGCACCGCGGCGTCATCGAAAC CGTGTACCTGCGCACGCCCTTCTCGGCCGGCAACGCCACAACATAAAGAAGCAAG CAACATCAACAACAGCTGCCGCCATGGGCTCCAGTGAGCAGGAACTGAAAGCCATTGTCAAAGATCTTGGTTGTGGGCCATATTTTTTGGGCACCTATGACAAGCGCTTTCCAGGCTTTGTTTCTCCACACAAGCTCGCCTGCGCCATAGTCAATACGGCCGGTCG CGAGACTGGGGGCGTACACTGGATGGCCTTTGCCTGGAACCCGCACTCAAAAACA TGCTACCTCTTTGAGCCCTTTGGCTTTTCTGACCAGCGACTCAAGCAGGTTTACCA GTTTGAGTACGAGTCACTCCTGCGCCGTAGCGCCATTGCTTCTTCCCCCGACCGCTGTATAACGCTGGAAAAGTCCACCCAAAGCGTACAGGGGCCCAACTCGGCCGCCTGTGGACTATTCTGCTGCATGTTTCTCCACGCCTTTGCCAACTGGCCCCAAACTCCC ATGGATCACAACCCCACCATGAACCTTATTACCGGGGTACCCAACTCCATGCTCAA CAGTCCCCAGGTACAGCCCACCCTGCGTCGCAACCAGGAACAGCTCTACAGCTTC CTGGAGCGCCACTCGCCCTACTTCCGCAGCCACAGTGCGCAGATTAGGAGCGCC ACTTCTTTTTGTCACTTGAAAAACATGTAAAAATAATGTACTAGAGACACTTTCAATA AAGGCAAATGCTTTTATTTGTACACTCTCGGGTGATTATTTACCCCCACCCTTGCCG TCTGCGCCGTTTAAAAATCAAAGGGGTTCTGCCGCGCATCGCTATGCGCCACTGG CAGGGACACGTTGCGATACTGGTGTTTAGTGCTCCACTTAAACTCAGGCACAACCA TCCGCGGCAGCTCGGTGAAGTTTTCACTCCACAGGCTGCGCACCATCACCAACGC GTTTAGCAGGTCGGGCGCCGATATCTTGAAGTCGCAGTTGGGGCCTCCGCCCTGC GCGCGCGAGTTGCGATACACAGGGTTGCAGCACTGGAACACTATCAGCGCCGGG TGGTGCACGCTGGCCAGCACGCTCTTGTCGGAGATCAGATCCGCGTCCAGGTCCT CCGCGTTGCTCAGGGCGAACGGAGTCAACTTTGGTAGCTGCCTTCCCAAAAAGGG CGCGTGCCCAGGCTTTGAGTTGCACTCGCACCGTAGTGGCATCAAAAGGTGACCG TGCCCGGTCTGGGCGTTAGGATACAGCGCCTGCATAAAAGCCTTGATCTGCTTAAA AGCCACCTGAGCCTTTGCGCCTTCAGAGAAGAACATGCCGCAAGACTTGCCGGAA AACTGATTGGCCGGACAGGCCGCGTCGTGCACGCAGCACCTTGCGTCGGTGTTG GAGATCTGCACCACATTTCGGCCCCACCGGTTCTTCACGATCTTGGCCTTGCTAGA CTGCTCCTTCAGCGCGCGCTGCCCGTTTTCGCTCGTCACATCCATTTCAATCACGT GCTCCTTATTTATCATAATGCTTCCGTGTAGACACTTAAGCTCGCCTTCGATCTCAG CGCAGCGGTGCAGCCACAACGCGCAGCCCGTGGGCTCGTGATGCTTGTAGGTCA CCTCTGCAAACGACTGCAGGTACGCCTGCAGGAATCGCCCCATCATCGTCACAAA GGTCTTGTTGCTGGTGAAGGTCAGCTGCAACCCGCGGTGCTCCTCGTTCAGCCAG GTCTTGCATACGGCCGCCAGAGCTTCCACTTGGTCAGGCAGTAGTTTGAAGTTCG CCTTTAGATCGTTATCCACGTGGTACTTGTCCATCAGCGCGCGCGCAGCCTCCATG CCCTTCTCCCACGCAGACACGATCGGCACACTCAGCGGGTTCATCACCGTAATTTC ACTTTCCGCTTCGCTGGGCTCTTCCTCTTCCTCTTGCGTCCGCATACCACGCGCCA CTGGGTCGTCTTCATTCAGCCGCCGCACTGTGCGCTTACCTCCTTTGCCATGCTTG ATTAGCACCGGTGGGTTGCTGAAACCCACCATTTGTAGCGCCACATCTTCTCTTTC TTCCTCGCTGTCCACGATTACCTCTGGTGATGGCGGGCGCTCGGGCTTGGGAGAAGGGCGCTTCTTTTTCTTCTTGGGCGCAATGGCCAAATCCGCCGCCGAGGTCGATGGCCGCGGGCTGGGTGTGCGCGGCACCAGCGCGTCTTGTGATGAGTCTTCCTCGT CCTCGGACTCGATACGCCGCCTCATCCGCTTTTTTGGGGGCGCCCGGGGAGGCG GCGGCGACGGGGACGGGGACGACACGTCCTCCATGGTTGGGGGACGTCGCGCC GCACCGCGTCCGCGCTCGGGGGTGGTTTCGCGCTGCTCCTCTTCCCGACTGGCCATTTCCTTCTCCTATAGGCAGAAAAAGATCATGGAGTCAGTCGAGAAGAAGGACAGCCTAACCGCCCCCTCTGAGTTCGCCACCACCGCCTCCACCGATGCCGCCAACGCG CCTACCACCTTCCCCGTCGAGGCACCCCCGCTTGAGGAGGAGGAAGTGATTATCG AGCAGGACCCAGGTTTTGTAAGCGAAGACGACGAGGACCGCTCAGTACCAACAGA GGATAAAAAGCAAGACCAGGACAACGCAGAGGCAAACGAGGAACAAGTCGGGCGGGGGGACGAAAGGCATGGCGACTACCTAGATGTGGGAGACGACGTGCTGTTGAAGCATCTGCAGCGCCAGTGCGCCATTATCTGCGACGCGTTGCAAGAGCGCAGCGAT GTGCCCCTCGCCATAGCGGATGTCAGCCTTGCCTACGAACGCCACCTATTCTCAC CGCGCGTACCCCCCAAACGCCAAGAAAACGGCACATGCGAGCCCAACCCGCGCC TCAACTTCTACCCCGTATTTGCCGTGCCAGAGGTGCTTGCCACCTATCACATCTTTT TCCAAAACTGCAAGATACCCCTATCCTGCCGTGCCAACCGCAGCCGAGCGGACAA GCAGCTGGCCTTGCGGCAGGGCGCTGTCATACCTGATATCGCCTCGCTCAACGAA GTGCCAAAAATCTTTGAGGGTCTTGGACGCGACGAGAAGCGCGCGGCAAACGCTC TGCAACAGGAAAACAGCGAAAATGAAAGTCACTCTGGAGTGTTGGTGGAACTCGA GGGTGACAACGCGCGCCTAGCCGTACTAAAACGCAGCATCGAGGTCACCCACTTT GCCTACCCGGCACTTAACCTACCCCCCAAGGTCATGAGCACAGTCATGAGTGAGC TGATCGTGCGCCGTGCGCAGCCCCTGGAGAGGGATGCAAATTTGCAAGAACAAAC AGAGGAGGGCCTACCCGCAGTTGGCGACGAGCAGCTAGCGCGCTGGCTTCAAAC GCGCGAGCCTGCCGACTTGGAGGAGCGACGCAAACTAATGATGGCCGCAGTGCT CGTTACCGTGGAGCTTGAGTGCATGCAGCGGTTCTTTGCTGACCCGGAGATGCAG CGCAAGCTAGAGGAAACATTGCACTACACCTTTCGACAGGGCTACGTACGCCAGG CCTGCAAGATCTCCAACGTGGAGCTCTGCAACCTGGTCTCCTACCTTGGAATTTTG CACGAAAACCGCCTTGGGCAAAACGTGCTTCATTCCACGCTCAAGGGCGAGGCGC GCCGCGACTACGTCCGCGACTGCGTTTACTTATTTCTATGCTACACCTGGCAGACG GCCATGGGCGTTTGGCAGCAGTGCTTGGAGGAGTGCAACCTCAAGGAGCTGCAG AAACTGCTAAAGCAAAACTTGAAGGACCTATGGACGGCCTTCAACGAGCGCTCCG TGGCCGCGCACCTGGCGGACATCATTTTCCCCGAACGCCTGCTTAAAACCCTGCA ACAGGGTCTGCCAGACTTCACCAGTCAAAGCATGTTGCAGAACTTTAGGAACTTTA TCCTAGAGCGCTCAGGAATCTTGCCCGCCACCTGCTGTGCACTTCCTAGCGACTTT GTGCCCATTAAGTACCGCGAATGCCCTCCGCCGCTTTGGGGCCACTGCTACCTTC TGCAGCTAGCCAACTACCTTGCCTACCACTCTGACATAATGGAAGACGTGAGCGGT GACGGTCTACTGGAGTGTCACTGTCGCTGCAACCTATGCACCCCGCACCGCTCCC TGGTTTGCAATTCGCAGCTGCTTAACGAAAGTCAAATTATCGGTACCTTTGAGCTG CAGGGTCCCTCGCCTGACGAAAAGTCCGCGGCTCCGGGGTTGAAACTCACTCCG GGGCTGTGGACGTCGGCTTACCTTCGCAAATTTGTACCTGAGGACTACCACGCCC ACGAGATTAGGTTCTACGAAGACCAATCCCGCCCGCCTAATGCGGAGCTTACCGCCTGCGTCATTACCCAGGGCCACATTCTTGGCCAATTGCAAGCCATCAACAAAGCCCGCCAAGAGTTTCTGCTACGAAAGGGACGGGGGGTTTACTTGGACCCCCAGTCCGG CGAGGAGCTCAACCCAATCCCCCCGCCGCCGCAGCCCTATCAGCAGCAGCCGCG GGCCCTTGCTTCCCAGGATGGCACCCAAAAAGAAGCTGCAGCTGCCGCCGCCAC CCACGGACGAGGAGGAATACTGGGACAGTCAGGCAGAGGAGGTTTTGGACGAGGAGGAGGAGGACATGATGGAAGACTGGGAGAGCCTAGACGAGGAAGCTTCCGAGGTCGAAGAGGTGTCAGACGAAACACCGTCACCCTCGGTCGCATTCCCCTCGCCGGC GCCCCAGAAATCGGCAACCGGTTCCAGCATGGCTACAACCTCCGCTCCTCAGGCG CCGCCGGCACTGCCCGTTCGCCGACCCAACCGTAGATGGGACACCACTGGAACC AGGGCCGGTAAGTCCAAGCAGCCGCCGCCGTTAGCCCAAGAGCAACAACAGCGCCAAGGCTACCGCTCATGGCGCGGGCACAAGAACGCCATAGTTGCTTGCTTGCAAGACTGTGGGGGCAACATCTCCTTCGCCCGCCGCTTTCTTCTCTACCATCACGGCGT GGCCTTCCCCCGTAACATCCTGCATTACTACCGTCATCTCTACAGCCCATACTGCA CCGGCGGCAGCGGCAGCAACAGCAGCGGCCACACAGAAGCAAAGGCGACCGGA TAGCAAGACTCTGACAAAGCCCAAGAAATCCACAGCGGCGGCAGCAGCAGGAGG AGGAGCGCTGCGTCTGGCGCCCAACGAACCCGTATCGACCCGCGAGCTTAGAAA CAGGATTTTTCCCACTCTGTATGCTATATTTCAACAGAGCAGGGGCCAAGAACAAG AGCTGAAAATAAAAAACAGGTCTCTGCGATCCCTCACCCGCAGCTGCCTGTATCAC AAAAGCGAAGATCAGCTTCGGCGCACGCTGGAAGACGCGGAGGCTCTCTTCAGTA AATACTGCGCGCTGACTCTTAAGGACTAGTTTCGCGCCCTTTCTCAAATTTAAGCG CGAAAACTACGTCATCTCCAGCGGCCACACCCGGCGCCAGCACCTGTTGTCAGCG CCATTATGAGCAAGGAAATTCCCACGCCCTACATGTGGAGTTACCAGCCACAAATG GGACTTGCGGCTGGAGCTGCCCAAGACTACTCAACCCGAATAAACTACATGAGCG CGGGACCCCACATGATATCCCGGGTCAACGGAATACGCGCCCACCGAAACCGAAT TCTCCTGGAACAGGCGGCTATTACCACCACACCTCGTAATAACCTTAATCCCCGTA GTTGGCCCGCTGCCCTGGTGTACCAGGAAAGTCCCGCTCCCACCACTGTGGTACT TCCCAGAGACGCCCAGGCCGAAGTTCAGATGACTAACTCAGGGGCGCAGCTTGC GGGCGGCTTTCGTCACAGGGTGCGGTCGCCCGGGCAGGGTATAACTCACCTGAC AATCAGAGGGCGAGGTATTCAGCTCAACGACGAGTCGGTGAGCTCCTCGCTTGGT CTCCGTCCGGACGGGACATTTCAGATCGGCGGCGCCGGCCGCTCTTCATTCACGC CTCGTCAGGCAATCCTAACTCTGCAGACCTCGTCCTCTGAGCCGCGCTCTGGAGG CATTGGAACTCTGCAATTTATTGAGGAGTTTGTGCCATCGGTCTACTTTAACCCCTT CTCGGGACCTCCCGGCCACTATCCGGATCAATTTATTCCTAACTTTGACGCGGTAA AGGACTCGGCGGACGGCTACGACTGAATGTTAAGTGGAGAGGCAGAGCAACTGC GCCTGAAACACCTGGTCCACTGTCGCCGCCACAAGTGCTTTGCCCGCGACTCCGG TGAGTTTTGCTACTTTGAATTGCCCGAGGATCATATCGAGGGCCCGGCGCACGGC GTCCGGCTTACCGCCCAGGGAGAGCTTGCCCGTAGCCTGATTCGGGAGTTTACCC AGCGCCCCCTGCTAGTTGAGCGGGACAGGGGACCCTGTGTTCTCACTGTGATTTG CAACTGTCCTAACCCTGGATTACATCAAGATCCTCTAGTTAATGTCAGGTCGCCTAA GTCGATTAACTAGAGTACCCGGGGATCTTATTCCCTTTAACTAATAAAAAAAAATAA TAAAGCATCACTTACTTAAAATCAGTTAGCAAATTTCTGTCCAGTTTATTCAGCAGCACCTCCTTGCCCTCCTCCCAGCTCTGGTATTGCAGCTTCCTCCTGGCTGCAAACTTTCTCCACAATCTAAATGGAATGTCAGTTTCCTCCTGTTCCTGTCCATCCGCACCCAC TATCTTCATGTTGTTGCAGATGAAGCGCGCAAGACCGTCTGAAGATACCTTCAACC CCGTGTATCCATATGACACGGAAACCGGTCCTCCAACTGTGCCTTTTCTTACTCCT CCCTTTGTATCCCCCAATGGGTTTCAAGAGAGTCCCCCTGGGGTACTCTCTTTGCGCCTATCCGAACCTCTAGTTACCTCCAATGGCATGCTTGCGCTCAAAATGGGCAACGGCCTCTCTCTGGACGAGGCCGGCAACCTTACCTCCCAAAATGTAACCACTGTGAG CCCACCTCTCAAAAAAACCAAGTCAAACATAAACCTGGAAATATCTGCACCCCTCA CAGTTACCTCAGAAGCCCTAACTGTGGCTGCCGCCGCACCTCTAATGGTCGCGGG CAACACACTCACCATGCAATCACAGGCCCCGCTAACCGTGCACGACTCCAAACTTAGCATTGCCACCCAAGGACCCCTCACAGTGTCAGAAGGAAAGCTAGCCCTGCAAACATCAGGCCCCCTCACCACCACCGATAGCAGTACCCTTACTATCACTGCCTCACCCC CTCTAACTACTGCCACTGGTAGCTTGGGCATTGACTTGAAAGAGCCCATTTATACA CAAAATGGAAAACTAGGACTAAAGTACGGGGCTCCTTTGCATGTAACAGACGACCT AAACACTTTGACCGTAGCAACTGGTCCAGGTGTGACTATTAATAATACTTCCTTGCA AACTAAAGTTACTGGAGCCTTGGGTTTTGATTCACAAGGCAATATGCAACTTAATGT AGCAGGAGGACTAAGGATTGATTCTCAAAACAGACGCCTTATACTTGATGTTAGTT ATCCGTTTGATGCTCAAAACCAACTAAATCTAAGACTAGGACAGGGCCCTCTTTTTA TAAACTCAGCCCACAACTTGGATATTAACTACAACAAAGGCCTTTACTTGTTTACAG CTTCAAACAATTCCAAAAAGCTTGAGGTTAACCTAAGCACTGCCAAGGGGTTGATG TTTGACGCTACAGCCATAGCCATTAATGCAGGAGATGGGCTTGAATTTGGTTCACC TAATGCACCAAACACAAATCCCCTCAAAACAAAAATTGGCCATGGCCTAGAATTTGA TTCAAACAAGGCTATGGTTCCTAAACTAGGAACTGGCCTTAGTTTTGACAGCACAG GTGCCATTACAGTAGGAAACAAAAATAATGATAAGCTAACTTTGTGGACCACACCA GCTCCATCTCCTAACTGTAGACTAAATGCAGAGAAAGATGCTAAACTCACTTTGGT CTTAACAAAATGTGGCAGTCAAATACTTGCTACAGTTTCAGTTTTGGCTGTTAAAGG CAGTTTGGCTCCAATATCTGGAACAGTTCAAAGTGCTCATCTTATTATAAGATTTGA CGAAAATGGAGTGCTACTAAACAATTCCTTCCTGGACCCAGAATATTGGAACTTTA GAAATGGAGATCTTACTGAAGGCACAGCCTATACAAACGCTGTTGGATTTATGCCT AACCTATCAGCTTATCCAAAATCTCACGGTAAAACTGCCAAAAGTAACATTGTCAGT CAAGTTTACTTAAACGGAGACAAAACTAAACCTGTAACACTAACCATTACACTAAAC GGTACACAGGAAACAGGAGACACAACTCCAAGTGCATACTCTATGTCATTTTCATG GGACTGGTCTGGCCACAACTACATTAATGAAATATTTGCCACATCCTCTTACACTTT TTCATACATTGCCCAAGAATAAAGAATCGTTTGTGTTATGTTTCAACGTGTTTATTTT TCAATTGCAGAAAATTTCAAGTCATTTTTCATTCAGTAGTATAGCCCCACCACCACA TAGCTTATACAGATCACCGTACCTTAATCAAACTCACAGAACCCTAGTATTCAACCT GCCACCTCCCTCCCAACACACAGAGTACACAGTCCTTTCTCCCCGGCTGGCCTTAA AAAGCATCATATCATGGGTAACAGACATATTCTTAGGTGTTATATTCCACACGGTTT CCTGTCGAGCCAAACGCTCATCAGTGATATTAATAAACTCCCCGGGCAGCTCACTT AAGTTCATGTCGCTGTCCAGCTGCTGAGCCACAGGCTGCTGTCCAACTTGCGGTT GCTTAACGGGCGGCGAAGGAGAAGTCCACGCCTACATGGGGGTAGAGTCATAATCGTGCATCAGGATAGGGCGGTGGTGCTGCAGCAGCGCGCGAATAAACTGCTGCCGCCGCCGCTCCGTCCTGCAGGAATACAACATGGCAGTGGTCTCCTCAGCGATGATT CGCACCGCCCGCAGCATAAGGCGCCTTGTCCTCCGGGCACAGCAGCGCACCCTG ATCTCACTTAAATCAGCACAGTAACTGCAGCACAGCACCACAATATTGTTCAAAATC CCACAGTGCAAGGCGCTGTATCCAAAGCTCATGGCGGGGACCACAGAACCCACGTGGCCATCATACCACAAGCGCAGGTAGATTAAGTGGCGACCCCTCATAAACACGCTGGACATAAACATTACCTCTTTTGGCATGTTGTAATTCACCACCTCCCGGTACCATAT AAACCTCTGATTAAACATGGCGCCATCCACCACCATCCTAAACCAGCTGGCCAAAA CCTGCCCGCCGGCTATACACTGCAGGGAACCGGGACTGGAACAATGACAGTGGA GAGCCCAGGACTCGTAACCATGGATCATCATGCTCGTCATGATATCAATGTTGGCACAACACAGGCACACGTGCATACACTTCCTCAGGATTACAAGCTCCTCCCGCGTTAGAACCATATCCCAGGGAACAACCCATTCCTGAATCAGCGTAAATCCCACACTGCAGG GAAGACCTCGCACGTAACTCACGTTGTGCATTGTCAAAGTGTTACATTCGGGCAGC AGCGGATGATCCTCCAGTATGGTAGCGCGGGTTTCTGTCTCAAAAGGAGGTAGAC GATCCCTACTGTACGGAGTGCGCCGAGACAACCGAGATCGTGTTGGTCGTAGTGT CATGCCAAATGGAACGCCGGACGTAGTCATATTTCCTGAAGCAAAACCAGGTGCG GGCGTGACAAACAGATCTGCGTCTCCGGTCTCGCCGCTTAGATCGCTCTGTGTAG TAGTTGTAGTATATCCACTCTCTCAAAGCATCCAGGCGCCCCCTGGCTTCGGGTTC TATGTAAACTCCTTCATGCGCCGCTGCCCTGATAACATCCACCACCGCAGAATAAG CCACACCCAGCCAACCTACACATTCGTTCTGCGAGTCACACACGGGAGGAGCGGG AAGAGCTGGAAGAACCATGTTTTTTTTTTTATTCCAAAAGATTATCCAAAACCTCAAA ATGAAGATCTATTAAGTGAACGCGCTCCCCTCCGGTGGCGTGGTCAAACTCTACAG CCAAAGAACAGATAATGGCATTTGTAAGATGTTGCACAATGGCTTCCAAAAGGCAA ACGGCCCTCACGTCCAAGTGGACGTAAAGGCTAAACCCTTCAGGGTGAATCTCCT CTATAAACATTCCAGCACCTTCAACCATGCCCAAATAATTCTCATCTCGCCACCTTC TCAATATATCTCTAAGCAAATCCCGAATATTAAGTCCGGCCATTGTAAAAATCTGCT CCAGAGCGCCCTCCACCTTCAGCCTCAAGCAGCGAATCATGATTGCAAAAATTCAG GTTCCTCACAGACCTGTATAAGATTCAAAAGCGGAACATTAACAAAAATACCGCGA TCCCGTAGGTCCCTTCGCAGGGCCAGCTGAACATAATCGTGCAGGTCTGCACGGA CCAGCGCGGCCACTTCCCCGCCAGGAACCATGACAAAAGAACCCACACTGATTAT GACACGCATACTCGGAGCTATGCTAACCAGCGTAGCCCCGATGTAAGCTTGTTGC ATGGGCGGCGATATAAAATGCAAGGTGCTGCTCAAAAAATCAGGCAAAGCCTCGC GCAAAAAAGAAAGCACATCGTAGTCATGCTCATGCAGATAAAGGCAGGTAAGCTCC GGAACCACCACAGAAAAAGACACCATTTTTCTCTCAAACATGTCTGCGGGTTTCTG CATAAACACAAAATAAAATAACAAAAAAACATTTAAACATTAGAAGCCTGTCTTACAA CAGGAAAAACAACCCTTATAAGCATAAGACGGACTACGGCCATGCCGGCGTGACC GTAAAAAAACTGGTCACCGTGATTAAAAAGCACCACCGACAGCTCCTCGGTCATGT CCGGAGTCATAATGTAAGACTCGGTAAACACATCAGGTTGATTCACATCGGTCAGT GCTAAAAAGCGACCGAAATAGCCCGGGGGAATACATACCCGCAGGCGTAGAGACA ACATTACAGCCCCCATAGGAGGTATAACAAAATTAATAGGAGAGAAAAACACATAA ACACCTGAAAAACCCTCCTGCCTAGGCAAAATAGCACCCTCCCGCTCCAGAACAACATACAGCGCTTCCACAGCGGCAGCCATAACAGTCAGCCTTACCAGTAAAAAAGAAAACCTATTAAAAAAACACCACTCGACACGGCACCAGCTCAATCAGTCACAGTGTAAA AAAGGGCCAAGTGCAGAGCGAGTATATATAGGACTAAAAAATGACGTAACGGTTAA AGTCCACAAAAAACACCCAGAAAACCGCACGCGAACCTACGCCCAGAAACGAAAG CCAAAAAACCCACAACTTCCTCAAATCGTCACTTCCGTTTTCCCACGTTACGTCACTTCCCATTTTAAGAAAACTACAATTCCCAACACATACAAGTTACTCCGCCCTAAAACCTACGTCACCCGCCCCGTTCCCACGCCCCGCGCCACGTCACAAACTCCACCCCCTC ATTAT ATATTGGCTTCAATCCAAAATAAGGTATATTATTGATGATG Example 5First generation adenoviral gene transfer vectors are rendered replication deficient by a partial deletion of the E1 gene and therapeutic gene is inserted into that locus. If transgene expression is driven by a strong promoter oriented in the same direction as the Ad E1 gene, then there is read though into the partial E1b region with expression of the adenoviral pIX gene (Nakai 2007). This resulted in a limited duration of transgene expression of transgene in vivo. The read though was decreased by using a weaker promoter such as Ef1a. To minimize the possibility of read thorough, an adenoviral vector was constructed expressing a cDNA / genomic hybrid gene expressing multiple forms of VEGF with VEGF165>VEGF189>>VEGF121 driven by the strong CMV promoter to drive high level expression but two polyA sites to minimize read through into the adjacent E1b and pIX genes. Polyadenylation. The process of polyadenylation at the 3’ end of nascent primary RNA is one step in formation of a mature mRNA. The process is co- transcriptional and is mediated by a large enzyme complex including factors that recognize the correct site based on certain RNA sequences. It requires two steps with RNA cleavage followed by the template-free addition of 30-200 adenyl residues. Polyadenylation depends on the interactions of specific sequences and trans- acting polyadenylation factors. The fundamental process depends on recognition of the sequence AAUAAA by cleavage and polyadenylation factor complex (CPSF) and an upstream sequence GUUGUGGU by cleavage stimulation factor complex (CSTF). The cleavage and polyA addition sites lie between these two recognition sequences. However, there is a wide range of efficiency, and it is estimated that 60% of genes have multiple polyadenylation sites Therefore, readthrough of polyA sites is a common occurrence. In some cases, there are tissue specific read throughs that result in variant functions from the same gene (Gruber 2019). Different polyA sequences also provide alternate 3’ untranslated regions to the VEGF-All6A+ mRNA which may prolong mRNA half file thereby increasing mRNA and VEGF level. Examples of polyadenylation signals that have been used in gene therapy are derived from the rabbit beta globin gene (531bp) and the human growth hormone genes (477bp) and the bovine growth hormone gene (208bp).. Both of these are longer 20than SV40 and include potential binding sites for additional proteins of the terminationcomplex. Alternate polyA signals can be chosen from genes that a have a single polyadenylation site such as GAPDH or RPL3. These may be further mutagenized to promote recognition by multiple termination factors to increase overall efficiency of termination. As needed, multiple polyA sites may be screened to identify one that is 25efficient in the context of Ad5VEGF-All6A+, in one embodiment in multiple cell types. Ifthe desired level of termination cannot be achieved, serial polyA sites may be utilized. Exemplary PolyA sequences GAPDH polyA (500 bp) GGGCTGGCATTGCCCTCAACGACCACTTTGTCAAGCTCATTTCCTGGTATGTGGCT 30GGGGCCAGAGACTGGCTCTTAAAAAGTGCAGGGTCTGGCGCCCTCTGGTGGCTGGCTCAGAAAAAGGGCCCTGACAACTCTTTTCATCTTCTAGGTATGACAACGAATTT GGCTACAGCAACAGGGTGGTGGACCTCATGGCCCACATGGCCTCCAAGGAGTAA GACCCCTGGACCACCAGCCCCAGCAAGAGCACAAGAGGAAGAGAGAGACCCTCA CTGCTGGGGAGTCCCTGCCACACTCAGTCCCCCACCACACTGAATCTCCCCTCCT 35 CACAGTTGCCATGTAGACCCCTTGAAGAGGGGAGGGGCCTAGGGAGCCGCACCT TGTCATGTACCATCAATAAAGTACCCTGTGCTCAACCAGTTACTTGTCCTGTCTTAT TCTAGGGTCTGGGGCAGAGGGGAGGGAAGCTGGGCTTGTGTCAAGGTGAGACAT TCTTGC (SEQ ID NO:50) TUBB polyA (330 bp) 40 GTCCCCAGAGGAGAGGGGAACCCTCCTCCATCTTTTTTGCAACATCTCATTTCTTC CTTTTGCTGTTGCTTCCCCCCTCACACACTTGGTTTTGTTCTATCCTACATTTGAGA TTTCTATTTTATGTTGAACTTGCTGCTTTTTTTCATATTGAAAAGATGACATCGCCCC AAGAGCCAAAAATAAATGGGAATTGAAAAAAGCTGCGAGATGTGTGCTTATTTAGG GAAACACGGCTGGCTGATGGAGGCATGGGGCCTGAGTTCAGTTGCACTGCTCTCC TTAAATTGACACTTAATATTGAGTCCCTGTCCTACGGATTCAACCAAC (SEQ ID NO:51) RPL3 polya (540 bp) CCCTGTCTCCTTCTCGTCTCCACAGCACTGGCATCACCCAAGCTGTGCAAACAGCA GAGACCCAGCTGCCTCACCCTGGTGACAAACATTTGCACAATGCCCACTGCTCCA GGCTGGATTTCTACAGCTCAGCTGCAGAACCAGGCCCAGCTTTTACCTCCCTCCA 10 GGGACTGAGGGTGGGGGACAGAGTGGGAGGCCAGAAGGCAAACCCAGCGAAGC TACAGAAAGGAGGGCAGTGGCCTTGGGGAGCACAAGGCACCTCAAGGGCCCCCA TCTGCCTCCCCAGTCCCAGCCTCTCTCCTGAAGAAAGAGGCAAGATGTCAGTGGA AAATAACTTTTATTGAGACCCCACCAACTGCAAAATCTGTTCCTGGCATTAAGCTCC TTCTTCCTTTGCAATTCGGTCTTTCTTCAGTGGTCCCTGTGGGGAGAGAGGCAGTG 15 GTCAGAGGTAGAAGATGACAGGTGACAGCAGATGCCCACTCTAGAGGAGACCAAG ACTCTGGGCCAGTCTCCACAGCCACAAGAGAGGCCTAAGGCATC (SEQ ID NO:52) rabbit beta globin polyA (531 bp) AATTCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAA TGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGG 20ACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGG GCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCC CATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGAA ACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGA 25TTTTTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCC CTCTTCTCTTATGGAGATCCC (SEQ ID NO:53) hGH polyA (477 bp) GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCA 30CTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCA AGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGT GCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCT CCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGC 35 TAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCC AACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACA GGCGTGAACCACTGCTCCCTTCCCTGTCCTT (SEQ ID NO:54) bGH polyA (208bp) CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTG 40 ACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATC GCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGC AAGGGGGAGGATTGGGAAGAGAATAGCAGGCATGCTGGGGA (SEQ ID NO:55) All first generation Ad gene transfer vectors have a similar configuration with a partial deletion of the AdE1A and E1B genes. Depending on the promoter, transgene and poly A site the extent of read through may differ. The addition of two polyA sites in tandem is applicable to any transgene. Example 6 Adenoviral gene transfer vectors are made by deletion of essential genes leaving room for the addition of expression cassettes for the therapeutic gene. In principle, transgene cassette can be located in any of the deleted Ad loci gene in any orientation with respect to the adenoviral genome. It was shown that maximum transgene expression was obtained by putting the transgene in the E1 region in the reverse orientation with respect to the Ad early genes (Suzuki 2015). If the orientation of the expression cassette was reversed, then the read through would enter the inverted terminal repeats of the adenovirus and therefore not result in adenoviral gene expression. In the event that polyadenylation was inefficient, the primary transcript would run off the left hand end of the adenoviral template and not be properly processed resulting in rapid degradation in the nucleus. There is a largeamount to turnover of improperly processed mRNA in the nucleus of all cells and this anormal cellular process (Wang 2020). In a study comparing different locations and orientations of transgene in adenoviral gene transfer vectors, it was shown that insertion of expression cassette into the E1 gene in the reverse orientation relative to that of AdE1 gene expression provided for a higher level of transgene expression (Suzuki et al2015). In addition, it is known that low level of expression of adenoviral genes includethe pIX gene from a forward oriented transgene promoter is a contributor to anti-vector immunity (Nakai et al 2007). Therefore, constructs were made that express the cDNA / genomic hybrid VEGF gene in an expression cassette transcribed in the direction of the left hand inverted terminal repeat of adenovirus. Example 7 This example provides for a VEGF expression cassette with two poly adenylation sites from rabbit beta globin and human growth hormone. The VEGF gene is transcribed in the direction of the left hand inverted terminal repeat of adenovirus. AdVEGF(3i) is likely to have high transgene expression and no readthrough into the Ad E1b region. The following is a description of “VEGF(3i)” (human vascular endothelial growth factor version 1) and “VEGF(3is)” (human vascular endothelial growth factor isoform version 2), gene therapy expression cassettes designed to express the major angiogenic isoforms of vascular endothelial growth factor (VEGF) delivered by an adenovirus gene transfer vector. The examples shown are with adenovirus serotype 5, but the adenovirus could be of any serotype, human or nonhuman. The expression cassette of VEGF(3i) is designed to express VEGF isoforms 165>189>>121 by an adenovirus gene transfer vector and has two polyA sites to inhibit read through transcription. The expression cassette of VEGF(3is) is designed to express 189, 165, 121 in normal ratios and has two polyA sites to inhibit read through transcription. VEGF(3i) is based on the expression cassette used in Ad5VEGF-All6+ (US Patent No.7,368,553). VEGF(3is) is based on the expression cassette used in Ad5VEGF-All. The expression cassette in Ad5VEGF-All is similar to that to VEGF-All6A+ except the splice donor and acceptor sequences in “All” generate 189, 165, and 121 in similar ratios whereas the splicing sequences in “All6A+” are designed to promote usage of exon 6 and boost level of VEGF189. Exemplary Sequences of Vector Designed to Provide Higher Expression and less read through transcription SEQ ID NO:56 CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGG CGGAAGTGTGATGTTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAA AAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGG TTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTC GCGGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGC GCGTAATACTGGTACCGCGGCCGCGGGGATCCTTTACAATTGAAGGACAGGGAAG GGAGCAGTGGTTCACGCCTGTAATCCCAGCAATTTGGGAGGCCAAGGTGGGTAGA TCACCTGAGATTAGGAGTTGGAGACCAGCCTGGCCAATATGGTGAAACCCCGTCT CTACCAAAAAAACAAAAATTAGCTGAGCCTGGTCATGCATGCCTGGAATCCCAACA ACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGATTGCAG TGAGCCAAGATTGTGCCACTGCACTCCAGCTTGGTTCCCAATAGACCCCGCAGGC CCTACAGGTTGTCTTCCCAACTTGCCCCTTGCTCCATACCACCCCCCTCCACCCCA TAATATTATAGAAGGACACCTAGTCAGACAAAATGATGCAACTTAATTTTATTAGGA CAAGGCTGGTGGGCACTGGAGTGGCAACTTCCAGGGCCAGGAGAGGCACTGGGG AGGGGTCACAGGGATGCCACCCGAATTCAGCGATTCTAGAGGGATCTCCATAAGA GAAGAGGGACAGCTATGACTGGGAGTAGTCAGGAGAGGAGGAAAAATCTGGCTAG TAAAACATGTAAGGAAAATTTTAGGGATGTTAAAGAAAAAAATAACACAAAACAAAA TATAAAAAAAATCTAACCTCAAGTCAAGGCTTTTCTATGGAATAAGGAATGGACAGC AGGGGGCTGTTTCATATACTGATGACCTCTTTATAGCCAACCTTTGTTCATGGCAG CCAGCATATGGGCATATGTTGCCAAACTCTAAACCAAATACTCATTCTGATGTTTTA AATGATTTGCCCTCCCATATGTCCTTCCGAGTGAGAGACACAAAAAATTCCAACAC ACTATTGCAATGAAAATAAATTTCCTTTATTAGCCAGAAGTCAGATGCTCAAGGGGC TTCATGATGTCCCCATAATTTTTGGCAGAGGGAAAAAGATCTCAGTGGTATTTGTGA GCCAGGGCATTGGCCACACCAGCCACCACCTTCTGATAGGCAGCCTGCACACTAGTTCAAGCTTTCACCGCCTCGGCTTGTCACACCTGAGGGAAAGGGAAAACAAAGGCTGGGGTCAGGGCCAAGTGAGGAGGCCTGGCGATGAGGCAGGCGGCCTCCCCATT CCTGGGGGCCCCTGGGTCACTGCAGCCTCCGGCACCATAAGAGCAGAGGGGACA GGAAGGTGTGGTCCTGGGGCAGAAAGCCCCAGTATGAGAACAGCCCCAGCCCTG CCCTCAGGGAGCCCCGGCCTGAGCAGCAGCTCCACTCAGGGGCTCCCAGTCTACCCTCCTGAGCTTGCAATCTACTTGAGACAAGACAAGGACATGGGAACACTTTACAAAGCAACAAATGAACGGATACCAAAGAACAGTCCCCACTTGACATTTTAAGAGCTGA TGGGTGACCAGAGCTGGATGAAGTTAATCAGAAGAGGCTCCCTGCTGAGGAGGGT TTTCAGTTCAGTCTCTAGGGGCTGGTGTGGGGAAGAGAGTGGGCAGATCCACTAG TAACGGCCGCCAGTGTGCTGGAATTCGCCCTTCGCAGATCTCAGGCAGGCAGCTAGAAACTGAGCAAGCAGCTGGCCCCTCTCAGGCGCTCTCCCGCTCGCTCGCTCGCTCACTCTCTTTCTCTCTCTCTCTCCCCATCTCTGTGTGATGCCCCTCTCTGACTTGCT TGCCCTCTGGGAACCAACCTGCAAGTACGTTCGTTTAACTCAAGCTGCCTCGCCTT GCATCTCGAGTCTGTGTTTTTGCAGGAACATTTACACGTCTGCGGATCTTGTACAA ACAAATGCTTTCTCCGCTCTGAGCAAGGCCCACAGGGACTGCAAAAAGGCAAAAG GAAAGACATCTAAGCTAGAGCATCAGCAGAGAGAGAGAAAAAAAATCACCATGCAA CACCCCCTAACATGTCCGCAGCTGCACCCCCACCCAGCCGGTCAGCCCCCAGGC CCTGGAAGGATCCGAGCGCTACAGCAAAAGACAGAGAGAGCGGCGGAAAGAGGC AGCACTGGCTAGGACACCTGCCGCAGGAAGAGGCGGGCACAGACGGGCAGAGA GTGCAGGGAGAGGCTGCCATAAGGGGCAATGCTGTGTCTCTGGGAGACAAGGGT GAGTCTCAGGCCACAGGGACCCAACTGCTGTTGCCCCCATCGGAGCACGCCTTGA CTCTTCACCTGCTGGGGATGGCAATCAGGGGCCACCTTCTCCCCGTGCAAGGCTC ATGTCCAGGCCCTTCCACCAAGGTGGGCTAAAGTAGGGTGTGATGGGAGGCTAAG CCCGGAGGCAGTGTCCCCAGGCCAGGCCGCTGGTGGCCAGAGGGCCCAGGGCA GGGCCCACCACAGCCTCCGACCCGGAGGAAGAGGCTGCCCTGCAAGGAGGCCTC TGTGGGTGCCATGGGTTGGGCCAGAATAGGGGGCTCCCCTCCAGAGGCCCCACC TCCGTGAGGAGCCAGGGCACTTCCACCAGATGAAGGGAGGCCGCCACATGGTGT CTGATCCCACCCAAGCTCCTCCTTCAGCCAAGGAGTCATTCAGCAAGCTGCCTCCA GTCATTCACAGCCCTTCTTGGGCCATGTCTGCCCTCCCCACCACCCTCAGCTTCCA GACGAGTGCAGAAGCCTAGAGCAATGGAAACCAGTTGGGTGAGCAGGCACCTGT GCCAACATGGGCCTGCCACCAGTGCCCAGTGGGTGAGAGAAAATCGGTGCCCAG CCAAGCCAGGGTCCCCTCCCTTAATCCTCCAGGCCAAGTCGGCACCCCCATTCAC CCCAACCCTGGACCAGCAATGCCACCACCAAATCTACCCGTTGGTGCCAATTAGT GGAGTGAGAGAGTGAGAGAGAGACACGGGCCAGGAGGATGAGAGCCAGGGAGG GACCAGGGGAGGGAGGCAGGGTTACAGGGAATGGCAGGCGGAGGTTGTACTGG GGGCCAGGGAGGCTCCAGGGCATTAGACAGCAGCGGGCACCAACTTACACGCTC CAGGACTTATATCTAGATTTCTTGCGCTTTCGTTTTTGCCCCTTTCCCTTTCCTCGA ACTGATTTTCTGGAAAAGAAAAAAACAGAGACAGAGAAAGAGCGGGGGCGGTGGG GGGAGTAAAAGAAGTGCTCAGGGGGGCAGGGATGGGGGAACGACCAAAGCAAAG CCACACAGGGCCGCTTCCCGGAGGAAGTGTCAGGAGGCAGGTGGTCTCTGGGGA GGCATGCGCGGGCGCACACAGGCGTGTCTGGGCAGCAAGCACTCGATGGCTCTTTCTTCTCCTCACGCTGCCCACCATGGGATGGCAAACCCAGCCCCTGACAAGGCTTTGGTGGGAAGCCGAGACTGGGTGGAGGGCACAGGACCCAAAGGTCTCCACACTC ACAGTGGCTCCCAGTCCCCGGCAGGGGGCAAAGCCTGAGGGAAGGCTCTTTGCC CAGCAGCCCTGTCCAAGTCTGACCCTGAAGGTCCGGGGGTGATAAAAGGTAGGCC AGACTTTGGGGAGAAGGTCAGAGACCTGCCTGGATGGGGAGCAGGAGTGGGAGGGAGGGCTGTGTATCAGGCCTTGTGCCTTCATTTGCAACTGCGACAGAACCTCTGGGAATCCCGGTGTGGGGGAAGCGGCTACCTTGGGAGCTGGCACGGAACCAAGAGC AACACCAGCCTGCTCAGCACGACCTGGACTGGGAGGCAGGGCTGGGTGTCCTGG AGCCCTGGGCAGGCAGCAGGATGGGGTGGGAGTTAAGGAGGTCTGGGGAGGAG AGGCTTGGGCGGTACTTGGCAGGGAGTTCTCTCCCCAGCCTGTCAAAGCCTGCTACACCATCTCACCAGACACTCTTCCGAGCCCAGGCGAGCCCCCTACTCTCCCCATGGCAGAGCAGTCATTTGGGGAAACAGGAAGGGGGGCAGGCTGTAGCCTGTCCCCT TCAAGAGAACCAGAGCTCTCCATGCCTGCCAAGCCCAAGAGAACACACCTCAGGA TGTCTGTCACAGGGAAGAAAGGAGGGGGAGAAGGGACCAGAGAGGGCAAGTCTG TCCCCCTTAGGAGAAAGCACCAAAGGGTGGAAGGAAGGTTTCCGCATCCCCTCGC TCTGGAAGCTGGGAGCTGAGGGAAGAGGCAAGGGGTTGAGGCCTGGTGGGGGCT TCAATGTCCGCACAGCACTGGAGGCAGACAAGATGGTGTGGGGGAAAGGGCAGG GCACAGGTGCTCTCTCTCAGTCTCTCTTTCCCTGCAAGCTCTTGCTGATGCCAGCC GCCCACCCTGTCTTGAAGGGTTACTGCCGCCAAACCTTGTCCCCCACCCCATCCT ACCTGCCCCTTAACACGGAGCACTCACAAGCCTCTGAAAATGACCAACATTCAACT TTTTCTCCCTGGCCAAGAGGGCTGTGTGTCTGCCGCCTGCCGCCTACAGGAGGGC ATGCACTGAGAAACCACCCTCCAGCCGGCCTCGCATCCAACTGCACCGTCACAGC AGCCACCAAAAGAGGCCATTTCCTCTGACACACAAAAGCTGGCCTCTCTGCCACC CACTCCCTCTCCCCACTGTGGGTGTCCTAGAGCAAGCCAGTGAGCCAGTGTCCAC AGTGCCCCCTGACACACCGAAACAGCAAGTCCTGGTCAGAAATGATCTGGAGACC CAGAAGGCATTGTCCCTTCCAAAGGAAGTGCCAGGCTCCTGGCTATGTTTTCTCAC TAGCCCTAGAGCCATCATCCTGGAGTTGGCTCCATCCCATTGTTGCTGCCACCACA AGTCCCCCACAAGACCAAGTCCCTGACCCAGGGAGGCTATGGGAGCCCCCAACA GAGGTAGCCAAGAGCCCCAAACCAAGACAACCGGCCATGGAGAGGGAGAAGTGC TAAAGTCAGGGCCACTTACTTTTCTTGTCGAGCTCTATCTTTCTTTGGTCTGCATTC ACATTTGTTGTGCTGTAGGAAGCTCATCTCTCCTATGTGCTGGCCTTGGTGAGGTT TGATCCGCATAATCTGCATGGTGATGTTGGACTCCTCAGTGGGCACACACTCCAG GCCCTCGTCATTGCAGCAGCCCCCGCATCGCATCAGGGGCACACAGGATGGCTT GAAGATGTACTCGATCTCATCAGGGTACTCCTGGAAGATGTCCACCAGGGTCTCG ATCGGATGGCAGTAGCTGCGCTGATAGACATCCATGAACTTCACCACTTCGTGATG ATTCTGCCCTCCTCCTTCTGCCATGGGTGCAGCCTGGGACCACTTGGCATGGTGG AGGTAGAGCAGCAAGGCAAGGCTCCAATGCACCCAAGACAGCAGAAAGTTCATGG TTTCGGAGGCCCGACCGGAATTCGATATCCTGATCTGACGGTTCACTAAACCAGCT CTGCTTATATAGACCTCCCACCGTACACGCCTACCGCCCATTTGCGTCAATGGGGC GGAGTTGTTACGACATTTTGGAAAGTCCCGTTGATTTTGGTGCCAAAACAAACTCC CATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCACCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGC CAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGAT ACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGT CAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCGGAACTCCATATATGGGCTATGAACTAATGACCCCGTAATTGATTACTATTAG GTACCGTCGACTCGAAGATCTGGGCGTGGTTAAGGGTGGGAAAGAATATATAAGG TGGGGGTCTTATGTAGTTTTGTATCTGTTTTGCAGCAGCCGCCGCCGCCATGAGCA CCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCCCGTCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGG AGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGCGGGATTG TGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCC GCCCGCGATGACAAGTTGACGGCTCTTTTGGCACAATTGGATTCTTTGACCCGGG AACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTG AAGGCTTCCTCCCCTCCCAATGCGGTTTAAAACATAAATAAAAAACCAGACTCTGTT TGGATTTGGATCAAGCAAGTGTCTTGCTGTCTTTATTTAGGGGTTTTGCGCGCGCG GTAGGCCCGGGACCAGCGGTCTCGGTCGTTGAGGGTCCTGTGTATTTTTTCCAGG ACGTGGTAAAGGTGACTCTGGATGTTCAGATACATGGGCATAAGCCCGTCTCTGG GGTGGAGGTAGCACCACTGCAGAGCTTCATGCTGCGGGGTGGTGTTGTAGATGAT CCAGTCGTAGCAGGAGCGCTGGGCGTGGTGCCTAAAAATGTCTTTCAGTAGCAAG CTGATTGCCAGGGGCAGGCCCTTGGTGTAAGTGTTTACAAAGCGGTTAAGCTGGG ATGGGTGCATACGTGGGGATATGAGATGCATCTTGGACTGTATTTTTAGGTTGGCT ATGTTCCCAGCCATATCCCTCCGGGGATTCATGTTGTGCAGAACCACCAGCACAGT GTATCCGGTGCACTTGGGAAATTTGTCATGTAGCTTAGAAGGAAATGCGTGGAAGA ACTTGGAGACGCCCTTGTGACCTCCAAGATTTTCCATGCATTCGTCCATAATGATG GCAATGGGCCCACGGGCGGCGGCCTGGGCGAAGATATTTCTGGGATCACTAACG TCATAGTTGTGTTCCAGGATGAGATCGTCATAGGCCATTTTTACAAAGCGCGGGCG GAGGGTGCCAGACTGCGGTATAATGGTTCCATCCGGCCCAGGGGCGTAGTTACCC TCACAGATTTGCATTTCCCACGCTTTGAGTTCAGATGGGGGGATCATGTCTACCTG CGGGGCGATGAAGAAAACGGTTTCCGGGGTAGGGGAGATCAGCTGGGAAGAAAG CAGGTTCCTGAGCAGCTGCGACTTACCGCAGCCGGTGGGCCCGTAAATCACACCT ATTACCGGCTGCAACTGGTAGTTAAGAGAGCTGCAGCTGCCGTCATCCCTGAGCA GGGGGGCCACTTCGTTAAGCATGTCCCTGACTCGCATGTTTTCCCTGACCAAATCC GCCAGAAGGCGCTCGCCGCCCAGCGATAGCAGTTCTTGCAAGGAAGCAAAGTTTT TCAACGGTTTGAGACCGTCCGCCGTAGGCATGCTTTTGAGCGTTTGACCAAGCAG TTCCAGGCGGTCCCACAGCTCGGTCACCTGCTCTACGGCATCTCGATCCAGCATA TCTCCTCGTTTCGCGGGTTGGGGCGGCTTTCGCTGTACGGCAGTAGTCGGGTGCT CGTCCAGACGGGCCAGGGTCATGTCTTTCCACGGGCGCAGGGTCCTCGTCAGCG TAGTCTGGGTCACGGTGAAGGGGTGCG...

Claims

WHAT IS CLAIMED IS:

1. A vector to express one or more VEGF isoforms, comprising: an expression cassette comprising a promoter operably linked to a nucleic acid sequence comprising VEGF exons 1-5, 6A, 7, and 8 which is linked to at least one polyA sequence, wherein the polyA sequence has reduced readthrough relative to an individual SV40 polyA sequence, wherein the splice acceptor (SA) of exon 8 is modified to enhance splicing at the splice acceptor of exon 8, wherein a sequence 3’ to the expression cassette is modified to mutate a downstream SA site, wherein if the vector is an adenovirus vector the polyA sequence has reduced readthrough adenovirus early gene expression and higher transgene expression relative to an individual SV40 polyA sequence, wherein the expression cassette is in reverse orientation relative to at least one other functional element that is 5’ or 3’ to the expression cassette, or a combination thereof.

2. The vector of claim 1 wherein the promoter is a viral promoter.

3. The vector of claim 1 wherein the promoter is not an adenovirus promoter.

4. The vector of any one of claims 1 to 3 which has two, three or more polyA sequences.

5. The vector of claim 4 which has two or more copies of the same polyA sequence which is optionally a SV40 polyA sequence.

6. The vector of claim 4 which has at least two, three or four different polyA sequences.

7. The vector of any one of claims 1 to 6 wherein the polyA sequence comprises ahuman GAPDH, human TUBB (tubulin), human RPL3 (ribosomal protein large 3), human ITGA1 (Integrin A1), human GH (growth hormone), rabbit BG (beta globin), or bovine GH (growth hormone) polyA sequences, or a combination thereof.

8. The vector of any one of claims 1 to 7 which is a viral vector.

9. The vector of claim 8 which is an adenovirus vector.

10. The vector of claim 8 or 9 wherein the expression cassette is in reverse orientation relative to the flanking viral sequences.

11. The vector of claim 8, 9 or 10 wherein the E1b SA is mutated.

12. The vector of any one of claims 1 to 11 wherein the splice acceptor in exon 8 is modified.

13. The vector of any one of claims 1 to 12 which expresses two or more isoforms of VEGF.

14. The vector of any one of claims 1 to 13 which expresses VEGF121.

15. The vector of any one of claims 1 to 14 which expresses VEGF165.

16. The vector of any one of claims 1 to 15 which expresses VEGF189.

17. The vector of any one of claims 1 to 16 which expresses VEGF121, VEGF165 and VEGF189.

18. The vector of any one of claims 13 to 17 which wherein the ratio of the isoforms is about 1:1:1.

19. The vector of any one of claims 13 to 17 which wherein the ratio of the isoforms is VEGF189 > VEGF165 > VEGF121.

20. A recombinant adenoviral vector comprising an expression cassette comprising apromoter operably linked to a nucleic acid sequence comprising VEGF exons 1-5, 6A, 7, and 8 which is linked to at least one polyA sequence, wherein the polyA sequence has reduced readthrough relative to a single SV40 polyA sequence, wherein the splice acceptor (SA) of exon 8 is modified to enhance splicing at the splice acceptor of exon 8, wherein a sequence 3’ to the expression cassette ismodified to mutate a SA site, wherein the expression cassette is in reverse orientation, or a combination thereof 21. The adenoviral vector of claim 20 wherein an E1B splice site is modified.

22. The adenoviral vector of claim 20 or 21 wherein the splice acceptor in exon 8 is modified.

23. The adenoviral vector of claim 20, 21 or 22 which comprises at least two polyA sequences.

24. The adenoviral vector of any one of claims 20 to 23 wherein the at least one polyA sequence comprises a human GAPDH, human TUBB (tubulin), human RPL3 (ribosomal protein large 3), human ITGA1 (Integrin A1), human GH (growth hormone), bovine GH, or rabbit BG (beta globin) polyA sequences, or a combination thereof.

25. The adenoviral vector of any one of claims 20 to 24 wherein the promoter is a viral promoter.

26. The adenoviral vector of any one of claims 20 to 25 wherein the promoter is not an adenovirus promoter.

27. The adenoviral vector of any one of claims 20 to 26 wherein the expression cassette is in reverse orientation relative to the flanking viral sequences.

28. The adenoviral vector of any one of claims 20 to 27 which expresses two or more isoforms of VEGF.

29. The adenoviral vector of any one of claims 20 to 28 which expresses VEGF121.

30. The adenoviral vector of any one of claims 20 to 29 which expresses VEGF165.

31. The adenoviral vector of any one of claims 20 to 30 which expresses VEGF189.

32. The adenoviral vector of any one of claims 20 to 31 which expresses VEGF121,VEGF165 and VEGF189.

33. The adenoviral vector of any one of claims 28 to 32 which wherein the ratio of the isoforms is about 1:1:

1.

34. The adenoviral vector of any one of claims 28 to 32 which wherein the ratio of the isoforms is VEGF189 > VEGF165 > VEGF121.

35. The adenoviral vector of any one of claims 20 to 34 wherein the adenovirus is E1- and / or E3-.

36. The adenoviral vector of any one of claims 20 to 35 wherein the adenovirus genome or capsid is from a human adenovirus.

37. The adenoviral vector of any one of claims 20 to 35 wherein the adenovirus genome or capsid is from a non-human primate adenovirus.

38. A composition comprising particles comprising mRNA isolated from expression of the vector of any one of claims 1 to 37.

39. The composition of claim 38 wherein the particles are nanoparticles.

40. The composition of claim 38 or 39 wherein the particles comprise one or more lipids.

41. The composition of claim 40 wherein the particles comprise DSPC, cholesterol, PEG-DMA, SM-102, or any combination thereof.

42. A method of directing blood vessel growth in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising the vector of any one of claims 1 to 37 or the composition of any one of claims 38 to 41.

43. The method of claim 42 wherein the VEGF is directed to a target location based on the site of administration in an organ or a tissue.

44. The method of claim 42 or 43 wherein the administration is to a region in the mammal affected by a vascular occlusion.

45. The method of any one of claims 42 to 44 wherein the administration is to a heart.

46. The method of any one of claims 42 to 45 wherein the administration is to a location suffering from ischemia.

47. The method of any one of claims 42 to 46 wherein the mammal is a human.

48. The method of any one of claims 42 to 47 wherein the mammal has, ischemic heart disease or peripheral arterial disease.

49. The method of any one of claims 42 to 48 wherein the mammal has had a stroke.

50. The method of any one of claims 42 to 49 wherein the vector expresses two or more isoforms of VEGF.

51. The method of any one of claims 42 to 50 wherein the vector expresses VEGF121.

52. The method of any one of claims 42 to 51 wherein the adenovirus expresses VEGF165.

53. The method of any one of claims 42 to 52 wherein the adenovirus expresses VEGF189.

54. The method of any one of claims 42 to 53 wherein the adenovirus expresses VEGF121, VEGF165 and VEGF189.

55. The method of claim 54 wherein the ratio of the isoforms is about 1:1:

1.

56. The method of claim 54 wherein the ratio of the isoforms is VEGF189 > VEGF165 > VEGF121.

57. The method of any one of claims 42 to 56 wherein the vector is a human adenovirus.

58. The method of any one of claims 42 to 56 wherein the adenovirus is a non- human primate adenovirus.

Citation Information

Patent Citations

  • Polymer-based delivery system for immunotherapy of cancer

    US20070081972A1

  • Drug delivery device

    US4863457A

  • Sustained release drug delivery devices

    US5378475A

  • Biocompatible ocular implants

    US5443505A

  • Penton base protein and methods of using same

    US5559099A